<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Botulinum toxin type A for facial wrinkles - Camargo, CPires - 2021 | Cochrane Library</title> <meta content="Botulinum toxin type A for facial wrinkles - Camargo, CPires - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011301.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Botulinum toxin type A for facial wrinkles - Camargo, CPires - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011301.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011301.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Botulinum toxin type A for facial wrinkles" name="citation_title"/> <meta content="Cristina Pires Camargo" name="citation_author"/> <meta content="Universidade de São Paulo" name="citation_author_institution"/> <meta content="consultoriodracristina@gmail.com" name="citation_author_email"/> <meta content="Jun Xia" name="citation_author"/> <meta content="The University of Nottingham Ningbo" name="citation_author_institution"/> <meta content="Caroline S Costa" name="citation_author"/> <meta content="Universidade Federal do Piaui" name="citation_author_institution"/> <meta content="Rolf Gemperli" name="citation_author"/> <meta content="Universidade de São Paulo" name="citation_author_institution"/> <meta content="Maria DC Tatini" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Max K Bulsara" name="citation_author"/> <meta content="Rachel Riera" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD011301.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/07/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011301.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011301.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011301.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bias; Botulinum Toxins, Type A [adverse effects, *therapeutic use]; Dermal Fillers [therapeutic use]; Face; Placebos [therapeutic use]; Randomized Controlled Trials as Topic; Skin Aging [*drug effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011301.pub2&amp;doi=10.1002/14651858.CD011301.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="i9CklieH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011301\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011301\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011301\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011301\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","th","ms","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011301.pub2",title:"Botulinum toxin type A for facial wrinkles",firstPublishedDate:"Jul 5, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011301.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011301.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011301.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011301.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011301.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011301.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011301.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011301.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011301.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011301.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7979 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011301.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-sec-0795"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-sec-0044"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-sec-0789"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/appendices#CD011301-sec-0800"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/table_n/CD011301StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/table_n/CD011301StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Botulinum toxin type A for facial wrinkles</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/information#CD011301-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Cristina Pires Camargo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/information#CD011301-cr-0005">Jun Xia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/information#CD011301-cr-0006">Caroline S Costa</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/information#CD011301-cr-0007">Rolf Gemperli</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/information#CD011301-cr-0008">Maria DC Tatini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/information#CD011301-cr-0009">Max K Bulsara</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011301.pub2/information#CD011301-cr-0010">Rachel Riera</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/information/en#CD011301-sec-0812">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 July 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011301.pub2">https://doi.org/10.1002/14651858.CD011301.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011301-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011301-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011301-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011301-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011301-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD011301-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011301-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011301-abs-0001" lang="en"> <section id="CD011301-sec-0001"> <h3 class="title" id="CD011301-sec-0001">Background</h3> <p>Botulinum toxin type A (BontA) is the most frequent treatment for facial wrinkles, but its effectiveness and safety have not previously been assessed in a Cochrane Review. </p> </section> <section id="CD011301-sec-0002"> <h3 class="title" id="CD011301-sec-0002">Objectives</h3> <p>To assess the effects of all commercially available botulinum toxin type A products for the treatment of any type of facial wrinkles. </p> </section> <section id="CD011301-sec-0003"> <h3 class="title" id="CD011301-sec-0003">Search methods</h3> <p>We searched the following databases up to May 2020: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registers, and checked the reference lists of included studies for further references to relevant randomised controlled trials (RCTs). </p> </section> <section id="CD011301-sec-0004"> <h3 class="title" id="CD011301-sec-0004">Selection criteria</h3> <p>We included RCTs with over 50 participants, comparing BontA versus placebo, other types of BontA, or fillers (hyaluronic acid), for treating facial wrinkles in adults. </p> </section> <section id="CD011301-sec-0005"> <h3 class="title" id="CD011301-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. Primary outcomes were participant assessment of success and major adverse events (AEs) (eyelid ptosis, eyelid sensory disorder, strabismus). Secondary outcomes included physician assessment of success; proportion of participants with at least one AE and duration of treatment effect. We used GRADE to assess the certainty of the evidence for each outcome. </p> </section> <section id="CD011301-sec-0006"> <h3 class="title" id="CD011301-sec-0006">Main results</h3> <p>We included 65 RCTs, involving 14,919 randomised participants. Most participants were female, aged 18 to 65 years. All participants were outpatients (private office or day clinic). Study duration was between one week and one year. No studies were assessed as low risk of bias in all domains; the overall risk of bias was unclear for most studies. </p> <p>The most common comparator was placebo (36 studies). An active control was used in 19 studies. There were eight dose‐ranging studies of onabotulinumtoxinA, and a small number of studies compared against fillers. Treatment was given in one cycle (54 studies), two cycles (three studies), or three or more cycles (eight studies). </p> <p>The treated regions were glabella (43 studies), crow's feet (seven studies), forehead (two studies), perioral (two studies), full face (one study), or more than two regions (nine studies). Most studies analysed moderate to severe wrinkles; mean duration of treatment was 20 weeks. </p> <p>The following results summarise the main comparisons, based on studies of one treatment cycle for the glabella. AEs were collected over the duration of these studies (over four to 24 weeks). </p> <p>Compared to placebo, onabotulinumtoxinA‐20 U probably has a higher success rate when assessed by participants (risk ratio (RR) 19.45, 95% confidence interval (CI) 8.60 to 43.99; 575 participants; 4 studies; moderate‐certainty evidence) or physicians (RR 17.10, 95% CI 10.07 to 29.05; 1339 participants; 7 studies; moderate‐certainty evidence) at week four. Major AEs are probably higher with onabotulinumtoxinA‐20 U (Peto OR 3.62, 95% CI 1.50 to 8.74; 1390 participants; 8 studies; moderate‐certainty evidence), but there may be no difference in any AEs (RR 1.14, 95% CI 0.89 to 1.45; 1388 participants; 8 studies; low‐certainty evidence). </p> <p>Compared to placebo, abobotulinumtoxinA‐50 U has a higher participant‐assessed success rate at week four (RR 21.22, 95% CI 7.40 to 60.56; 915 participants; 6 studies; high‐certainty evidence); and probably has a higher physician‐assessed success rate (RR 14.93, 95% CI 8.09 to 27.55; 1059 participants; 7 studies; moderate‐certainty evidence). There are probably more major AEs with abobotulinumtoxinA‐50 U (Peto OR 3.36, 95% CI 0.88 to 12.87; 1294 participants; 7 studies; moderate‐certainty evidence). Any<b> </b>AE may be more common with abobotulinumtoxinA‐50 U (RR 1.25, 95% CI 1.05 to 1.49; 1471 participants; 8 studies; low‐certainty evidence). </p> <p>Compared to placebo, incobotulinumtoxinA‐20 U probably has a higher participant‐assessed success rate at week four (RR 66.57, 95% CI 13.50 to 328.28; 547 participants; 2 studies; moderate‐certainty evidence), and physician‐assessed success rate (RR 134.62, 95% CI 19.05 to 951.45; 547 participants; 2 studies; moderate‐certainty evidence). Major AEs were not observed (547 participants; 2 studies; moderate‐certainty evidence). There may be no difference between groups in any AEs (RR 1.17, 95% CI 0.90 to 1.53; 547 participants; 2 studies; low‐certainty evidence). </p> <p>AbobotulinumtoxinA‐50 U is no different to onabotulinumtoxinA‐20 U in participant‐assessed success rate (RR 1.00, 95% CI 0.92 to 1.08, 388 participants, 1 study, high‐certainty evidence) and physician‐assessed success rate (RR 1.01, 95% CI 0.95 to 1.06; 388 participants; 1 study; high‐certainty evidence) at week four. Major AEs are probably more likely in the abobotulinumtoxinA‐50 U group than the onabotulinumtoxinA‐20 U group (Peto OR 2.65, 95% CI 0.77 to 9.09; 433 participants; 1 study; moderate‐certainty evidence). There is probably no difference in any AE (RR 1.02, 95% CI 0.67 to 1.54; 492 participants; 2 studies; moderate‐certainty evidence). </p> <p>IncobotulinumtoxinA‐24 U may be no different to onabotulinumtoxinA‐24 U in physician‐assessed success rate at week four (RR 1.01, 95% CI 0.96 to 1.05; 381 participants; 1 study; low‐certainty evidence) (participant assessment was not measured). One participant reported ptosis with onabotulinumtoxinA, but we are uncertain of the risk of AEs (Peto OR 0.02, 95% CI 0.00 to 1.77; 381 participants; 1 study; very low‐certainty evidence). </p> <p>Compared to placebo, daxibotulinumtoxinA‐40 U probably has a higher participant‐assessed success rate (RR 21.10, 95% CI 11.31 to 39.34; 683 participants; 2 studies; moderate‐certainty evidence) and physician‐assessed success rate (RR 23.40, 95% CI 12.56 to 43.61; 683 participants; 2 studies; moderate‐certainty evidence) at week four. Major AEs were not observed (716 participants; 2 studies; moderate‐certainty evidence). There may be an increase in any AE with daxibotulinumtoxinA compared to placebo (RR 2.23, 95% CI 1.46 to 3.40; 716 participants; 2 studies; moderate‐certainty evidence). </p> <p>Major AEs reported were mainly ptosis; BontA is also known to carry a risk of strabismus or eyelid sensory disorders. </p> </section> <section id="CD011301-sec-0007"> <h3 class="title" id="CD011301-sec-0007">Authors' conclusions</h3> <p>BontA treatment reduces wrinkles within four weeks of treatment, but probably increases risk of ptosis. We found several heterogeneous studies (different types or doses of BontA, number of cycles, and different facial regions) hindering meta‐analyses. The certainty of the evidence for effectiveness outcomes was high, low or moderate; for AEs, very low to moderate. Future RCTs should compare the most common BontA (onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, daxibotulinumtoxinA, prabotulinumtoxinA) and evaluate long‐term outcomes. There is a lack of evidence about the effects of multiple cycles of BontA, frequency of major AEs, duration of effect, efficacy of recently‐approved BontA and comparisons with other treatments. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011301-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011301-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011301-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011301-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011301-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011301-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011301-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011301-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD011301-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011301-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011301-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011301-abs-0002" lang="en"> <h3>How well does botulinum toxin (type A; often called ‘Botox’) treat wrinkles on the face? </h3> <p><b>Key messages</b> </p> <p>Injecting botulinum toxin type A (a Botox‐like treatment) reduces wrinkles between the eyebrows, and is relatively safe to use. The effects on wrinkles were seen when measured at four weeks after the injection. Injecting botulinum toxin type A probably increases the risk of eyelid drooping. More studies are needed to assess the longer‐term benefits and harms of repeated treatment with botulinum toxin. </p> <p><b>Treating facial wrinkles</b> </p> <p>Continuous movement of muscles in the face can cause the skin to wrinkle as it ages and becomes less elastic. Botulinum toxin type A is a chemical that relaxes muscles; it is produced by a type of bacteria. It is commonly used to smooth out lines and wrinkles by injecting it into the muscles of the face to stop their movement for a short time. Muscle activity usually stops completely within five to 15 days after the injection. The effects on the muscles are temporary and usually last for around four to six months. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to find out how well botulinum toxin could treat wrinkles on the face, and if it causes any unwanted effects. </p> <p><b>What did we do?</b> </p> <p>We searched for studies that tested the effects of botulinum toxin to treat wrinkles on the face. </p> <p><b>What did we find?</b> </p> <p>We found 65 studies in 14,919 people (mostly women) who went to a day clinic or private office for treatment. The studies lasted from one week to one year; the average length of treatment was 20 weeks. The studies compared one type of botulinum toxin against another type, against a placebo (an injection that did not contain any botulinum toxin), or against an alternative treatment. Several studies were funded by pharmaceutical companies. </p> <p>The studies tested four types of botulinum toxin that were licensed for use and some other types that were not yet licensed. </p> <p>All studies assessed the success of treatment by measuring wrinkles and lines when facial muscles were at their most tense. Most studies treated wrinkles that develop between the eyebrows, known as 'glabellar lines'. </p> <p><b>What are the main results of our review?</b> </p> <p>At four weeks after injection, all types of botulinum toxin reduced glabellar lines more than a placebo. This effect was seen whether the wrinkles were assessed by doctors or by the people who had the injections. </p> <p>Unwanted effects are probably more common with botulinum toxin than with placebo injections. The most commonly reported unwanted effects are drooping eyelids, squinting (when the eyes point in different directions) and numbness of the eyelid. </p> <p>Two studies compared two different types of botulinum toxin and found no difference between the types for how well they reduced glabellar lines. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our confidence in the evidence is moderate to high that botulinum toxin reduces wrinkles between the eyebrows better than a placebo. We are less confident in some of the evidence for other comparisons or studies, because some studies enrolled only a small number of people, and in some studies it was unclear how people were assigned to different treatment groups or if people knew which treatment they received. Further research is likely to increase our confidence in the evidence. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is current up to May 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011301-sec-0795" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011301-sec-0795"></div> <h3 class="title" id="CD011301-sec-0796">Implications for practice</h3> <section id="CD011301-sec-0796"> <p>This systematic review found that BontA is effective for reducing facial wrinkles within four weeks of treatment, but carries a risk of ptosis. There was a lack of long‐term data, and data on adverse effects were limited. The formulations of BontA tested appeared to be similarly effective in short‐term assessment. Longer‐term effects of treatment are unclear, and this applies to both efficacy and adverse effects. </p> <p>Analysing the data, some ethnicities (Middle East, Latin America) and gender (male) are underrepresented. Depending on the ethnicity, anatomic characteristics such as skin width, oiliness of the skin, and the skeletal structure, can interfere in the BontA treatment. </p> <p>In general, males have stronger muscles than females; this fact could interfere in the relationship between the units of BontA needed to treat and duration of effect. Most of the studies analysed moderate‐to‐severe glabellar lines, but in clinical practice, physicians treat mild‐to‐moderate glabellar lines.  </p> <p>Regarding major adverse events, only ptosis was reported in the trials; however, BontA is known to carry a risk of strabismus and eyelid sensory disorders. The trials reported ptosis in less than 5% of BontA‐treated participants, and no episodes of ptosis were reported in placebo‐treated trial participants.  </p> </section> <h3 class="title" id="CD011301-sec-0797">Implications for research</h3> <section id="CD011301-sec-0797"> <p>In recent years, new BontA formulations have become available. However, despite all the safety and clinical indications, some crucial questions remain that future BontA research should aim to address. </p> <p>Therefore, according to the PICOT acronym, further research could focus on the following.</p> <p> <ul id="CD011301-list-0041"> <li> <p>Population: different ethnicities should be assessed.</p> </li> <li> <p>Intervention: studies should assess multiples cycles of treatment and seek to find the most effective dilution. There should be a standard conversion ratio among all available BontA brands. </p> </li> <li> <p>Comparator: it would help to compare all available BontA brands regarding the duration of treatment effect (time between wrinkles treatment session) with assessment of different facial regions (glabella, canthal lines, frontal lines), liquid BontA versus lyophylised BontA, what is the most effective treatment association (hyaluronic acid, peeling, laser, radiofrequency, surgery), and what are the consequences of therapy of several facial regions in the same session. </p> </li> <li> <p>Outcome: helpful outcomes to measure in future studies include duration of treatment in multiples sessions, the time between BontA dilution and clinical application, the effectiveness and safety of multiple cycles of treatment, and the longer‐term effectiveness of multiple cycles of treatment. </p> </li> </ul> </p> <p>Future studies should also aim to improve study methodology. The main issue identified in the existing literature was failure to describe adequate methods of randomisation or allocation concealment. There is a need for better powered studies and more homogeneity of study design.  There is a need for new studies that answer clinical questions such as the duration of the effect of BontA, one cycle versus multiple cycles, as well as active comparator studies, so we can more confidently compare different BontA treatment options. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011301-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011301-sec-0008"></div> <div class="table" id="CD011301-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of Findings Table ‐ OnabotulinumtoxinA 20U compared to placebo in glabellar lines</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>OnabotulinumtoxinA 20U compared to placebo in glabellar lines</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : glabellar lines <b>Setting</b> : Outpatient <b>Intervention</b> : OnabotulinumtoxinA 20U <b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with OnabotulinumtoxinA 20U</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Partcipant assessment of success<br/>assessed with: Validated tools, considering wrinkles and lines at maximum contraction <br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>65 per 100</b><br/>(29 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 19.45</b><br/>(8.60 to 43.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>575<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major adverse events <br/>follow up: range 4 weeks to 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>2 per 100</b><br/>(1 to 5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 3.62</b><br/>(1.50 to 8.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1390<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician assessment of success<br/>assessed with: Validate tools, wrinkles and lines at maximum contraction<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>61 per 100</b><br/>(36 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 17.10</b><br/>(10.07 to 29.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1339<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events<br/>follow up: range 4 weeks to 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>27 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>31 per 100</b><br/>(24 to 39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.14</b><br/>(0.89 to 1.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1388<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of treatment effect<br/>assessed with: weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean duration of treatment effect was <b>0.4</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>18.4 higher</b><br/>(16.17 higher to 20.63 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; <b>MD:</b> Mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103355840383514" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103355840383514</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> Downgraded one level due to serious risk of bias:, unclear risk of bias from blinding of participants, personnel, and outcome assessors.<br/><b>b.</b> Downgraded one level due to serious imprecision: wide 95% CI, crossing the null. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011301-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of Findings Table ‐ AbobotulinumtoxinA 50U compared to placebo for glabellar lines</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>AbobotulinumtoxinA 50U compared to placebo for glabellar lines</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : glabellar lines <b>Setting</b> : Outpatient <b>Intervention</b> : AbobotulinumtoxinA 50U <b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with AbobotulinumtoxinA 50U</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant assessment of success by analysing scores and scales ‐ 20 weeks (Validated tools, wrinkles and lines at maximum contraction)<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>16 per 100</b><br/>(5 to 51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 5.33</b><br/>(1.67 to 16.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)<br/>follow up: range 4 weeks to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 100</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.36</b><br/>(0.88 to 12.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1294<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unable to calculate the risk with the intervention as no major adverse events occurred in the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician assessment of success by analysing scores and scales ‐ 4 weeks<br/>assessed with: Validated tools, wrinkles and lines at maximum contraction<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>53 per 100</b><br/>(30 to 96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 15.78</b><br/>(8.75 to 28.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1060<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events<br/>follow up: range 4 weeks to 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>25 per 100</b><br/>(21 to 30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.25</b><br/>(1.05 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1471<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of treatment effect<br/>assessed with: weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean duration of treatment effect was <b>99.7</b> days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>17.3 days higher</b><br/>(15.82 higher to 18.78 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>MD:</b> Mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103454361439144" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103454361439144</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> Downgraded one level due to serious imprecision: wide 95% CI, crossing the null.<br/><b>b.</b> Downgraded one level due to serious risk of bias: unclear risk of bias from blinding of participants, personnel, and assessors. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011301-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of Findings Table ‐ IncobotulinumtoxinA 20U compared to placebo for glabellar lines</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>IncobotulinumtoxinA 20U compared to placebo for glabellar lines</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : glabellar lines <b>Setting</b> : Outpatient <b>Intervention</b> : IncobotulinumtoxinA 20U <b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with IncobotulinumtoxinA 20U</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant assessment of success by analysing scores and scales ‐ 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>37 per 100</b><br/>(7 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 66.57</b><br/>(13.50 to 328.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>547<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major adverse events<br/>follow up: range 4 weeks to 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>No major adverse events were observed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>547<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician assessment of success by analysing scores and scales<br/>assessed with: Validated tools, wrinkles and lines at maximum contraction<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 100</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 134.62</b><br/>(19.05 to 951.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>547<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unable to calculate the risk with the intervention as no events occurred in the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events<br/>follow up: range 4 weeks to 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>29 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>34 per 100</b><br/>(26 to 45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.17</b><br/>(0.90 to 1.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>547<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of treatment effect ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103474800544813" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103474800544813</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> Downgraded one level due to serious risk of bias: unclear risk of bias from blinding of participants, personnel, and assessors.<br/><b>b.</b> Downgraded one level due to serious imprecision: wide 95% CI, crossing the null </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011301-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of Findings Table ‐ AbobotulinumtoxinA 50U compared to OnabotulinumtoxinA 20U in glabellar lines</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>AbobotulinumtoxinA 50U compared to OnabotulinumtoxinA 20U in glabellar lines</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : glabellar lines <b>Setting</b> : Outpatient <b>Intervention</b> : AbobotulinumtoxinA 50U <b>Comparison</b>: OnabotulinumtoxinA 20U </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with OnabotulinumtoxinA 20U</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with AbobotulinumtoxinA 50U</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant assessment success by analysing scores and scales ‐ 4 weeks<br/>assessed with: Validated tools, wrinkles and lines at maximum contraction<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>894 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>894 per 1000</b><br/>(822 to 965) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.00</b><br/>(0.92 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>388<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major adverse events ‐ Any major adverse events (eyelid ptosis, eyelid sensory disorder, s<br/>follow up: range 4 weeks to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>2 per 100</b><br/>(1 to 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 2.65</b><br/>(0.77 to 9.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>433<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction)<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>95 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>96 per 100</b><br/>(90 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.01</b><br/>(0.95 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>388<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events<br/>follow up: range 4 weeks to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>19 per 100</b><br/>(12 to 28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.02</b><br/>(0.67 to 1.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>492<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of treatment effect ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103510517664820" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103510517664820</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> Downgraded one level due to serious imprecision: wide 95% CI, crossing the null. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011301-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of Findings Table ‐ IncobotulinumtoxinA 24U compared to OnabotulinumtoxinA 24U in glabellar lines</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>IncobotulinumtoxinA 24U compared to OnabotulinumtoxinA 24U in glabellar lines</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : glabellar lines <b>Setting</b> : Outpatient <b>Intervention</b> : IncobotulinumtoxinA 24U <b>Comparison</b>: OnabotulinumtoxinA 24U </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with OnabotulinumtoxinA 24U</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with IncobotulinumtoxinA 24U</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant assessment of success by analysing scores and scales ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major adverse events<br/>follow up: range 4 weeks to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 100</b><br/>(0 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.02</b><br/>(0.00 to 1.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>381<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,</sup><sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ptosis was reported in one participant in onabotulinumtoxinA group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction)<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>96 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>97 per 100</b><br/>(92 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.01</b><br/>(0.96 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>381<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events<br/>follow up: range 4 weeks to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 100</b><br/>(0 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.02</b><br/>(0.00 to 1.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>381<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,</sup><sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of treatment effect ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103538603772987" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103538603772987</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> Downgraded one level due to serious risk of bias: unclear risk of bias from randomisation, allocation concealment and blinding.<br/><b>b.</b> Downgraded one level due to serious imprecision: wide 95% CI, crossing the null.<br/><b>c.</b> Downgraded one level due to serious imprecision: low number of events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011301-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of Findings Table ‐ DaxibotulinumtoxinA 40U compared to placebo in glabellar lines</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>DaxibotulinumtoxinA 40U compared to placebo in glabellar lines</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : glabellar lines <b>Setting</b> : Outpatient <b>Intervention</b> : DaxibotulinumtoxinA 40U <b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with DaxibotulinumtoxinA 40U</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction)<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 100</b><br/>(43 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 21.10</b><br/>(11.31 to 39.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>683<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major adverse events<br/>follow up: range 4 weeks to 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>No major adverse events were observed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>716<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction)<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>88 per 100</b><br/>(47 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 23.40</b><br/>(12.56 to 43.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>683<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events<br/>follow up: range 4 weeks to 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>9 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>21 per 100</b><br/>(14 to 32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.23</b><br/>(1.46 to 3.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>716<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of treatment effect</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean duration of treatment effect was <b>0.4</b> weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>22.8 weeks higher</b><br/>(20.74 higher to 24.8 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>MD:</b> Mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103545427906155" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103545427906155</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> Downgraded one level due to serious risk of bias: unclear allocation concealment. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011301-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011301-sec-0009"></div> <p>Please note that unfamiliar terms may be listed in the Glossary in <a href="./appendices#CD011301-sec-0801">Appendix 1</a>. </p> <section id="CD011301-sec-0010"> <h3 class="title" id="CD011301-sec-0010">Description of the condition</h3> <p>Aging is a biological process; however, it is not well accepted by all in western cultures, who desire to retain a youthful appearance and optimal level of beauty, equating it with increased socialisation, power, success, and happiness. Preventing and treating the consequences of aging in the body has become almost a fixation (<a href="./references#CD011301-bbs2-0117" title="GarnhamB .Designing ‘older’ rather than denying ageing: Problematizing anti-ageing discourse in relation to cosmetic surgery undertaken by older people. Journal of Aging Studies2013;27(1):38-46. [MEDLINE: 23273555]">Garnham 2013</a>). </p> <p>Facial ageing depends on intrinsic factors, which include genetics (heredity) and ethnicity, and extrinsic factors, such as environmental conditions (e.g. sun exposure, smoking habits, and nutritional status). All of these factors contribute towards the appearance of ageing signs: fat absorption, flaccidity, and wrinkles (<a href="./references#CD011301-bbs2-0134" title="SveikataK , BalciunieneI , TutkuvieneJ .Factors influencing face aging. Literature review. Stomatologija2011;13(4):113-6. [MEDLINE: 22362337]">Sveikata 2011</a>). The aging process turns the skin thinner, drier, and less elastic, and less able to protect itself from internal and external aggressions. Due to these factors, the continuous muscle movement (facial expression) can lead to wrinkles.One of the first stages of facial aging includes the appearance of dynamic wrinkles. Additionally, the appearance of dynamic wrinkles occurs through increased muscle tone, as shown by electromyographic alterations <a href="./references#CD011301-bbs2-0127" title="Le LouarnC .Botulinum toxin and the Face Recurve concept: decreasing resting tone and muscular regeneration [Toxine botulique et Face Recurve®: actionsur le tonus de repos et la régénération musculaire]. Annales de Chirurgie Plastique et Esthetique2007;52(3):165-76. [MEDLINE: 17320262]">Le Louarn 2007</a>. Over an individual's lifetime, however, resting muscle tone increases and creases the skin causing fine wrinkles and lines in the skin surface (hyperdynamic wrinkles). If these wrinkles do not receive any treatment, the skin shows a permanent mark (static wrinkles) (<a href="./references#CD011301-bbs2-0106" title="CarruthersJD , GlogauRG , BlitzerAS , Facial Aesthetics Consensus Group Faculty.Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies-consensus recommendations. Plastic &amp; Reconstructive Surgery2008;121(5 Suppl):5S-30S. [MEDLINE: 18449026]">Carruthers 2008a</a>). Due to this fact, the dynamic rhytides treatment is more indicated in the clinical practice. Facial wrinkles can be classified in glabellar lines (vertical lines or furrows in the region between the eyebrows, above the nose); forehead lines (vertical or diagonal lines in the forehead region), crow's feet lines (lines or furrows in the periorbicular region, around the eyes). </p> <p>Several surgical and non‐surgical procedures for dynamic wrinkles are available. Amongst all therapies, botulinum toxin type A (BontA) injections are considered the most frequent treatment for this condition. According to the American Society of aesthetic surgery statistics, 4,597,886 injections of BontA were performed in 2016 (<a href="./references#CD011301-bbs2-0101" title="The American Society for Aesthetic Plastic Surgery.2016 Cosmetic Surgery National Data Bank Statistics. www.surgery.org/sites/default/files/ASAPS-Stats2016.pdf (accessed 9 November 2017).">ASAPS 2016</a>). The reason for BontA success can be attributed to low cost, no recovery time and temporary effect (<a href="./references#CD011301-bbs2-0119" title="GlogauR , KaneM , BeddingfieldF , SomogyiC , LeiX , CaulkinsC , et al.OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines. Dermatologic Surgery2012;38(11):1794-803. [MEDLINE: 23106853]">Glogau 2012</a>). The BontA average cost for wrinkle treatment is USD 385 per session (<a href="./references#CD011301-bbs2-0102" title="The American Society for Aesthetic Plastic Surgery.Botulinum Toxin. www.plasticsurgery.org/cosmetic-procedures/botulinum-toxin/cost (accessed 9 November 2017).">ASAPS 2017</a>). This treatment is performed in outpatients, during daily activities. The temporary effect ranges from four to six months. </p> </section> <section id="CD011301-sec-0011"> <h3 class="title" id="CD011301-sec-0011">Description of the intervention</h3> <p>Botulinum toxin has been used since the 1980s; there are eight subtypes available (A, B, C1, C2, D, E, F, and G). Serotypes A and B are commercially available (<a href="./references#CD011301-bbs2-0104" title="BerryMG , StanekJJ .Botulinum neurotoxin A: a review. Journal of Plastic, Reconstructive &amp; Aesthetic Surgery2012;65(10):1283-91. [MEDLINE: 22552262 ]">Berry 2012</a>). Botulinum toxinA is the most used in clinical practice due to its duration effect. Moreover, several brands are available in the market. Although all these toxins are type A, all companies have their particular strains. Due to this fact, each brand has specific biological characteristics: units equivalence (ratio) and dermal diffusion (<a href="./references#CD011301-bbs2-0119" title="GlogauR , KaneM , BeddingfieldF , SomogyiC , LeiX , CaulkinsC , et al.OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines. Dermatologic Surgery2012;38(11):1794-803. [MEDLINE: 23106853]">Glogau 2012</a>). </p> <p>For this reason, there is a conversion ratio.</p> <p> <ul id="CD011301-list-0001"> <li> <p>OnabotulinumtoxinA: AbobotulinumtoxinA, ratio = 1 unit (U) : 2.5 U or 3U</p> </li> <li> <p>OnabotulinumtoxinA: IncobobotulinintoxinA, ratio = 1 U:1 U</p> </li> <li> <p>The other BontA brands (daxibotulintoxinA (DWP450), PraxibotulinumtoxinA, HBTX‐A, Prosigne®, CBFC26, MT10109L, Medytox®, Neuronox®) follow the conversion ratio of 1:1 </p> </li> </ul> </p> <p>Despite these biological properties differences, the medical community recommend guidelines to treat facial wrinkles. </p> <p>In 2008 and 2016, an American committee discussed the dose treatment related to onabotulinumtoxinA.</p> <p> <ul id="CD011301-list-0002"> <li> <p>Glabellar region, the therapeutical dose range from 12 U to 40 U, 2 U to 4 U per injection, distributed in three to seven intramuscular injections points (procerus muscle, corrugator supercilii muscle, orbicularis oculi, muscle depressor supercilii muscle)frontal lines, the therapeutical dose range from 8 U to 25 U distributed in four to eight points of intramuscular injection along the frontal muscle wrinkles with a 2.0 cm above the eyebrows; and crow's feet, the therapeutical dose range from 6 U to 15 U distributed in two to five subcutaneous injections per side (one injection at least 1.5 cm to 2.0 cm from lateral canthus, one injection in the orbital rim next to the eyebrow extremity, and one injection near the zygomatic process in the orbital rim, the other injections along the crow’s feet lines laterally to the previous injections) (<a href="./references#CD011301-bbs2-0133" title="SundaramH , SignoriniM , LiewnS , Trindade de AlmeidaAR , WuY , BrazAV , et al.Global aesthetics consensus: botulinum toxin type A—evidence-based review emerging concepts, and consensus recommendations for aesthetic use, including updates on complications. Plastic and Reconstructive Surgery2016;137(3):518e-29e. [PMID: 26910696]">Sundaram 2016</a>) (<a href="./references#CD011301-bbs2-0106" title="CarruthersJD , GlogauRG , BlitzerAS , Facial Aesthetics Consensus Group Faculty.Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies-consensus recommendations. Plastic &amp; Reconstructive Surgery2008;121(5 Suppl):5S-30S. [MEDLINE: 18449026]">Carruthers 2008a</a>). </p> </li> </ul> </p> <p>In 2010, a European committee addressed the same issues and created an equivalent botulinum toxin type A guideline based on the other brand of BontA, AbobotulinumtoxinA biological properties: </p> <p> <ul id="CD011301-list-0003"> <li> <p>for the glabellar region, 50U (Speywood units) in five points;</p> </li> <li> <p>for frontal lines, 20 U to 60 U in four to six points; and</p> </li> <li> <p>for crow's feet, 30 U to 60 U in three points per side (<a href="./references#CD011301-bbs2-0103" title="AscherB , TalaricoS , CassutoD , EscobarS , HexselD , JaenP , et al.International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit) – Part 1: upper facial wrinkles. Journal of the European Academy of Dermatology &amp; Venereology2010;24(11):1278-84. [MEDLINE: 20337830]">Ascher 2010</a>). </p> </li> </ul> </p> <p>The guidelines shown above studied the most common BontA used in the clinical practice.</p> <p>Until now, the medical community does not know if these brands behave differently regarding effectiveness, duration of treatment and adverse events. </p> </section> <section id="CD011301-sec-0012"> <h3 class="title" id="CD011301-sec-0012">How the intervention might work</h3> <p>After injection into the muscle, botulinum toxin diffuses to the nerve terminal, where it binds, preventing the release of the neurotransmitter, acetylcholine, from the nerve synapse; thus, preventing its effect on the neuromuscular junction and consequently the muscle does not contract and does not crease the skin (no hyperdynamic wrinkle). Complete lack of muscle activity occurs after approximately five to 15 days (<a href="./references#CD011301-bbs2-0104" title="BerryMG , StanekJJ .Botulinum neurotoxin A: a review. Journal of Plastic, Reconstructive &amp; Aesthetic Surgery2012;65(10):1283-91. [MEDLINE: 22552262 ]">Berry 2012</a>). </p> <p>It is perceived that there are fewer wrinkles due to the non‐contraction of specific facial muscles (<a href="./references#CD011301-bbs2-0113" title="FagienS .Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plastic and Reconstructive Surgery2003;112(Suppl 5):40S-52S.">Fagien 2003</a>). However, this muscle atrophy due to chemical effect provokes regeneration at the nerve terminal known as 'sprouting'. This process, which lasts for 120 days, will originate in a new terminal at the neuromuscular junction, which will bring back muscle activity (<a href="./references#CD011301-bbs2-0104" title="BerryMG , StanekJJ .Botulinum neurotoxin A: a review. Journal of Plastic, Reconstructive &amp; Aesthetic Surgery2012;65(10):1283-91. [MEDLINE: 22552262 ]">Berry 2012</a>). Because of this, the duration of clinical treatment is in the range of three to six months. </p> <p>It is important that during the consultation prior to the botulinum toxin procedure, the medical professional establishes the expectations of the person and whether these will be achieved, explains all possible outcomes, safety issues, duration of treatment, and potential adverse effects, and examines the anatomic regions, in rest and contraction, and any pre‐existing asymmetry. Otherwise, the botulinum toxin treatment may cause frustration and disappointment. </p> <p>Moreover, for an optimal result, all medical professionals (dermatologists, plastic surgeons) should have a complete knowledge of functional muscle anatomy (<a href="./references#CD011301-bbs2-0106" title="CarruthersJD , GlogauRG , BlitzerAS , Facial Aesthetics Consensus Group Faculty.Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies-consensus recommendations. Plastic &amp; Reconstructive Surgery2008;121(5 Suppl):5S-30S. [MEDLINE: 18449026]">Carruthers 2008a</a>). This injection attenuates wrinkle appearance progressively (within 15 days), but the effect is temporary (four to six months) (<a href="./references#CD011301-bbs2-0104" title="BerryMG , StanekJJ .Botulinum neurotoxin A: a review. Journal of Plastic, Reconstructive &amp; Aesthetic Surgery2012;65(10):1283-91. [MEDLINE: 22552262 ]">Berry 2012</a>; <a href="./references#CD011301-bbs2-0106" title="CarruthersJD , GlogauRG , BlitzerAS , Facial Aesthetics Consensus Group Faculty.Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies-consensus recommendations. Plastic &amp; Reconstructive Surgery2008;121(5 Suppl):5S-30S. [MEDLINE: 18449026]">Carruthers 2008a</a>). </p> </section> <section id="CD011301-sec-0013"> <h3 class="title" id="CD011301-sec-0013">Why it is important to do this review</h3> <p>Botulinum toxin has been used to reduce hyperdynamic facial wrinkles for more than 20 years. During this period, several formulations have appeared on the market. Although these neurotoxins are not comparable, the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other drugs evaluation boards have been attempting to organise and classify them. Currently, there are several botulinum toxin type A products on the market: Botox®/Vistabel®/Vistabex® (Allergan); Dysport®/Disport® (Ipsen); Azzulure® (Galderma); XEOMIN®/Bocouture®/Xeomeen® (Merz Aesthetics); Neuronox®/Siax® (Medytox); Prosigne® (Cristalia); Lantox® (Dermacare), also known as BTXA™ (Lanzhou Institute of Biological Products (LIBP)® ‐ Hong Kong); and Lanzox® (Kalbe ‐ Indonesia) (<a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>). </p> <p>A Cochrane Review that assessed treatments for wrinkles and other skin changes provoked by photoageing included an evaluation of topical treatments (tretinoin, lactic, glycolic acids, moisturiser), and oral and topical polysaccharides and surgical procedures (CO2 laser, YAG laser, dermabrasion), but did not assess botulinum toxin for facial wrinkles (<a href="./references#CD011301-bbs2-0131" title="SamuelM , BrookeR , HollisS , GriffithsCEM .Interventions for photodamaged skin. Cochrane Database of Systematic Reviews2005, Issue 1. Art. No: CD001782. [DOI: 10.1002/14651858.CD001782.pub2]">Samuel 2005</a>). </p> <p>It is important to compare the efficacy of BontA versus different BontA brands, filler (hyaluronic acid, methacrylate, calcium hydroxyapatite, Polyalkylimide, Polylactic acid), and surgery. Also, it is crucial to analyse BontA safety, for example, the major adverse effects are: blepharoptosis (abnormal low‐lying upper eyelid margin with the eye in primary gaze) and strabismus (inability of one eye to attain binocular vision with the other because of imbalance of the muscles of the eyeball).  </p> <p>So far, no systematic reviews have been conducted on the effectiveness and safety of botulinum toxin type A in cosmetic procedures. As a consequence of the lack of robust clinical evidence, decisions about the use of different therapies for facial wrinkles are made at the discretion of plastic surgeons or dermatologists working with the person concerned. </p> <p>The aim of the present systematic review is to determine the effectiveness of botulinum toxin for the treatment of any type of facial wrinkle (dynamic or static). </p> <p>The methods for this review were published as a protocol '<i>Botulinum toxin for facial wrinkles</i>' (<a href="./references#CD011301-bbs2-0135" title="CamargoCP , CostaCS , GemperliR , TatiniMD , BulsaraMK , RieraR .Botulinum toxin for facial wrinkles. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD011301. [DOI: 10.1002/14651858.CD011301]">Camargo 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011301-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011301-sec-0014"></div> <p>To assess the effects of all commercially available botulinum toxin type A products for the treatment of any type of facial wrinkles. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011301-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011301-sec-0015"></div> <section id="CD011301-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011301-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included, randomised controlled trials (RCTs). Additionally, we also included split‐face designs (studies that compared two different treatments, each one applied to one side of the face). We did not include cluster‐ and cross‐over trials. All the studies had to have 50 or more participants. </p> </section> <section id="CD011301-sec-0018"> <h4 class="title">Types of participants</h4> <p>Individuals of either gender, aged 18 years and above, with a diagnosis of dynamic or static facial wrinkles (glabellar, forehead, or crow's feet). </p> </section> <section id="CD011301-sec-0019"> <h4 class="title">Types of interventions</h4> <p>All types of botulinum toxin type A in any dose, single or multiple treatments, compared to placebo, other types of botulinum toxin type A, and fillers (hyaluronic acid). </p> </section> <section id="CD011301-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We included studies assessing at least one of the outcomes below.</p> <section id="CD011301-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>1. Participant assessment of success, measured by validated scores or scales (<a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0105" title="CarruthersJ , CarruthersA .A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatologic Surgery2003;29(8):802-9. [MEDLINE: 12859378]">Carruthers 2003</a>; <a href="./references#CD011301-bbs2-0123" title="HoneckP , WeissC , SterryW , RzanyB , Gladys StudyGgroup.Reproducibility of a four-point clinical severity score for glabellar frown lines. British Journal of Dermatology2003;149(2):306-10. [MEDLINE: 12932236]">Honeck 2003</a>; <a href="./references#CD011301-bbs2-0124" title="HundT , AscherB , RzanyB , Smile Study Group.Reproducibility of two four-point clinical severity scores for lateral canthal lines (crow's feet). Dermatologic Surgery2006;32(10):1256-60. [MEDLINE: 17034375]">Hund 2006</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>). We considered wrinkles and lines at maximum contraction assessed by the following tools. </p> <p> <ul id="CD011301-list-0004"> <li> <p>Four‐point scale (<a href="./references#CD011301-bbs2-0105" title="CarruthersJ , CarruthersA .A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatologic Surgery2003;29(8):802-9. [MEDLINE: 12859378]">Carruthers 2003</a>) </p> </li> <li> <p>Patient Frown Wrinkle Severity (PFWS) scale (<a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>) </p> </li> <li> <p>Facial Line Treatment Satisfaction (FTS) Questionnaire (14‐item) (<a href="./references#CD011301-bbs2-0112" title="CoxSE , FinnJC , StetlerL , MackowiakJ , KowalskiJW .Development of the facial lines treatment satisfaction questionnaire and initial results for botulinum toxin type A–treated patients. Dermatologic Surgery2003;29(5):444-9. [MEDLINE: 12752509]">Cox 2003</a>) </p> </li> <li> <p>Facial Line Outcomes Questionnaire (FLO‐7) (<a href="./references#CD011301-bbs2-0112" title="CoxSE , FinnJC , StetlerL , MackowiakJ , KowalskiJW .Development of the facial lines treatment satisfaction questionnaire and initial results for botulinum toxin type A–treated patients. Dermatologic Surgery2003;29(5):444-9. [MEDLINE: 12752509]">Cox 2003</a>; <a href="./references#CD011301-bbs2-0114" title="FagienS , CoxSE , FinnJC , WerschlerWP , KowalskiJW .Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2007;33(1 Spec No):S2-S9. [MEDLINE: 17241410]">Fagien 2007b</a>) </p> </li> <li> <p>Self perception of age (SPA) (<a href="./references#CD011301-bbs2-0114" title="FagienS , CoxSE , FinnJC , WerschlerWP , KowalskiJW .Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2007;33(1 Spec No):S2-S9. [MEDLINE: 17241410]">Fagien 2007b</a>; <a href="./references#CD011301-bbs2-0115" title="FagienS , CarruthersJD .A comprehensive review of patient-reposted satisfaction with botulinum toxin type A for aesthetic procedures. Plastic &amp; Reconstructive Surgery2008;122(6):1915-25. [MEDLINE: 19050545]">Fagien 2008</a>) </p> </li> <li> <p>5‐point Merz Aesthetic Scale (<a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>) </p> </li> </ul> </p> <p>2. Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus).</p> </section> <section id="CD011301-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>1. Physician assessment of success, measured by validated scores or scales (<a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0110" title="CarruthersJ , FlynnT , GeisterT , GortelmeyerT , HardasB , HimmrichS , et al.Validated assessment scales for the mid face. Dermatologic Surgery2012;38(2 Spec no.):320-32. [MEDLINE: 22316188]">Carruthers 2012</a>; <a href="./references#CD011301-bbs2-0116" title="FlynnT , CarruthersA , CarruthersJ , GeisterTL , GortelmeyerR , HardasB , et al.Validated assessment scales for upper face. Dermatologic Surgery2012;38(2 Spec no):309-19. [MEDLINE: 22316187]">Flynn 2012</a>; <a href="./references#CD011301-bbs2-0126" title="KaneMA , BlitzerA , BarndtFS , GloguG , MonheitGD , NarinsRS , et al.Development and validation of a new clinically-meaningful rating scale for measuring lateral canthal line severity. Aesthetic Surgery Journal2012;32(3):275-85. [MEDLINE: 22395318 ]">Kane 2012</a>; <a href="./references#CD011301-bbs2-0128" title="NarinsRS , CarruthersJ , FlynnTC , GeisterTL , GortelmeyerR , HardasB , et al.Validated assessment scales for the lower face. Dermatologic Surgery2012;38(2 Spec no.):333-42. [MEDLINE: 22316189]">Narins 2012</a>; <a href="./references#CD011301-bbs2-0130" title="RzanyB , CarruthersA , CarruthersJ , FlynnTC , GeisterTL , GortelmeyerR , et al.Validated composite assessment scales for the global face. Dermatologic Surgery2012;38(2 Spec no.):294-308. [MEDLINE: 22316186]">Rzany 2012</a>; <a href="./references#CD011301-bbs2-0132" title="SattlerG , CarruthersA , CarruthersJ , FlynnTC , GeisterTL , GortelmeyerR , et al.Validated assessment scale for neck volume. Dermatologic Surgery2012;38(2 Spec no):343-50. [MEDLINE: 22316190]">Sattler 2012</a>). We considered wrinkles and lines at maximum contraction assessed by the following tools. </p> <p> <ul id="CD011301-list-0005"> <li> <p>Five‐point scale (<a href="./references#CD011301-bbs2-0116" title="FlynnT , CarruthersA , CarruthersJ , GeisterTL , GortelmeyerR , HardasB , et al.Validated assessment scales for upper face. Dermatologic Surgery2012;38(2 Spec no):309-19. [MEDLINE: 22316187]">Flynn 2012</a>) </p> </li> <li> <p>Investigator Global AssessmenteFrown Wrinkle Severity (IGA‐FWS) (<a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>) </p> </li> <li> <p>Facial Wrinkle Scale (FWS) (<a href="./references#CD011301-bbs2-0105" title="CarruthersJ , CarruthersA .A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatologic Surgery2003;29(8):802-9. [MEDLINE: 12859378]">Carruthers 2003</a>) </p> </li> <li> <p>Brow Positioning Grading Scale (five‐point scale) (<a href="./references#CD011301-bbs2-0107" title="CarruthersA , CarruthersJ , HardasB , KaurM , GoertelmeyerR , JonesD , et al.A validated grading scale for forehead lines. Dermatologic Surgery2008;34(Suppl 2):S155-60. [MEDLINE: 19021673]">Carruthers 2008b</a>) </p> </li> <li> <p>Forehead Lines Grading Scale (five‐point scale) (<a href="./references#CD011301-bbs2-0108" title="CarruthersA , CarruthersJ , HardasB , KaurM , GoertelmeyerR , JonesD , et al.A validated brow positioning grading scale. Dermatologic Surgery2008;34(Suppl 2):S150-4. [MEDLINE: 19021672]">Carruthers 2008c</a>) </p> </li> <li> <p>Crow's Feet Grading Scale (<a href="./references#CD011301-bbs2-0109" title="CarruthersA , CarruthersJ , HardasB , KaurM , GoertelmeyerR , JonesD , et al.A validated grading scale for crow’s feet. Dermatologic Surgery2008;34(Suppl 2):S173-8. [MEDLINE: 19021676]">Carruthers 2008d</a>) </p> </li> <li> <p>5‐point Merz Aesthetic Scale (<a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>) </p> </li> </ul> </p> <p>2. Any adverse event, measured by the proportion of participants presenting at least one adverse event. </p> <p>3. Duration of treatment effect</p> <section id="CD011301-sec-0023"> <h6 class="title">Timing of outcome measurement</h6> <p>We assessed these outcome measures before and after treatment (predominantly focusing on 4, 8, 12, 16 weeks, or more). </p> </section> </section> </section> </section> <section id="CD011301-sec-0024"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant RCTs regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD011301-sec-0025"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Skin Information Specialist searched the following databases up to 5 May 2020 using strategies based on the draft strategy for MEDLINE in our published protocol (<a href="./references#CD011301-bbs2-0135" title="CamargoCP , CostaCS , GemperliR , TatiniMD , BulsaraMK , RieraR .Botulinum toxin for facial wrinkles. Cochrane Database of Systematic Reviews2014, Issue 9. Art. No: CD011301. [DOI: 10.1002/14651858.CD011301]">Camargo 2014</a>): </p> <p> <ul id="CD011301-list-0006"> <li> <p>the Cochrane Skin Specialised Register using the search strategy listed in <a href="./appendices#CD011301-sec-0802">Appendix 2</a>; </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) 2020, Issue 5 in the Cochrane Library using the strategy listed in <a href="./appendices#CD011301-sec-0803">Appendix 3</a> </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy listed in <a href="./appendices#CD011301-sec-0804">Appendix 4</a>; </p> </li> <li> <p>Embase via Ovid (from 1974) using the strategy listed in <a href="./appendices#CD011301-sec-0805">Appendix 5</a>; and </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the strategy listed in <a href="./appendices#CD011301-sec-0806">Appendix 6</a>. </p> </li> </ul> </p> <section id="CD011301-sec-0026"> <h5 class="title">Trials registers</h5> <p>We (CPC, RR) searched the following trials registers up to 5 May 2020 using the search terms in <a href="./appendices#CD011301-sec-0807">Appendix 7</a>: </p> <p> <ul id="CD011301-list-0007"> <li> <p>the ISRCTN registry (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>the Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>); </p> </li> <li> <p>the World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>); and </p> </li> <li> <p>the EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">www.clinicaltrialsregister.eu</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011301-sec-0027"> <h4 class="title">Searching other resources</h4> <section id="CD011301-sec-0028"> <h5 class="title">References from included studies</h5> <p>We checked the bibliographies of included studies for further references to relevant trials. </p> </section> <section id="CD011301-sec-0029"> <h5 class="title">Unpublished literature</h5> <p>We contacted specialists in the field, authors of the included trials, and pharmaceutical companies, to request relevant unpublished data. </p> <p>We  handsearched the following plastic and dermatological conference proceedings for further references to relevant RCTs: </p> <p> <ul id="CD011301-list-0008"> <li> <p>AAD Annual Meeting (2013‐2016); and</p> </li> <li> <p>Brazilian Congress of Dermatologic Society (2013‐2016).</p> </li> </ul> </p> </section> <section id="CD011301-sec-0030"> <h5 class="title">Adverse events</h5> <p>We did not perform a separate search for adverse effects of botulinum toxin. However, we examined data on adverse effects from the included studies we identified. </p> </section> </section> </section> <section id="CD011301-sec-0031"> <h3 class="title" id="CD011301-sec-0031">Data collection and analysis</h3> <section id="CD011301-sec-0032"> <h4 class="title">Selection of studies</h4> <p>Two review authors (CPC and RG) independently assessed and selected studies. We checked the full text of studies for inclusion or exclusion. We recorded reasons for exclusion in the '<a href="./references#CD011301-sec-0819" title="">Characteristics of excluded studies</a>' tables in the review. </p> <p>We referred to a third review (CSC) in any case of disagreement.</p> </section> <section id="CD011301-sec-0033"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (CPC and RG) created, piloted, and managed data extraction forms. They independently extracted data from the full text of the included studies, and a third review author (RR) resolved any discrepancies. </p> <p>We considered the following data and inserted into the data extraction form:</p> <p> <ul id="CD011301-list-0009"> <li> <p>publication information (e.g. journal, year, and authors);</p> </li> <li> <p>study design, including details of randomisation methods and blinding of treatments;</p> </li> <li> <p>methodology, such as inclusion and exclusion criteria and risk of bias (e.g. selection, performance, detection, and attrition); </p> </li> <li> <p>population;</p> </li> <li> <p>outcome measures of the study (we will indicate where these are our prespecified outcomes for this review); </p> </li> <li> <p>dropouts; and</p> </li> <li> <p>treatment (e.g. total units, duration, and number of treatments).</p> </li> </ul> </p> </section> <section id="CD011301-sec-0034"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (CPC and RG) independently applied Cochrane's risk of bias tool (<a href="./references#CD011301-bbs2-0121" title="HigginsJPT , AltmanDG , Sterne JAC (editors).Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook.">Higgins 2017</a>). We referred to a third review author (RR) in any case of disagreement. </p> <p>We assessed the following domains to evaluate risk of bias (low, high, or unclear):</p> <p>(a) random sequence generation;<br/>(b) allocation concealment;<br/>(c) blinding (e.g. blinding of participants, personnel, and outcome assessment);<br/>(d) attrition (i.e. incomplete outcome reporting);<br/>(e) selective reporting bias; and<br/>(f) other risks of bias. </p> </section> <section id="CD011301-sec-0035"> <h4 class="title">Measures of treatment effect</h4> <p>Considering treatment effects with 95% confidence intervals (CIs), we reported dichotomous outcomes as risk ratios (RR) and continuous outcomes as standardised mean difference (SMD) when studies used different scales. In rare events (any major adverse event) we reported dichotomous outcomes as Peto odds ratio (OR), since when there is a low number of events, OR is similar to RR. </p> <p> <div class="table" id="CD011301-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Score scale</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Method</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assessment of outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Type of variable</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4‐point scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 = none</p> <p>1 = mild</p> <p>2 = moderate</p> <p>3 = severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean/median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ordinal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9‐point scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>+4 = complete improvement (100%)</p> <p>0 = no change</p> <p>‐4 = 100% worse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean/median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ordinal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant satisfaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 to 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FLO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age perception</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ordinal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FTLS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7‐point scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean/median</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ordinal</p> </td> </tr> </tbody> </table> </div> </p> <p>We considered an 'event' for a dichotomous variable (success) when the patients showed 2‐points of improvement in the wrinkles scale. </p> </section> <section id="CD011301-sec-0036"> <h4 class="title">Unit of analysis issues</h4> <p>We considered the individual participant as the unit of analysis. We also considered each side or region of the face as the unit of analysis for split‐face studies, and described these studies narratively. </p> </section> <section id="CD011301-sec-0037"> <h4 class="title">Dealing with missing data</h4> <p>In case of missing data, we contacted study authors for more information. When the authors did not respond satisfactorily, we did not use the study for quantitative analysis, and we used intention‐to‐treat (ITT) analysis. We utilised dropouts as ITT analysis. </p> <p>We considered outcome data complete if the analysis included more than 80% of participants. We applied these criteria to all trials. When data were missing and the study was not included in a meta‐analysis, we discussed it in the text of this review. </p> </section> <section id="CD011301-sec-0038"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to quantify the level of statistical heterogeneity for each outcome. According to the I² statistic, we classified heterogeneity as follows: low heterogeneity (0% to 25%), moderate (25% to 75%), or substantial (more than 75%) as suggested in the <i>Cochrane Handbook for Systematic Review of Interventions</i> (<a href="./references#CD011301-bbs2-0122" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s).Cochrane Handbook for Systematic Review of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Higgins 2020</a>). </p> <p>We performed a random‐effect meta‐analysis by default, since regardless of statistical heterogeneity, we expected a significant clinical and/or methodological heterogeneity among included RCTs. </p> </section> <section id="CD011301-sec-0039"> <h4 class="title">Assessment of reporting biases</h4> <p>We contacted study authors to clarify non‐reporting of their outcomes. We did not perform a funnel plot because there was less than 10 papers in each analysis. </p> </section> <section id="CD011301-sec-0040"> <h4 class="title">Data synthesis</h4> <p>We summarised data using the Review Manager 5 software (<a href="./references#CD011301-bbs2-0129" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan 5.4).Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">RevMan</a>). When pooling data was not appropriate or possible (lack of data), we described the results in the main text. </p> </section> <section id="CD011301-sec-0041"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned the following subgroups analyses:</p> <p> <ul id="CD011301-list-0010"> <li> <p>age;</p> </li> <li> <p>gender;</p> </li> <li> <p>ethnic group;</p> </li> <li> <p>type of wrinkles: static or dynamic; and</p> </li> <li> <p>total doses per area of the face (e.g. glabellar, forehead, periorbicular).</p> </li> </ul> </p> <p>We also planned to undertaken sensitivity analyses by removing studies at high risk of bias. </p> <p>However, we did not carry out any subgroup analyses due to lack of available data.</p> </section> <section id="CD011301-sec-0042"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analysis considering studies with high risk of bias (allocation) and comparing the results with the overall findings. However, due to the low number of included studies in quantitative synthesis, we deemed this analysis inappropriate. </p> </section> <section id="CD011301-sec-0043"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created six summary of findings tables for the comparisons below (chosen based on clinical relevance considering type of toxin and face region): </p> <p> <ol id="CD011301-list-0011"> <li> <p>OnabotulinumtoxinA 20 units compared to placebo, one cycle of treatment in glabellar lines for facial wrinkles </p> </li> <li> <p>AbobotulinumtoxinA 50 units compared to placebo, one cycle of treatment in glabellar lines for facial wrinkles </p> </li> <li> <p>IncobotulinumtoxinA 20 units compared to placebo, one cycle of treatment in glabellar lines for facial wrinkles </p> </li> <li> <p>AbobotulinumtoxinA 50 units compared to onabotulinumtoxinA 20 units, one cycle of treatment in glabellar lines for facial wrinkles </p> </li> <li> <p>OnabotulinumtoxinA 24 units compared to incobotulinumtoxinA 24 units, one cycle of treatment in glabellar lines for facial wrinkles </p> </li> <li> <p>DaxibotulinumtoxinA 40 units compared to placebo, one cycle of treatment in glabellar lines for facial wrinkles </p> </li> </ol> </p> <p>We included both our primary and secondary outcomes in each table. For participant‐ and physician‐assessment of success we chose the time point closest to four weeks to include in our summary of findings tables. For the major adverse events and treatment duration, we used the longer time point reported. We used the five GRADE criteria (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the evidence related with each prespecified primary outcomes. We used methods described in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011301-bbs2-0122" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s).Cochrane Handbook for Systematic Review of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Higgins 2020</a>), and used the platform GRADEpro GDT (<a href="./references#CD011301-bbs2-0120" title="McMaster University (developed by Evidence Prime)GRADEpro GDT.Hamilton (ON): McMaster University (developed by Evidence Prime), 2021. Available at gradepro.org.">GRADEpro GDT</a>). We explained each decisions for down‐ or upgrading the criteria using footnotes, and added comments where necessary. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011301-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011301-sec-0044"></div> <section id="CD011301-sec-0045"> <h3 class="title">Description of studies</h3> <section id="CD011301-sec-0046"> <h4 class="title">Results of the search</h4> <p>The <a href="#CD011301-sec-0025">Electronic searches</a> retrieved 441 records and our handsearches retrieved 15 further records. We had a total of 456 records. After removing duplicates, 425 records were screened. We excluded 325 records based on titles and abstracts. We obtained the full text of the remaining 100 records for further scrutiny against our inclusion criteria. We excluded 11 studies (see <a href="./references#CD011301-sec-0819" title="">Characteristics of excluded studies</a>).  Twenty‐four studies are awaiting classification (see <a href="./references#CD011301-sec-0820" title="">Characteristics of studies awaiting classification</a> ). We included 65 studies reported in 75  references (see <a href="./references#CD011301-sec-0818" title="">Characteristics of included studies</a>). Twenty‐seven studies were included in the quantitative synthesis. </p> <p>For a further description of our screening process, see the study flow diagram <a href="#CD011301-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD011301-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011301-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011301-sec-0047"> <h4 class="title">Included studies</h4> <p>We included 65 studies (reported in 75 references), which randomised a total of 14,919 participants. Four were published only as abstracts (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>; <a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>), and 61 were published as full text (see <a href="./references#CD011301-sec-0818" title="">Characteristics of included studies</a>). </p> <p>We sent 21 emails to the authors of the following studies asking for additional data (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>). </p> <p>We did not receive any answer from authors of 12 studies (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>). </p> <p>Nine authors answered our emails.</p> <p> <ul id="CD011301-list-0012"> <li> <p>Four authors answered that data were no longer available because the studies were carried out too long ago (<a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>). </p> </li> <li> <p><a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a> provided a SPSS file, but did not provide any information to clarify our questions. </p> </li> <li> <p><a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a> provided the full paper, but there was no additional information about missing data. </p> </li> <li> <p><a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a> answered the following: “The assessment for primary response was at maximal contraction” </p> </li> <li> <p><a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a> clarified a discrepancy confirming that 21U was the correct dose used. </p> </li> <li> <p><a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a> answered the following: “Concerning the data. This was an IPSEN initiated trial. All analysis was done through IPSEN. I would suggest that you contact IPSEN directly”. </p> </li> </ul> </p> <p>Despite our best efforts, we could not find a validated email for the authors of two studies (<a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>). </p> <section id="CD011301-sec-0048"> <h5 class="title">Design</h5> <p>Five studies were split‐face design (<a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>). The remaining studies were randomised controlled trials (RCTs) with parallel design. </p> </section> <section id="CD011301-sec-0049"> <h5 class="title">Setting</h5> <p>In total, 51 RCTs were multicentre studies.</p> <p> <ul id="CD011301-list-0013"> <li> <p>USA (n = 8) (<a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>) </p> </li> <li> <p>Canada (n = 3) (<a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>) </p> </li> <li> <p>Europe, single country (n = 4) (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>) </p> </li> <li> <p>Europe, two or more countries (n = 5) (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>) </p> </li> <li> <p>North America, two or more countries (n = 8) (<a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>) </p> </li> <li> <p>Transcontinental (n = 8) (<a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>; <a href="./references#CD011301-bbs2-0051" title="OgilvieP , RivkinAZ , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from phase 3 double-blind study. Dermatologic Surgery2019;45(5):689-99. [CENTRAL: CN-01941030] RivkinAZ , OgilvieP , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study. Dermatologic Surgery2020;46(1):50-60. [PMID: 30829771]">Ogilvie 2019</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>) </p> </li> <li> <p>Asia, single country (n = 11) (<a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>; <a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>; <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>) </p> </li> <li> <p>South America (n = 1) (<a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a>) </p> </li> <li> <p>No information (n = 3) (<a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>) </p> </li> </ul> </p> <p>Eight RCTs were developed in a single centre: USA (<a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>), Canada (<a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>), Brazil (<a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>), Austria (<a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>). </p> <p>Seven studies did not provide any information about setting (<a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0028" title="FagienS , CoxSE , FinnJC , WerschlerWP , KowalskiJW .Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2007;33(1 Spec No):S2-9. [CENTRAL: CN-00575067] [PMID: 17241410]">Fagien 2007a</a>; <a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>; <a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>; <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>). </p> <p>All patients were outpatients (private office or day clinic).</p> </section> <section id="CD011301-sec-0050"> <h5 class="title">Study duration</h5> <p>The mean duration of studies was 20.75 weeks ± 11.7 (<a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>) (range 1 to 52 weeks) (<a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>). The interval between treatments was 24 weeks (six months). Most of the studies analysed the effects from 16 weeks (when the muscle begins to work again) to 24 weeks (the new treatment interval). </p> </section> <section id="CD011301-sec-0051"> <h5 class="title">Funding</h5> <p>Most of the studies were reported to have received pharmaceutical industry funding.</p> </section> <section id="CD011301-sec-0052"> <h5 class="title">Participants</h5> <p>The total study population was 14,919 participants. Participants of <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a> partially overlapped with participants of <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>. </p> <section id="CD011301-sec-0053"> <h6 class="title">Age</h6> <p>Apart from four studies, which reported age by range (<a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=z1301221327000886719876557919808&amp;versionPK1=z1604161844186422445645530536107&amp;versionPK2=z1606221818100373919094761429442#STD-Ascher-2015" target="_blank">Ascher 2015</a>; <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="https://archie.cochrane.org/sections/documents/viewDiff?documentPK=z1301221327000886719876557919808&amp;versionPK1=z1604161844186422445645530536107&amp;versionPK2=z1606221818100373919094761429442#STD-Carruthers-A-2003" target="_blank">Carruthers A 2003</a>;<a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a> <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>), the majority of the studies (58 studies) reported mean age either by treatment group or by total study population. The mean age of study participants ranged from 18 to 65 years in the majority of studies. Two studies did not report the age, gender, or other demographic data (<a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>; <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>). </p> </section> <section id="CD011301-sec-0054"> <h6 class="title">Gender</h6> <p>Seven studies did not provide any information about gender (<a href="./references#CD011301-bbs2-0028" title="FagienS , CoxSE , FinnJC , WerschlerWP , KowalskiJW .Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2007;33(1 Spec No):S2-9. [CENTRAL: CN-00575067] [PMID: 17241410]">Fagien 2007a</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>; <a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>). Ten studies included only female participants (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>; <a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>). One paper studied only men (<a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>). </p> <p>The majority of the studies included more than 80% female participants (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>; <a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>; <a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>;  <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0051" title="OgilvieP , RivkinAZ , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from phase 3 double-blind study. Dermatologic Surgery2019;45(5):689-99. [CENTRAL: CN-01941030] RivkinAZ , OgilvieP , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study. Dermatologic Surgery2020;46(1):50-60. [PMID: 30829771]">Ogilvie 2019</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>; <a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>; <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>). </p> </section> <section id="CD011301-sec-0055"> <h6 class="title">Facial region</h6> <p> <ul id="CD011301-list-0014"> <li> <p>Glabellar lines (GL): 43 RCTs (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>; <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a>; <a href="./references#CD011301-bbs2-0028" title="FagienS , CoxSE , FinnJC , WerschlerWP , KowalskiJW .Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2007;33(1 Spec No):S2-9. [CENTRAL: CN-00575067] [PMID: 17241410]">Fagien 2007a</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>; <a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>; <a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>; <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>; <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>). </p> </li> <li> <p>Crow's feet lines: 7 RCTs (<a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>). </p> </li> <li> <p>Perioral lines: 2 RCTs (<a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>). </p> </li> <li> <p>Forehead line: 2 RCTs (<a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>). </p> </li> <li> <p>Forehead lines and crow's feet line: one RCT (<a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>). </p> </li> <li> <p>Upper lines (glabellar lines, crow's feet lines, forehead lines): 3 RCTs (<a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>). </p> </li> <li> <p>Forehead lines and glabellar lines: 3 RCTs (<a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0051" title="OgilvieP , RivkinAZ , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from phase 3 double-blind study. Dermatologic Surgery2019;45(5):689-99. [CENTRAL: CN-01941030] RivkinAZ , OgilvieP , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study. Dermatologic Surgery2020;46(1):50-60. [PMID: 30829771]">Ogilvie 2019</a>). </p> </li> <li> <p>Crow's feet lines and glabellar lines: 3 RCTs (<a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>). </p> </li> <li> <p>Full face: one RCT (<a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>). </p> </li> </ul> </p> </section> <section id="CD011301-sec-0056"> <h6 class="title">Severity of the wrinkles</h6> <p>Most of the papers which treated glabellar lines included moderate‐to‐severe glabellar lines according to Facial Wrinkle Scale score or Glabellar Lines Severity Scale. The others regions did not present details about severity. </p> </section> <section id="CD011301-sec-0057"> <h6 class="title">Sample size</h6> <p>The sample size of the studies ranged from 56 to 917 participants (mean = 230.14).</p> </section> </section> <section id="CD011301-sec-0058"> <h5 class="title">Unit of analysis</h5> <p>Five studies were split‐face design (<a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>). In the remaining studies, the unit of analysis was the individual. In meta‐analysis we only compared parallel study groups. </p> </section> <section id="CD011301-sec-0059"> <h5 class="title">Intervention</h5> <section id="CD011301-sec-0060"> <h6 class="title">Types of botulinum toxin type A (BontA)</h6> <p>11 commercial types of BontA (produced from different strains of BontA with unique biological behaviour) were addressed in RCTS: </p> <p> <ul id="CD011301-list-0015"> <li> <p>Botox®, Vistabel®, Vistabex® (Allergan ‐ onabotulinumtoxinA (<a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>; <a href="./references#CD011301-bbs2-0028" title="FagienS , CoxSE , FinnJC , WerschlerWP , KowalskiJW .Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2007;33(1 Spec No):S2-9. [CENTRAL: CN-00575067] [PMID: 17241410]">Fagien 2007a</a>; <a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0051" title="OgilvieP , RivkinAZ , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from phase 3 double-blind study. Dermatologic Surgery2019;45(5):689-99. [CENTRAL: CN-01941030] RivkinAZ , OgilvieP , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study. Dermatologic Surgery2020;46(1):50-60. [PMID: 30829771]">Ogilvie 2019</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>; <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>;  <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>) </p> </li> <li> <p>Dysport® (Ipsen); Azzulure® (Galderma ‐ abobotulinumtoxinA (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>) </p> </li> <li> <p>Xeomeen®, Xeomin®, Bocouture® (Merz Aesthetics ‐ incobotulinumtoxinA (<a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>) </p> </li> <li> <p>HBTX‐A (<a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>) </p> </li> <li> <p>Neuronox®, Botulift®, Siax®, Medytox® (Medytox, Inc., Cheonwon‐gun, Republic of Korea) (<a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>; <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>) </p> </li> <li> <p>Liquid BontA (MT10109L) (<a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>) </p> </li> <li> <p>DaxibotulinumtoxinA (DWP450) (Daewoong Pharmaceutical, Seoul, Korea) (<a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>) </p> </li> <li> <p>Liquid BontA (Ipsen) (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>) </p> </li> <li> <p>CBFC26 (SNUH) (<a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>) </p> </li> <li> <p>Prosigne® (Lanzhou Institute of Biological Products) (<a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a>) </p> </li> <li> <p>PrabotulinumtoxinA (<a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0061"> <h6 class="title">Number of cycles</h6> <p> <ul id="CD011301-list-0016"> <li> <p>One single cycle of treatment: 54 RCTs (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>; <a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>; <a href="./references#CD011301-bbs2-0028" title="FagienS , CoxSE , FinnJC , WerschlerWP , KowalskiJW .Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2007;33(1 Spec No):S2-9. [CENTRAL: CN-00575067] [PMID: 17241410]">Fagien 2007a</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>; <a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>; <a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>; <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a> ; <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>) </p> </li> <li> <p>Two cycles of treatment: 3 RCTs (<a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0051" title="OgilvieP , RivkinAZ , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from phase 3 double-blind study. Dermatologic Surgery2019;45(5):689-99. [CENTRAL: CN-01941030] RivkinAZ , OgilvieP , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study. Dermatologic Surgery2020;46(1):50-60. [PMID: 30829771]">Ogilvie 2019</a>) </p> </li> <li> <p>Three or more cycles treatments: 8 RCTs (<a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>; <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0062"> <h6 class="title">Dose of the treatment</h6> <p>The dose ranged according to the facial region and BontA's brand.</p> <section id="CD011301-sec-0063"> <p><b>Glabellar lines</b></p> <p> <ul id="CD011301-list-0017"> <li> <p>OnabotulinumtoxinA, from 8 U to 80 U (<a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>;  <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>; <a href="./references#CD011301-bbs2-0028" title="FagienS , CoxSE , FinnJC , WerschlerWP , KowalskiJW .Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2007;33(1 Spec No):S2-9. [CENTRAL: CN-00575067] [PMID: 17241410]">Fagien 2007a</a>; <a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0051" title="OgilvieP , RivkinAZ , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from phase 3 double-blind study. Dermatologic Surgery2019;45(5):689-99. [CENTRAL: CN-01941030] RivkinAZ , OgilvieP , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study. Dermatologic Surgery2020;46(1):50-60. [PMID: 30829771]">Ogilvie 2019</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>; <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>) </p> </li> <li> <p>AbobotulinumtoxinA, from 20 U to 75 U (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>;  <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>) </p> </li> <li> <p>IncobotulinumtoxinA, from 20 U to 24 U (<a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>) </p> </li> <li> <p>HBTX‐A, 20U (<a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>) </p> </li> <li> <p>NewBontA [Medytox®], 20 U (<a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>) </p> </li> <li> <p>NewBontA [Neuronox®], 20 U (<a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>) </p> </li> <li> <p>DaxibotulinumtoxinA (DWP450), 20 U to 60 U (<a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>) </p> </li> <li> <p>MT10109L, 20 U (<a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>) </p> </li> <li> <p>LiquidBontA 20 U to 75 U (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>) </p> </li> <li> <p>CBFC26, 20 U (<a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>) </p> </li> <li> <p>NewBontA [Prosigne®], 20 U (<a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a>) </p> </li> <li> <p>PrabotulinumtoxinA 20U to 60 U (<a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0064"> <p><b>Forehead lines</b></p> <p> <ul id="CD011301-list-0018"> <li> <p>OnabotulinumtoxinA, 10U to 48 U (<a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>) </p> </li> <li> <p>IncobotulinumtoxinA, 10 U to 20 U (<a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0065"> <p><b>Crow's feet lines</b></p> <p> <ul id="CD011301-list-0019"> <li> <p>OnabotulinumtoxinA 7.5 U to 24 U (<a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>) </p> </li> <li> <p>AbobotulinumtoxinA 30 U (<a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>) </p> </li> <li> <p>IncobotulinumtoxinA 7.5 U to 12 U (<a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>) </p> </li> <li> <p>Neuronox® 24U‐ (<a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0066"> <p><b>Perioral lines</b></p> <p> <ul id="CD011301-list-0020"> <li> <p>OnabotulinumtoxinA, from7.5 U to 12 U (<a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>) </p> </li> </ul> </p> </section> </section> <section id="CD011301-sec-0067"> <h6 class="title">Distribution of the injection points</h6> <p>The distribution of all injections points followed the American and European consensus.</p> <p> <ul id="CD011301-list-0021"> <li> <p>Glabellar lines‐ three to seven intramuscular injections points (procerus muscle, corrugator supercilii muscle, orbicularis oculi, muscle depressor supercilii muscle) (<a href="#CD011301-fig-0002">Figure 2</a>) </p> </li> <li> <p>Forehead lines‐ four to eight points of intramuscular injection along the frontal muscle wrinkles with a 2.0 cm above the eyebrows; and </p> </li> <li> <p>Crow's feet‐ one injection at least 1.5 cm to 2.0 cm from lateral canthus, one injection in the orbital rim next to the eyebrow caudal extremity, and one injection near the zygomatic process in the orbital rim, the other injections along the crow’s feet lines laterally to the previous injections per side (<a href="./references#CD011301-bbs2-0106" title="CarruthersJD , GlogauRG , BlitzerAS , Facial Aesthetics Consensus Group Faculty.Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies-consensus recommendations. Plastic &amp; Reconstructive Surgery2008;121(5 Suppl):5S-30S. [MEDLINE: 18449026]">Carruthers 2008a</a>; <a href="./references#CD011301-bbs2-0103" title="AscherB , TalaricoS , CassutoD , EscobarS , HexselD , JaenP , et al.International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit) – Part 1: upper facial wrinkles. Journal of the European Academy of Dermatology &amp; Venereology2010;24(11):1278-84. [MEDLINE: 20337830]">Ascher 2010</a>; <a href="./references#CD011301-bbs2-0133" title="SundaramH , SignoriniM , LiewnS , Trindade de AlmeidaAR , WuY , BrazAV , et al.Global aesthetics consensus: botulinum toxin type A—evidence-based review emerging concepts, and consensus recommendations for aesthetic use, including updates on complications. Plastic and Reconstructive Surgery2016;137(3):518e-29e. [PMID: 26910696]">Sundaram 2016</a>) </p> </li> <li> <p>Perioral lines‐ four injections, two symmetric injections per lip (lower and upper lip) (<a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>) </p> </li> </ul> </p> <div class="figure" id="CD011301-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Illustration of injection sites in glabellar region. Copyright [2020] [Cristina Pires Camargo]Reproduced with permission" data-id="CD011301-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-FIG-02.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Illustration of injection sites in glabellar region. Copyright [2020] [Cristina Pires Camargo]Reproduced with permission </p> </div> </div> </div> </section> <section id="CD011301-sec-0068"> <h6 class="title">Comparisons</h6> <p><i>BontA versus placebo, at least one cycle of treatment (36 studies); BontA at different doses, one cycle of treatment (21 studies); BontA versus placebo, at least two cycles of treatment (11 studies); BontA versus facial cream (one study); BontA associated to fillers (2 studies)</i> </p> <p>The studies tested the effect of different types of BontA in facial wrinkles through the following comparisons. </p> <section id="CD011301-sec-0069"> <p><b>OnabotulinumtoxinA versus placebo</b></p> <p> <ul id="CD011301-list-0022"> <li> <p>OnabotulinumtoxinA versus placebo, glabellar lines, one cycle of treatment<b>,</b> both genders (<a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0028" title="FagienS , CoxSE , FinnJC , WerschlerWP , KowalskiJW .Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2007;33(1 Spec No):S2-9. [CENTRAL: CN-00575067] [PMID: 17241410]">Fagien 2007a</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>) </p> </li> <li> <p>OnabotulinumtoxinA versus placebo, crow's feet lines, one cycle of treatment, both genders (<a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>) </p> </li> <li> <p>OnabotulinumtoxinA versus placebo, glabellar lines, and crow's feet lines, one cycle of treatment, both genders (<a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>) </p> </li> <li> <p>OnabotulinumtoxinA versus placebo, glabellar lines, forehead lines, and crow's feet lines, one cycle of treatment, both genders (<a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>) </p> </li> <li> <p>OnabotulinumtoxinA versus placebo, glabellar lines, five cycles of treatment (<a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0070"> <p><b>OnabotulinumtoxinA, different doses</b></p> <p> <ul id="CD011301-list-0023"> <li> <p>OnabotulinumtoxinA, different doses, one cycle of treatment, glabellar lines in men (<a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>) </p> </li> <li> <p>OnabotulinumtoxinA, different doses, one cycle of treatment, glabellar lines in women (<a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>) </p> </li> <li> <p>OnabotulinumtoxinA, different doses, one cycle of treatment, upper wrinkles (forehead lines, glabellar lines, crow's feet lines) in women (<a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>) </p> </li> <li> <p>OnabotulinumtoxinA, different doses, one cycle of treatment, forehead lines, dose‐ranging in women (<a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>) </p> </li> <li> <p>OnabotulinumtoxinA, different doses, one cycle of treatment, forehead lines and glabella lines, dose‐ranging, both genders (<a href="./references#CD011301-bbs2-0051" title="OgilvieP , RivkinAZ , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from phase 3 double-blind study. Dermatologic Surgery2019;45(5):689-99. [CENTRAL: CN-01941030] RivkinAZ , OgilvieP , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study. Dermatologic Surgery2020;46(1):50-60. [PMID: 30829771]">Ogilvie 2019</a>) </p> </li> <li> <p>OnabotulinumtoxinA, different doses, one cycle of treatment, perioral lines in women (<a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0071"> <p><b>OnabotulinumtoxinA versus placebo</b></p> <p> <ul id="CD011301-list-0024"> <li> <p>OnabotulinumtoxinA versus placebo, glabellar lines, two‐three cycles of treatment, both genders (<a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>) </p> </li> <li> <p>OnabotulinumtoxinA versus placebo, glabellar lines and crow's feet lines, two cycles of treatment, both genders (<a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>) </p> </li> <li> <p>OnabotulinumtoxinA versus placebo, glabellar lines, five cycles of treatment, both genders (<a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>). We only use double‐blind data. </p> </li> </ul> </p> </section> <section id="CD011301-sec-0072"> <p><b>AbobotulinumtoxinA versus placebo</b></p> <p> <ul id="CD011301-list-0025"> <li> <p>AbobotulinumtoxinA versus placebo, one cycle of treatment, glabellar lines (<a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>) </p> </li> <li> <p>AbobotulinumtoxinA versus placebo, one cycle of treatment, glabellar lines, both gender<b> </b>(<a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0073"> <p><b>AbobotulinumtoxinA, different doses, versus placebo</b></p> <p> <ul id="CD011301-list-0026"> <li> <p>AbobotulinumtoxinA versus placebo, different doses, glabellar lines, both genders (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>) </p> </li> <li> <p>AbobotulinumtoxinA versus placebo, different doses, crow's feet, both genders (<a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>) </p> </li> <li> <p>AbobotulinumtoxinA versus placebo, multiple cycles of treatment, glabellar lines, both genders (<a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>) </p> </li> <li> <p>AbobotulinumtoxinA versus placebo, two cycles of treatment, glabellar lines, both genders (<a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>) </p> </li> <li> <p>AbobotulinumtoxinA versus placebo, three cycles of treatment, glabellar lines, both genders (<a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0074"> <p><b>AbobotulinumtoxinA, different doses</b></p> <p> <ul id="CD011301-list-0027"> <li> <p>AbobotulinumtoxinA, three different doses in full‐face treatment, both genders (<a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0075"> <p><b>IncobotulinumtoxinA versus placebo</b></p> <p> <ul id="CD011301-list-0028"> <li> <p>IncobotulinumtoxinA versus placebo, glabellar lines, both genders (<a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>) </p> </li> <li> <p>IncobotulinumtoxinA versus placebo, forehead lines, glabellar lines, and crow's feet lines, both genders (<a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0076"> <p><b>HBTX‐A versus placebo</b></p> <p> <ul id="CD011301-list-0029"> <li> <p>HBTX‐A versus placebo, glabellar lines, one cycle of treatment, both genders (<a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0077"> <p><b>Neuronox® versus placebo</b></p> <p> <ul id="CD011301-list-0030"> <li> <p>Neuronox® versus placebo, crow's feet lines, one cycle of treatment, both genders (<a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0078"> <p><b>Liquid BontA (Ipsen®), different doses, versus placebo</b></p> <p> <ul id="CD011301-list-0031"> <li> <p>Liquid BontA (Ipsen®) different doses versus placebo versus abobotulinumtoxinA, glabellar lines, both genders (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>) </p> </li> <li> <p>Liquid BontA (Ipsen®) versus placebo, glabellar lines, both genders (<a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0079"> <p><b>DaxibotulinumtoxinA versus placebo</b></p> <p> <ul id="CD011301-list-0032"> <li> <p>DaxibotulinumtoxinA versus placebo from one cycle to 5 cycles of treatment in crow's feet lines, both genders (<a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>) </p> </li> <li> <p>DaxibotulinumtoxinA, dose‐ranging, versus onabotulinumtoxinA, one cycle of treatment, both genders (<a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0080"> <p><b>PrabotulinimtoxinA versus placebo</b></p> <p> <ul id="CD011301-list-0033"> <li> <p>PrabotulinimtoxinA versus placebo, one cycle of treatment in glabellar lines, both genders (<a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0081"> <p><b>BontA versus active control</b></p> <p> <ul id="CD011301-list-0034"> <li> <p>OnabotulinumtoxinA versus AbobotulinumtoxinA, one cycle of treatment, glabellar lines and forehead lines, both genders (<a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>) </p> </li> <li> <p>OnabotulinumtoxinA versus AbobotulinumtoxinA, one cycle of treatment, glabellar lines, both genders (<a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>) </p> </li> <li> <p>OnabotulinumtoxinA versus AbobotulinumtoxinA, one cycle of treatment, glabellar lines, crow's feet lines, and forehead lines, both genders (<a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>) </p> </li> <li> <p>OnabotulinumtoxinA versus AbobotulinumtoxinA, one cycle of treatment, in crow's feet lines, both genders (<a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>) </p> </li> <li> <p>OnabotulinumtoxinA versus IncobotulinumtoxinA, one cycle of treatment, glabellar lines, both genders (<a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>) </p> </li> <li> <p>OnabotulinumtoxinA versus IncobotulinumtoxinA, one cycle of treatment, crow's feet lines, both genders (<a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>) </p> </li> <li> <p>OnabotulinumtoxinA versus AbobotulinumtoxinA versus IncobotulinumtoxinA, one cycle of treatment, glabellar lines, both genders (<a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>) </p> </li> <li> <p>Neuronox® versus onabotulinumtoxinA, one cycle of treatment, glabellar lines, both genders (<a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>) </p> </li> <li> <p>Liquid BontA (MT10109L) versus onabotulinumtoxinA, one cycle of treatment, glabellar lines, both genders (<a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>) </p> </li> <li> <p>New BontA (Medytox®) versus onabotulinumtoxinA, one cycle of treatment, glabellar lines, both genders (<a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>) </p> </li> <li> <p>DaxibotulinumtoxinA versus onabotulinumtoxinA, one cycle of treatment, glabellar lines, both genders (<a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>) </p> </li> <li> <p>CBFC26 versus onabotulinumtoxinA, one cycle of treatment, glabellar lines, both genders (<a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>) </p> </li> <li> <p>Liquid BontA (Ipsen®) different doses versus AbobotulinumtoxinA, glabellar lines, both genders (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>) </p> </li> <li> <p>PrabotulinimtoxinA versus placebo, one cycle of treatment in glabellar lines, both genders (<a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>) </p> </li> <li> <p>PrabotulinimtoxinA versus onabotulinumtoxinA, one cycle of treatment in glabellar lines, both genders (<a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0082"> <p><b>BontA associated with creams</b></p> <p> <ul id="CD011301-list-0035"> <li> <p>OnabotulinumtoxinA, one cycle of treatment, versus facial cream in glabellar lines in women (<a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>) </p> </li> </ul> </p> </section> <section id="CD011301-sec-0083"> <p><b>BontA associated with fillers</b></p> <p> <ul id="CD011301-list-0036"> <li> <p>OnabotulinumtoxinA associated with fillers (collagen), one cycle of treatment, versus onabotulinumtoxinA, glabellar lines (<a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>) </p> </li> <li> <p>OnabotulinumtoxinA associated with collagen, one cycle of treatment, versus collagen, glabellar lines, no information about genders (<a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>) </p> </li> <li> <p>OnabotulinumtoxinA associated with Hyaluronic acid, one cycle of treatment, versus onabotulinumtoxinA, lips and perioral lines, in women (<a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>) </p> </li> <li> <p>OnabotulinumtoxinA associated with Hyaluronic acid, one cycle of treatment, versus Hyaluronic acid, lips and perioral lines, in women (<a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>) </p> </li> </ul> </p> </section> </section> </section> <section id="CD011301-sec-0084"> <h5 class="title">Outcomes</h5> <section id="CD011301-sec-0085"> <h6 class="title">Primary outcomes</h6> <p> <ul id="CD011301-list-0037"> <li> <p>Thirty‐five studies evaluated participant assessment of success by analysing scores and scales (the responder rate at maximum contraction): <a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>; <a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0051" title="OgilvieP , RivkinAZ , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from phase 3 double-blind study. Dermatologic Surgery2019;45(5):689-99. [CENTRAL: CN-01941030] RivkinAZ , OgilvieP , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study. Dermatologic Surgery2020;46(1):50-60. [PMID: 30829771]">Ogilvie 2019</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>; <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>. The most common scales used by studies were Facial Wrinkle Scale and 5‐Point Scale. </p> </li> <li> <p>Forty‐six studies evaluated any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus): <a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>; <a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>; <a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a> <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>; <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>; <a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>; <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>. </p> </li> </ul> </p> </section> <section id="CD011301-sec-0086"> <h6 class="title">Secondary outcomes</h6> <p> <ul id="CD011301-list-0038"> <li> <p>Forty‐nine studies evaluated an assessment of the physician assessment of success by analysing scores and scales (responder rate at maximum contraction): <a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>; <a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>; <a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a> <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>; <a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>; <a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>; <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>;; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>; <a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>; <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>. The most common scale used by studies were Facial Wrinkle Scale and 5‐Point Scale. </p> </li> <li> <p>Fifty‐one studies evaluated the occurrence of any adverse event: <a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>; <a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>; <a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>; <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>; <a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>; <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>. </p> </li> <li> <p>Twenty‐one studies evaluated the duration of treatment effect (weeks): <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>) </p> </li> <li> <p>One RCT (<a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>) evaluated only HBTX‐A duration in days. </p> </li> </ul> </p> </section> </section> </section> <section id="CD011301-sec-0087"> <h4 class="title">Excluded studies</h4> <p>We excluded 11 studies. Four studies were not randomised clinical trials (<a href="./references#CD011301-bbs2-0068" title="HexselD , CartierH , HedénP , DelmarH , BergentzP , CamozzatoF , et al.Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment of upper facial lines. Dermatologic Surgery2018;44(12):1555-64. [DOI: 10.1097/DSS.0000000000001679]">Hexsel 2018</a>; <a href="./references#CD011301-bbs2-0069" title="MahmoudBH , OzogD , BurnettC , CohenJL .Prospective randomized split-face comparative study between topical botulinum toxin A surface application and local injection for crow's feet. Dermatologic Surgery2016;42(4):554-6. [CENTRAL: CN-01154179] ">Mahmoud 2016</a>; <a href="./references#CD011301-bbs2-0074" title="RzanyB , FlynnTC , SchlobeA , HeinzM , HarringtonL .Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(1 Pt 1):95-103. [CENTRAL: CN-00841632] ">Rzany 2013</a>; <a href="./references#CD011301-bbs2-0066" title="2014-003770-16.A prospective, open-label, multicenter, repeat-dose trial to investigate the safety and efficacy of NT 201 (incobotulinumtoxinA) in the combined treatment of upper facial lines (horizontal forehead lines, glabellar frown lines, and lateral periorbital lines). www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003770-16 (first received 22 January 2015). ">2014‐003770‐16</a>). Five studies analysed interventions outside the scope of this review (<a href="./references#CD011301-bbs2-0067" title="CartierH , HedénP , DelmarH , BergentzP , SkoglundC , EdwartzC , et al.Repeated full-face aesthetic combination treatment with abobotulinumtoxinA, hyaluronic acid filler, and skin-boosting hyaluronic acid after monotherapy with abobotulinumtoxinA or hyaluronic acid filler. Dermatologic Surgery2020;46(4):475-82. ">Cartier 2020</a>; <a href="./references#CD011301-bbs2-0072" title="NCT02297516.Safety and efficacy of azzalure/dysport, restylane/emervel filler and restylane skinbooster treatment. clinicaltrials.gov/ct2/show/NCT02297516 (first received 21 November 2014). ">NCT02297516</a>; <a href="./references#CD011301-bbs2-0073" title="PungaAR , AlimohammadiM , FagrellD , NybergF , ReesD , WongC .A randomized, comparative study to evaluate the efficacy and safety of two injection volumes of abobotulinumtoxinA in treatment of glabellar lines. Dermatologic Surgery2016;42(8):967-76. [CENTRAL: CN-01342684] ">Punga 2016</a>; <a href="./references#CD011301-bbs2-0075" title="WilsonAJ , ChangB , TaglientiAJ , ChinBC , ChangCS , FolsomN , et al.Quantitative analysis of onabotulinumtoxinA, abobotulinumtoxinA, and incobotulinumtoxinA: a randomized, double-blind, prospective clinical trial of comparative dynamic strain reduction. Plastic and Reconstructive Surgery2016;137(5):1423-33. [CENTRAL: CN-01260494] ">Wilson 2016</a>; <a href="./references#CD011301-bbs2-0076" title="ZhangW , XieY , LiuW , LeiJ , LiuY .Combination therapy of botulinum toxin type A and hyaluronic acid filler for facial rejuvenation. International Journal of Clinical and Experimental Medicine2018;11(5):5033-8. [CENTRAL: CN-01920192] ">Zhang 2018</a>). Two studies ended when the company involved (Johnson &amp; Johnson) changed their plans to produce the BontA (<a href="./references#CD011301-bbs2-0070" title="NCT00752050.Safety and efficacy study of repeat treatment with PurTox® botulinum toxin type A for frown lines between the eyebrows (PT-03b). clinicaltrials.gov/ct2/show/NCT00752050 (first received 15 September 2008). ">NCT00752050</a>; <a href="./references#CD011301-bbs2-0071" title="NCT00752297.Safety and efficacy study of PurTox® botulinum toxin type A to treat frown lines between the eyebrows (PT-03a). clinicaltrials.gov/ct2/show/NCT00752297 (first received 15 September 2008). ">NCT00752297</a>) (see <a href="./references#CD011301-sec-0819" title="">Characteristics of excluded studies</a>). </p> <section id="CD011301-sec-0088"> <h5 class="title">Ongoing studies</h5> <p>No studies were identified as ongoing. </p> </section> <section id="CD011301-sec-0089"> <h5 class="title">Studies awaiting classification</h5> <p>We identified 24 studies awaiting classification. These studies were listed as completed on the clinical trial register, but no relevant results are available yet. See <a href="./references#CD011301-sec-0820" title="">Characteristics of studies awaiting classification</a> for more details.  </p> </section> </section> </section> <section id="CD011301-sec-0090"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias of each study is detailed in the <a href="https://archie.cochrane.org/sections/documents/view?document=14803123444398680857100902123348&amp;format=REVMAN#CHARACTERISTICS_OF_INCLUDED_STUDIES" target="_blank">Characteristics of included studies</a> table. <a href="#CD011301-fig-0003">Figure 3</a> and <a href="#CD011301-fig-0004">Figure 4</a> present the risk of bias summary along with review authors' judgements about each risk of bias item for an individual study. The overall risk of bias of the studies was unclear in all of them as we categorised at least one of the domains as having an unclear risk of bias. </p> <div class="figure" id="CD011301-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011301-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD011301-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011301-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD011301-sec-0091"> <h4 class="title">Allocation</h4> <section id="CD011301-sec-0092"> <h5 class="title">Random sequence generation</h5> <p>Twenty‐five studies described randomisation sequence adequately and were considered as low risk of bias. One study used 'tossing a coin' to generate random sequence (<a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>) and the remaining 24 studies used computer‐generated random numbers (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>;<a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a> ; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a>; <a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0051" title="OgilvieP , RivkinAZ , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from phase 3 double-blind study. Dermatologic Surgery2019;45(5):689-99. [CENTRAL: CN-01941030] RivkinAZ , OgilvieP , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study. Dermatologic Surgery2020;46(1):50-60. [PMID: 30829771]">Ogilvie 2019</a> ; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>). </p> <p>Thirty‐nine studies studies were reported as being randomised, but further description of sequence generation was not reported; hence, we classified these as unclear risk of bias (<a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>; <a href="./references#CD011301-bbs2-0028" title="FagienS , CoxSE , FinnJC , WerschlerWP , KowalskiJW .Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2007;33(1 Spec No):S2-9. [CENTRAL: CN-00575067] [PMID: 17241410]">Fagien 2007a</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>; <a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>;<a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>; <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>; <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>; <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>). </p> <p><a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a> added an amendment to a supplementary randomisation for the third cycle (C), but no further information about the method was reported. We considered this study as presenting high risk of bias. </p> </section> <section id="CD011301-sec-0093"> <h5 class="title">Allocation sequence concealment</h5> <p>Nine studies described allocation concealment and were considered as low risk of bias (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>; <a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0051" title="OgilvieP , RivkinAZ , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from phase 3 double-blind study. Dermatologic Surgery2019;45(5):689-99. [CENTRAL: CN-01941030] RivkinAZ , OgilvieP , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study. Dermatologic Surgery2020;46(1):50-60. [PMID: 30829771]">Ogilvie 2019</a>). </p> <p>Fifty‐six studies had reported allocation, but the authors did not show the methods used for maintaining the allocation concealment, and we considered them as presenting unclear risk of bias (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>; <a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>; <a href="./references#CD011301-bbs2-0028" title="FagienS , CoxSE , FinnJC , WerschlerWP , KowalskiJW .Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2007;33(1 Spec No):S2-9. [CENTRAL: CN-00575067] [PMID: 17241410]">Fagien 2007a</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>; <a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>; <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>; <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>; <a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>; <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>). </p> </section> </section> <section id="CD011301-sec-0094"> <h4 class="title">Blinding</h4> <section id="CD011301-sec-0095"> <h5 class="title">Performance bias</h5> <p>Twenty‐six studies presented low risk of bias related to performance (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>, <a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>; <a href="./references#CD011301-bbs2-0028" title="FagienS , CoxSE , FinnJC , WerschlerWP , KowalskiJW .Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2007;33(1 Spec No):S2-9. [CENTRAL: CN-00575067] [PMID: 17241410]">Fagien 2007a</a>; <a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>). In these studies, the authors reported that the person responsible for blinding process was not directly involved in the research. </p> <p>Thirty‐seven studies did not mention the details of how they blinded the participants, and we considered this as an unclear risk of bias (<a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>;  <a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a> ; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>; <a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>; <a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>;  <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a> ; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0051" title="OgilvieP , RivkinAZ , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from phase 3 double-blind study. Dermatologic Surgery2019;45(5):689-99. [CENTRAL: CN-01941030] RivkinAZ , OgilvieP , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study. Dermatologic Surgery2020;46(1):50-60. [PMID: 30829771]">Ogilvie 2019</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>; <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>; <a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>; <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>). </p> <p>Two RCTs were considered high risk of bias (<a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>). <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a> was a single‐blinded study, and <a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a> was an open‐label trial. </p> </section> <section id="CD011301-sec-0096"> <h5 class="title">Detection bias</h5> <p>We judged 33 studies as low risk of bias because they provided information about blinding of outcome assessment (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>, <a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>;<a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>; <a href="./references#CD011301-bbs2-0028" title="FagienS , CoxSE , FinnJC , WerschlerWP , KowalskiJW .Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2007;33(1 Spec No):S2-9. [CENTRAL: CN-00575067] [PMID: 17241410]">Fagien 2007a</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>; <a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>). The authors reported that the person responsible for blinding maintenance was not involved in the research </p> <p>Thirty‐one studies did not describe detection bias, and we considered them as presenting unclear risk of bias (<a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>;<a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>, <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a> ; <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>; <a href="./references#CD011301-bbs2-0051" title="OgilvieP , RivkinAZ , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from phase 3 double-blind study. Dermatologic Surgery2019;45(5):689-99. [CENTRAL: CN-01941030] RivkinAZ , OgilvieP , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study. Dermatologic Surgery2020;46(1):50-60. [PMID: 30829771]">Ogilvie 2019</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>; <a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>). </p> <p>One study was judged as presenting a high‐risk of bias due to open‐label design (<a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>). </p> </section> </section> <section id="CD011301-sec-0097"> <h4 class="title">Incomplete outcome data</h4> <p>Low risk studies were defined as low dropout rate, comparable drop‐out rate between groups, and/or comparable reasons for dropout between groups. </p> <p>Thirty‐nine trials were considered low risk of bias (<a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a> ; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>; <a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>; <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>). We consider low risk of bias if the authors reported the reasons for dropout. </p> <p>Twenty‐five RCTs were considered unclear risk of bias because they did not provide any reason of dropouts (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>; <a href="./references#CD011301-bbs2-0028" title="FagienS , CoxSE , FinnJC , WerschlerWP , KowalskiJW .Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2007;33(1 Spec No):S2-9. [CENTRAL: CN-00575067] [PMID: 17241410]">Fagien 2007a</a>; <a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>; <a href="./references#CD011301-bbs2-0051" title="OgilvieP , RivkinAZ , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from phase 3 double-blind study. Dermatologic Surgery2019;45(5):689-99. [CENTRAL: CN-01941030] RivkinAZ , OgilvieP , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study. Dermatologic Surgery2020;46(1):50-60. [PMID: 30829771]">Ogilvie 2019</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>; <a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>; <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>). </p> <p>One study was consider as a high risk of bias. <a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a> reported protocol violation. </p> </section> <section id="CD011301-sec-0098"> <h4 class="title">Selective reporting</h4> <p>46 RCTs were considered low risk of bias (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>; <a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a>; <a href="./references#CD011301-bbs2-0028" title="FagienS , CoxSE , FinnJC , WerschlerWP , KowalskiJW .Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2007;33(1 Spec No):S2-9. [CENTRAL: CN-00575067] [PMID: 17241410]">Fagien 2007a</a>; <a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>; <a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>; <a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0051" title="OgilvieP , RivkinAZ , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from phase 3 double-blind study. Dermatologic Surgery2019;45(5):689-99. [CENTRAL: CN-01941030] RivkinAZ , OgilvieP , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study. Dermatologic Surgery2020;46(1):50-60. [PMID: 30829771]">Ogilvie 2019</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>; <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>; <a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>; <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>).  </p> <p>We consider low risk of bias if the authors presented all prespecified outcomes.</p> <p>Five studies were considered as presenting unclear risk of bias (<a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>; <a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>). </p> <p>Fourteen RCTs were considered as presenting high risk of bias (<a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>). <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a> did not report raw data for patient satisfaction, only P values; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a> reported different data in the text compared to the graphic; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a> reported an imbalance in baseline data and missing data; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a> did not report participant satisfaction, only P values; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a> reported better results were seen in the subgroup analysis by age (younger than 50 years old), but no data were shown; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a> reported only P values; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a> did not mention if the investigator assessment was done at rest or at contraction; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a> reported inconsistencies in the number of participants included in the study; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a> and <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a> did not report the following outcomes: the response rate at rest by investigator assessment, the proportion of one‐point responders based on the investigator’s rating of glabellar lines and forehead at rest, and investigator‐assessed and participant‐assessed outcomes; <a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a> reported only the outcomes assessed at week 4; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a> only reported P values; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a> reported only P values for investigator‐assessed responder rates on crow's feet lines (FWS), participant's global assessment of change in crow's feet lines, patient‐reported outcomes; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a> did not report the following outcomes: the scores at maximum frown and at rest, by the investigator assessment, at weeks 0, 2, 4, 12, and 16; the subjective assessment of improvement since the first visit by the participant assessment at weeks 2, 4, 12, and 16; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a> did not report patient satisfaction. </p> <p>Eight studies showed reported clinical trial register numbers (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a> (NCT01333397); <a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a> (NCT01189747); <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a> (NCT02096081); <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a> (NCT01271452); <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a> (NCT01189760); <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a> (NCT01777620); <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a> (NCT00777803); <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a> (NCT01237977). Of these studies, only <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a> had a high risk of bias (Reported Outcomes, no data shown). </p> </section> <section id="CD011301-sec-0099"> <h4 class="title">Other potential sources of bias</h4> <p>Thirty‐six studies were considered low risk of other sources of bias (<a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>; <a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>; <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>; <a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>; <a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>; <a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>; <a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>; <a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>; <a href="./references#CD011301-bbs2-0026" title="DayanSH , ArkinsJP , PatelAB , GalTJ .A double-blind, randomized, placebo-controlled health- outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem. Dermatologic Surgery2010;36(Suppl 4):2088-97. [CENTRAL: CN-00779861] ">Dayan 2010</a>; <a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>; <a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>; <a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>; <a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>; <a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>; <a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>; <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>;<a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>; <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>; <a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>; <a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>). </p> <p>In 20 studies, at least one of the authors was a sponsor employee, so we consider unclear risk of bias (<a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>; <a href="./references#CD011301-bbs2-0028" title="FagienS , CoxSE , FinnJC , WerschlerWP , KowalskiJW .Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2007;33(1 Spec No):S2-9. [CENTRAL: CN-00575067] [PMID: 17241410]">Fagien 2007a</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>; <a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a> ; <a href="./references#CD011301-bbs2-0051" title="OgilvieP , RivkinAZ , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from phase 3 double-blind study. Dermatologic Surgery2019;45(5):689-99. [CENTRAL: CN-01941030] RivkinAZ , OgilvieP , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study. Dermatologic Surgery2020;46(1):50-60. [PMID: 30829771]">Ogilvie 2019</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>;<a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>; <a href="./references#CD011301-bbs2-0061" title="SolishN , LiuY , RubioRG , GallagherCJ .A head-to-head dose-ranging study of daxibotulinumtoxinA for injection in the treatment of glabellar lines: results of the BELMONT study. Toxicon2018;156(Suppl 1):S106. [CENTRAL: CN-01794190] [DOI: 10.1016/j.toxicon.2018.11.255]">Solish 2018</a>, <a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>). One study was considered as unclear risk of bias because some parts of the text showed discrepancies (<a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>), and another was judged as unclear due to limited information provided about the trial (<a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>). </p> <p>Besides investigators bias, four studies had baseline imbalances that could influence the outcomes, so we consider them as unclear (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>; <a href="./references#CD011301-bbs2-0051" title="OgilvieP , RivkinAZ , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for treatment of forehead and glabellar lines: subject-reported satisfaction and impact from phase 3 double-blind study. Dermatologic Surgery2019;45(5):689-99. [CENTRAL: CN-01941030] RivkinAZ , OgilvieP , DayanS , YoelinSG , WeichmanBM , GarciaJK .OnabotulinumtoxinA for simultaneous treatment of upper facial lines: subject-reported satisfaction and impact from a phase 3 study. Dermatologic Surgery2020;46(1):50-60. [PMID: 30829771]">Ogilvie 2019</a>). </p> <p>Eight studies were considered as high risk of bias (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>). <a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a> reported protocol violations. In another study rated as high risk of bias, the sponsor was involved in data analysis of the trial (<a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>). Three studies reported at least one of the authors wa ae sponsor stockholder, so we considered this a high risk of bias (<a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>).   </p> </section> </section> <section id="CD011301-sec-0100"> <h3 class="title" id="CD011301-sec-0100">Effects of interventions</h3> <p>See: <a href="./full#CD011301-tbl-0001"><b>Summary of findings 1</b> Summary of Findings Table ‐ OnabotulinumtoxinA 20U compared to placebo in glabellar lines</a>; <a href="./full#CD011301-tbl-0002"><b>Summary of findings 2</b> Summary of Findings Table ‐ AbobotulinumtoxinA 50U compared to placebo for glabellar lines</a>; <a href="./full#CD011301-tbl-0003"><b>Summary of findings 3</b> Summary of Findings Table ‐ IncobotulinumtoxinA 20U compared to placebo for glabellar lines</a>; <a href="./full#CD011301-tbl-0004"><b>Summary of findings 4</b> Summary of Findings Table ‐ AbobotulinumtoxinA 50U compared to OnabotulinumtoxinA 20U in glabellar lines</a>; <a href="./full#CD011301-tbl-0005"><b>Summary of findings 5</b> Summary of Findings Table ‐ IncobotulinumtoxinA 24U compared to OnabotulinumtoxinA 24U in glabellar lines</a>; <a href="./full#CD011301-tbl-0006"><b>Summary of findings 6</b> Summary of Findings Table ‐ DaxibotulinumtoxinA 40U compared to placebo in glabellar lines</a> </p> <section id="CD011301-sec-0101"> <h4 class="title">COMPARISON 1. OnabotulinumtoxinmtoxinA 10 units versus placebo for glabellar lines, one cycle of treatment </h4> <p>One randomised controlled trial (RCT) (n = 94 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>). </p> <p>For this reason (one study), we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0102"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0103"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate, by participant assessment, was higher with onabotulinumtoxinA 10 U than placebo; however, because of the wide confidence intervals the results are very uncertain; at week 4 (risk ratio (RR) 40.36, 95% confidence interval (CI) 5.78 to 281.92; participants = 92; studies = 1); week 8 (RR 67.93, 95% CI 4.28 to 1078.29; participants = 91; studies = 1); week 12 (RR 26.29, 95% CI 3.71 to 186.39; participants = 90; studies = 1); and week 16 (RR 35.33, 95% CI 2.18 to 572.97; participants = 90; studies = 1) (<a href="./references#CD011301-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD011301-sec-0104"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major adverse events.</p> </section> </section> <section id="CD011301-sec-0105"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0106"> <h6 class="title">Physician assessment of success by analysing scores or scales</h6> <p>The responder rate was higher with onabotulinumtoxinA 10 U than placebo; however, because of the wide confidence intervals the results are very uncertain; at week 4 (RR 83.84, 95% CI 5.31 to 1325.05; participants = 92; studies = 1); at week 8 (RR 32.37, 95% CI 4.60 to 227.65; participants = 91; studies = 1); at week 12 (RR 46.72, 95% CI 2.91 to 749.60; participants = 90; studies = 1); and at week 16 (RR 23.93, 95% CI 1.44 to 396.41; participants = 90; studies = 1) (<a href="./references#CD011301-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD011301-sec-0107"> <h6 class="title">Total adverse events</h6> <p>No difference between groups was found (RR 1.14, 95% CI 0.84 to 1.55, participants = 95; studies = 1) (<a href="./references#CD011301-fig-0007" title="">Analysis 1.3</a>). </p> </section> <section id="CD011301-sec-0108"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0109"> <h4 class="title">COMPARISON 2. OnabotulinumtoxinA 20 units versus placebo glabellar lines, one cycle of treatment </h4> <p>Eight  RCTs (n = 1390  participants) assessed this comparison (<a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>), and the results are included in <a href="./full#CD011301-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD011301-sec-0110"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0111"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>Four RCTs assessed this outcome (<a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a> n = 94; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a> n = 77; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a> n = 113; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a> n = 292). </p> <p>The responder rate, by participant assessment, was higher with onabotulinumtoxinA 20 U than placebo at week 4 (RR 19.45, 95% CI 8.60 to 43.99; participants = 575; studies = 4; I<sup>2</sup> = 0%; moderate‐certainty evidence); at week 8 (RR 28.45, 95% CI 5.92 to 136.74; participants = 204; studies = 2, I<sup>2</sup> = 0%); at week 12 (RR 12.77, 95% CI 2.78 to 58.72; participants = 203; studies = 2, I<sup>2</sup> = 43%); at week 16 (RR 20.71, 95% CI 2.82 to 151.91; participants = 167; studies = 2; I<sup>2</sup> = 0%); at week 24 (RR 4.19, 95% CI 0.21 to 84.41; participants = 77; studies = 1) (<a href="./references#CD011301-fig-0008" title="">Analysis 2.1</a>). </p> </section> <section id="CD011301-sec-0112"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>Eight studies assessed this outcome (n = 1390) (<a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>). </p> <p>The frequency of adverse events was higher with onabotulinumtoxinA 20 U when compared to placebo (Peto OR 3.62, 95% CI 1.50 to 8.74, participants = 1390; studies = 8; moderate‐certainty evidence) (<a href="./references#CD011301-fig-0009" title="">Analysis 2.2</a>). </p> </section> </section> <section id="CD011301-sec-0113"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0114"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>Seven RCTs reported this outcome (n = 1339) (<a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>). </p> <p>The responder rate was higher with onabotulinumtoxinA 20 U when compared to placebo at week 4 (RR 17.10, 95% CI 10.07 to 29.05; participants = 1339; studies = 7; I<sup>2</sup> = 0%; moderate‐certainty evidence); at week 8 (RR 21.50, 95% CI 9.68 to 47.75; participants = 1046; studies = 6; I<sup>2</sup> = 15%); at week 12 (RR 10.81, 95% CI 5.79 to 20.16; participants = 1046; studies = 6; I<sup>2</sup> = 10%); at week 16 (RR 15.13, 95% CI 5.98 to 38.27; participants = 933; studies = 5; I<sup>2</sup> = 0%); at week 20 (RR 5.86, 95% CI 0.31 to 109.74; participants = 77; studies = 1); at week 24 (RR 4.19, 95% CI 0.21 to 84.41; participants = 77; studies = 1) (<a href="./references#CD011301-fig-0010" title="">Analysis 2.3</a>). </p> </section> <section id="CD011301-sec-0115"> <h6 class="title">Total adverse events</h6> <p>Eight  RCTs (n = 1388  participants) assessed this comparison (<a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>; <a href="./references#CD011301-bbs2-0013" title="CarruthersJD , LoweNJ , MenterMA , GibsonJ , EadieN , Botox Glabellar Lines II Study Group.Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plastic and Reconstructive Surgery2003;112(4):1089-98. [CENTRAL: CN-00450428] [PMID: 12973229]">Carruthers 2003b</a>; <a href="./references#CD011301-bbs2-0011" title="CarruthersJA , LoweNJ , MenterMA , GibsonJ , NordquistM , MordauntJ , et al.A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. Journal of the American Academy of Dermatology.2002;46(6):840-9. [CENTRAL: CN-00389568] [PMID: 12063480]">Carruthers 2002</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0064" title="WuY , ZhaoG , LiH , ZhengZ , ZhongS , YangZ , et al.Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study. Dermatologic Surgery2010;36(1):102-8. [CENTRAL: CN-00743925] WuY , ZhaoG , LiH , ZhengZ .Botulinum toxin type A for the treatment of glabellar lines in Chinese subjects: a multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Dermatology.2009;60(3 Suppl 1):AB80. [EMBASE: 70142039]">Wu 2010</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>). No difference between groups was found (RR 1.14, 95% CI 0.89 to 1.45; participants = 1388; studies = 8; I<sup>2</sup> = 28%, low‐certainty evidence) (<a href="./references#CD011301-fig-0011" title="">Analysis 2.4</a>). </p> </section> <section id="CD011301-sec-0116"> <h6 class="title">Duration of treatment effect</h6> <p>Only one RCT assessed this outcome (<a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>); for this reason we were not able to undertake a meta‐analysis and only a visual representation of the results is shown in the forest plots. The duration of treatment effect of onabotulinumtoxinA 20 U was higher than in the placebo group (mean difference (MD) 18.40, 95% CI 16.17 to 20.63; participants = 77; studies = 1; low‐certainty evidence) (<a href="./references#CD011301-fig-0012" title="">Analysis 2.5</a>). </p> </section> </section> </section> <section id="CD011301-sec-0117"> <h4 class="title">COMPARISON 3. OnabotulinumtoxinA 20 units versus 10 units for glabellar lines, one cycle of treatment </h4> <p>Two RCTs (n = 131 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>). </p> <section id="CD011301-sec-0118"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0119"> <h6 class="title">Participants assessment of success by analysing scores and scales</h6> <p>There were two studies (<a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>; <a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a>) which assessed this outcome. The meta‐analysis showed no clear or substantial difference between these doses at 4 weeks (RR 1.11, 95% CI 0.96 to 1.29; participants = 131; studies = 2; I² = 0%); 8 weeks (RR 1.24, 95% CI 1.01 to 1.52; participants = 131; studies = 2; I² = 0%); and 16 weeks (RR 1.23, 95% CI 0.75 to 2.01; participants = 131; studies = 2; I² = 0%) (<a href="./references#CD011301-fig-0013" title="">Analysis 3.1</a>). </p> </section> <section id="CD011301-sec-0120"> <h6 class="title">Major adverse events</h6> <p>The meta‐analysis showed no clear difference between these doses as the result was imprecise (Peto OR 1.93, 95% CI 0.20 to 18.70; participants = 131; studies = 2) (<a href="./references#CD011301-fig-0014" title="">Analysis 3.2</a>). </p> </section> </section> <section id="CD011301-sec-0121"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0122"> <h6 class="title">Physician assessment of success by analysing scores and scale scores or scales</h6> <p>The meta‐analysis showed no clear difference between doses at 4 weeks (RR 1.05, 95% CI 0.91 to 1.20; n = 131; studies = 2; I² = 0%); at 8 weeks (RR 1.53, 95% CI 0.76 to 3.10; n = 131; studies = 2; I² = 65%); and 16 weeks (RR 1.43, 95% CI 0.76 to 2.69; n = 131; studies = 2; I² = 0%) (<a href="./references#CD011301-fig-0015" title="">Analysis 3.3</a>). </p> </section> <section id="CD011301-sec-0123"> <h6 class="title">Total adverse events</h6> <p>There was no difference in number of events between doses (RR 1.08, 95% CI 0.49 to 2.37; n = 131; studies = 2; I² = 0%) (<a href="./references#CD011301-fig-0016" title="">Analysis 3.4</a>). </p> </section> <section id="CD011301-sec-0124"> <h6 class="title">Duration of treatment effect</h6> <p><a href="./references#CD011301-bbs2-0032" title="HariiK , KawashimaM .A double-blind, randomized, placebo-controlled, two- dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plastic Surgery2008;32(5):724-30. [CENTRAL: CN-00669238] KawashimaM , HariiK .An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. International Journal of Dermatology2009;48(7):768-76. [CENTRAL: CN-00720265] ">Harii 2008</a> was the only study in this comparison to report this outcome. The mean duration of effect of treatment was 9.4 weeks in the OnabotulinumtoxinA 20U group and 7.9 weeks in the onabotulinumtoxinA 10 U group (no additional data were provided; therefore, we were unable to create a forest plot). </p> </section> </section> </section> <section id="CD011301-sec-0125"> <h4 class="title">COMPARISION 4. OnabotulinumtoxinA 64 units versus placebo for upper wrinkles, one cycle of treatment. </h4> <p>Only one RCT (n = 469 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0126"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0127"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate (participant assessment) was higher in onabotulinumtoxinA 64 U than placebo at week 4 (RR 8.32, 95% CI 4.53 to 15.30; participants = 469; studies = 1); at week 8 (RR 106.50, 95% CI 6.66 to 1702.48; participants = 469; studies = 1); at week 12 (RR 44.50, 95% CI 2.76 to 717.83; participants = 469; studies = 1); at week 16 (RR 26.50, 95% CI 1.63 to 431.99; participants = 469; studies = 1); at week 20 (RR 5.50, 95% CI 0.31 to 98.84; participants = 469; studies = 1); and at week 24 (RR 1.50, 95% CI 0.06 to 36.61; participants = 469; studies = 1) (<a href="./references#CD011301-fig-0017" title="">Analysis 4.1</a>). </p> </section> <section id="CD011301-sec-0128"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>The major adverse events was similar with onabotulinumtoxinA 64 U and placebo (RR 1.00, 95% CI 0.09 to 10.91; participants = 469; studies = 1). (<a href="./references#CD011301-fig-0018" title="">Analysis 4.2</a>). </p> </section> </section> <section id="CD011301-sec-0129"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0130"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment was higher in onabotulinumtoxinA 64 U than placebo at week 4 (RR 8.32, 95% CI 4.53 to 15.30; participants = 469; studies = 1); at week 8 (RR 106.50, 95% CI 6.66 to 1702.48; participants = 469; studies = 1), at week 12 (RR 44.50, 95% CI 2.76 to 717.83; participants = 469; studies = 1), at week 16 (RR 26.50, 95% CI 1.63 to 431.99; participants = 469; studies = 1); at week 20 (RR 5.50, 95% CI 0.31 to 98.84; participants = 469; studies = 1); and at week 24 (RR 1.50, 95% CI 0.06 to 36.61; participants = 469; studies = 1) (<a href="./references#CD011301-fig-0019" title="">Analysis 4.3</a>). </p> </section> <section id="CD011301-sec-0131"> <h6 class="title">Total adverse events</h6> <p>There was higher rate of any adverse event with onabotulinumtoxinA 64 U (RR 1.32, 95% CI 1.03 to 1.71; participants = 469; studies = 1) (<a href="./references#CD011301-fig-0020" title="">Analysis 4.4</a>). </p> </section> <section id="CD011301-sec-0132"> <h6 class="title">Duration of treatment effect</h6> <p>The RCT did not report this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0133"> <h4 class="title">COMPARISION 5. OnabotulinumtoxinA 40 units versus placebo for upper wrinkles, one cycle of treatment. </h4> <p>Only one RCT (n = 474 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0134"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0135"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate (participant assessment) was higher in onabotulinumtoxinA 40 U than placebo at week 4 (RR 7.41, 95% CI 4.02 to 13.64; participants = 474; studies = 1); at week 8 (RR 86.13, 95% CI 5.38 to 1378.82; participants = 474; studies = 1); at week 12 (RR 39.87, 95% CI 2.47 to 644.08; participants = 474; studies = 1; I<sup>2</sup> = 0%); at week 16 (RR 11.32, 95% CI 0.67 to 190.86; participants = 474; studies = 1); at week 20 (RR 2.26, 95% CI 0.12 to 50.95; participants = 474; studies = 1); and at week 24 (RR 1.48, 95% CI 0.06 to 36.04; participants = 474; studies = 1) (<a href="./references#CD011301-fig-0021" title="">Analysis 5.1</a>). </p> </section> <section id="CD011301-sec-0136"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>The major adverse events was higher in onabotulinumtoxinA 40 U than placebo (RR 2.45, 95% CI 0.29 to 20.82; participants = 474; studies = 1). (<a href="./references#CD011301-fig-0022" title="">Analysis 5.2</a>). </p> </section> </section> <section id="CD011301-sec-0137"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0138"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment was higher in onabotulinumtoxinA 40U than placebo at week 4 (RR 7.41, 95% CI 4.02 to 13.64; participants = 474; studies = 1); at week 8 (RR 86.13, 95% CI 5.38 to 1378.82; participants = 474; studies = 1); at week 12 (RR 39.87, 95% CI 2.47 to 644.08; participants = 474; studies = 1); at week 16 (RR 11.32, 95% CI 0.67 to 190.86; participants = 474; studies = 1); at week 20 (RR 2.46, 95% CI 0.12 to 50.95; participants = 474; studies = 1); and at week 24 (RR 1.48, 95% CI 0.06 to 36.04; participants = 474; studies = 1) (<a href="./references#CD011301-fig-0023" title="">Analysis 5.3</a>). </p> </section> <section id="CD011301-sec-0139"> <h6 class="title">Total adverse event</h6> <p>There was higher in onabotulinumtoxinA 40 U than placebo (RR 1.45, 95% CI 1.13 to 1.86; participants = 474; studies = 1) (<a href="./references#CD011301-fig-0024" title="">Analysis 5.4</a>). </p> </section> <section id="CD011301-sec-0140"> <h6 class="title">Duration of treatment effect</h6> <p>The RCT did not report this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0141"> <h4 class="title">COMPARISION 6. OnabotulinumtoxinA 64 units versus onabotulinumtoxinA 40 units for upper wrinkles, one cycle of treatment. </h4> <p>Only one RCT (n = 631participants) assessed this comparison (<a href="./references#CD011301-bbs2-0027" title="De BoulleK , WerschlerWP , GoldMH , BruceS , SatlerG , OgilvieP , et al.Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatologic Surgery2018;44(11):1437-48. [CENTRAL: CN-01650294] ">De Boulle 2018</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0142"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0143"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate (participant assessment) was higher in onabotulinumtoxinA 64 U than OnabotulinumtoxinA 40 U at week 4 (RR 1.12, 95% CI 0.96 to 1.31; participants = 631; studies = 1); at week 8 (RR 1.24, 95% CI 0.98 to 1.57; participants = 631; studies = 1); at week 12 (RR 1.12, 95% CI 0.75 to 1.67; participants = 631; studies = 1); at week 16 (RR 2.40, 95% CI 1.21 to 4.78; participants = 631; studies = 1); at week 20 (RR 2.54, 95% CI 0.50 to 12.99; participants = 631; studies = 1). </p> <p>However, the responder rate (participant assessment) was similar with onabotulinumtoxinA 64 U and onabotulinumtoxinA 40 U at week 24 (RR 1.02, 95% CI 0.06 to 16.17; participants = 631; studies = 1) (<a href="./references#CD011301-fig-0025" title="">Analysis 6.1</a>). </p> </section> <section id="CD011301-sec-0144"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>No difference was found (RR 0.41, 95% CI 0.08 to 2.08; participants = 631; studies = 1) (<a href="./references#CD011301-fig-0026" title="">Analysis 6.2</a>). </p> </section> </section> <section id="CD011301-sec-0145"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0146"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment was higher in onabotulinumtoxinA 64 units than onabotulinumtoxinA 40 units at week 4 (RR 1.12, 95% CI 0.96 to 1.31; participants = 631; studies = 1); at week 8 (RR 1.24, 95% CI 0.98 to 1.57; participants = 631; studies = 1); at week 12 (RR 1.12, 95% CI 0.75 to 1.67; participants = 631; studies = 1); at week 16(RR 2.40, 95% CI 1.21 to 4.78; participants = 631; studies = 1); at week 20 (RR 2.54, 95% CI 0.50 to 12.99; participants = 631; studies = 1). </p> <p>However, the responder rate (participant assessment) was similar with onabotulinumtoxinA 64 U and OnabotulinumtoxinA 40 U at week 24 (RR 1.02, 95% CI 0.06 to 16.17; participants = 631; studies = 1) (<a href="./references#CD011301-fig-0027" title="">Analysis 6.3</a>). </p> </section> <section id="CD011301-sec-0147"> <h6 class="title">Total adverse events</h6> <p>No difference between groups was found (RR 0.91, 95% CI 0.77 to 1.08; participants = 631; studies = 1) (<a href="./references#CD011301-fig-0028" title="">Analysis 6.4</a>). </p> </section> <section id="CD011301-sec-0148"> <h6 class="title">Duration of treatment effect</h6> <p>The RCT did not report this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0149"> <h4 class="title">COMPARISON 7. OnabotulinumtoxinA 64 units versus 32 units for upper wrinkles, one cycle of treatment  </h4> <p>Only one RCT (n = 40 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0150"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0151"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate (participant assessment) was higher in onabotulinumtoxinA 64 U than in onabotulinumtoxinA 32 U at week 12 (RR 1.32, 95% CI 1.02 to 1.72; participants = 40; studies = 1) and week 16 (RR 1.73, 95% CI 1.15 to 2.60; participants = 40; studies = 1). However, there was no clear or substantial difference between groups at week 4 (RR 1.17, 95% CI 0.96 to 1.43; participants = 40; studies = 1); at week 8 (RR 1.12, 95% CI 0.91 to 1.38; participants = 40; studies = 1); week 20 (RR 4.00, 95% CI 0.97 to 16.55; participants = 40; studies = 1); and week 24 (RR 1.00, 95% CI 0.16 to 6.42; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0029" title="">Analysis 7.1</a>). </p> </section> <section id="CD011301-sec-0152"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0153"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0154"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment, was not different between onabotulinumtoxinA 32 U and onabotulinumtoxinA 64 U at weeks 4 and 8 (RR 1.00, 95% CI 0.91 to 1.10; participants = 40; studies = 1); at week 12 (RR 0.95, 95% CI 0.83 to 1.09; participants = 40; studies = 1). At weeks 16 and week 20 there was no clear difference between groups (RR 0.62, 95% CI 0.33 to 1.15; participants = 40; studies = 1) (RR 0.40, 95% CI 0.09 to 1.83; participants = 40; studies = 1). At week 24, both groups were less than 2/20(10%) (<a href="./references#CD011301-fig-0030" title="">Analysis 7.2</a>). </p> </section> <section id="CD011301-sec-0155"> <h6 class="title">Total adverse events</h6> <p>No difference between groups was found (RR 0.75, 95% CI 0.49 to 1.14; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0031" title="">Analysis 7.3</a>). </p> </section> <section id="CD011301-sec-0156"> <h6 class="title">Duration of treatment effect</h6> <p>The RCT assessed this outcome, but did not report the results.</p> </section> </section> </section> <section id="CD011301-sec-0157"> <h4 class="title">COMPARISON 8. OnabotulinumtoxinA 96 units versus 32 units for upper wrinkles, one cycle of treatment </h4> <p>Only one RCT (n = 40 participants) assessed this outcome (<a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0158"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0159"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate, by participant assessment, was similar between onabotulinumtoxinA 96U and onabotulinumtoxinA 32 U at weeks 4 and 8 (for both time points: RR 1.17, 95% CI 0.96 to 1.43; participants = 40; studies = 1); and there was no clear difference at week 24 (RR 3.50, 95% CI 0.83 to 14.83; participants = 40; studies = 1); and week 32 (RR 3.50, 95% CI 0.83 to 14.83; participants = 40; studies = 1). The responder rate, by participant assessment, was higher with onabotulinumtoxinA 96 U than onabotulinumtoxinA 32 U at week 12 (RR 1.32, 95% CI 1.02 to 1.72; participants = 40; studies = 1); week 16 (RR 1.64, 95% CI 1.07 to 2.50; participants = 40; studies = 1); week 20 (RR 6.00, 95% CI 1.54 to 23.44; participants = 40; studies = 1); and at week 28 (RR 4.50, 95% CI 1.11 to 18.27; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0032" title="">Analysis 8.1</a>). </p> </section> <section id="CD011301-sec-0160"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0161"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0162"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment, was similar between onabotulinumtoxinA 96 U and onabotulinumtoxinA 32 U at weeks 4 and 8 (RR 1.00, 95% CI 0.91 to 1.10; participants = 40; studies = 1) and at week 12 (RR 1.05, 95% CI 0.92 to 1.20; participants = 40; studies = 1). But at week 28 and week 32 we are uncertain which group is favoured due to the wide confidence intervals obtained: (RR 13.00, 95% CI 0.78 to 216.39; participants = 40; studies = 1), (RR 5.00, 95% CI 0.26 to 98.00; participants = 40; studies = 1). The responder rate, by physician assessment, was higher with onabotulinumtoxinA 96u than onabotulinumtoxinA 32 U at week 16 (RR 2.25, 95% CI 1.29 to 3.92; participants = 40; studies = 1); week 20 (RR 7.50, 95% CI 1.97 to 28.61; participants = 40; studies = 1); and week 24 (RR 27.00, 95% CI 1.71 to 425.36; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0033" title="">Analysis 8.2</a>). </p> </section> <section id="CD011301-sec-0163"> <h6 class="title">Total adverse events</h6> <p>No difference between groups was found (RR 1.25, 95% CI 0.81 to 1.94; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0034" title="">Analysis 8.3</a>). </p> </section> <section id="CD011301-sec-0164"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assessed this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0165"> <h4 class="title">COMPARISON 9. OnabotulinumtoxinA 96 units versus 64 units for upper wrinkles, one cycle of treatment. </h4> <p>Only one RCT (n = 40 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0017" title="CarruthersA , CarruthersJ .A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy. Journal of the American Academy of Dermatology2009;60(6):972-9. [CENTRAL: CN-00699077] CarruthersA , CarruthersJ .A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. Journal of Drugs in Dermatology.2009;8(10):924-9. [CENTRAL: CN-00722569] ">Carruthers 2009</a>). For this reason we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0166"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0167"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate, by participant assessment, was similar between onabotulinumtoxinA 96U and onabotulinumtoxinA 64U, at week 4 (RR 1.00, 95% CI 0.91 to 1.10; participants = 40; studies = 1), at week 8 (RR 1.05, 95% CI 0.92 to 1.20; participants = 40; studies = 1), at week 12 (RR 1.00, 95% CI 0.91 to 1.10; participants = 40; studies = 1), and at week 16 (RR 0.95, 95% CI 0.79 to 1.13; participants = 40; studies = 1). We are less certain of the effect at week 20 (RR 1.50, 95% CI 0.79 to 2.86; participants = 40; studies = 1), and at week 24 (RR 3.50, 95% CI 0.83 to 14.83; participants = 40; studies = 1). The responder rate, by participant assessment, were higher with onabotulinumtoxinA 96U than onabotulinumtoxinA 64U at week 28 and week 32; however, because of the very wide confidence interval the result is very uncertain: at week 28 (RR 19.00, 95% CI 1.18 to 305.88; participants = 40; studies = 1), and at week 32 (RR 17.00, 95% CI 1.05 to 276.03; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0035" title="">Analysis 9.1</a>). </p> </section> <section id="CD011301-sec-0168"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0169"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0170"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate, by participant assessment, was similar with onabotulinumtoxinA 96U versus onabotulinumtoxinA 64U, at week 4 (RR 0.95, 95% CI 0.83 to 1.09; participants = 40; studies = 1), at week 8 (RR 1.00, 95% CI 0.91 to 1.10; participants = 40; studies = 1), and at week 12 (RR 1.00, 95% CI 0.91 to 1.10; participants = 40; studies = 1). But we are less certain about the effect size at week 16 (RR 1.38, 95% CI 0.97 to 1.97; participants = 40; studies = 1). The responder rate was higher in the 96 U group at week 20 (RR 3.00, 95% CI 1.35 to 6.68; participants = 40; studies = 1), and at week 24 (RR 6.50, 95% CI 1.68 to 25.16; participants = 40; studies = 1). The responder rate, by participant assessment, were also higher with onabotulinumtoxinA 96 units than onabotulinumtoxinA 64 units at week 24 and week 32; however, because of the confidence interval the results are very uncertain: at week 28 (RR 13.00, 95% CI 0.78 to 216.39; participants = 40; studies = 1), and at week 32 (RR 5.00, 95% CI 0.26 to 98.00; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0036" title="">Analysis 9.2</a>). </p> </section> <section id="CD011301-sec-0171"> <h6 class="title">Any adverse event</h6> <p>No difference between groups was found but the confidence interval was wide (RR 0.94, 95% CI 0.67 to 1.31; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0037" title="">Analysis 9.3</a>). </p> </section> <section id="CD011301-sec-0172"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT studied this outcome as survival analysis. The authors showed a better duration of treatment effect in onabotulinumtoxinA 96 units group (61.3% of responders at week 24). </p> </section> </section> </section> <section id="CD011301-sec-0173"> <h4 class="title">COMPARISON 10. OnabotulinumtoxinA 32 units versus 16 units for forehead lines, one cycle of treatment </h4> <p>Only one RCT (n = 39 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0174"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0175"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate, by participant assessment was similar with onabotulinumtoxinA 32U versus onabotulinumtoxinA 16 U at week 8 (RR 1.05, 95% CI 0.36 to 3.07; participants = 39; studies = 1) (<a href="./references#CD011301-fig-0038" title="">Analysis 10.1</a>). </p> </section> <section id="CD011301-sec-0176"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>Eyelid swelling was similar with onabotulinumtoxinA 32 U and onabotulinumtoxinA 16U (RR 1.05; 95% CI 0.24 to 4.59, n = 39; studies = 1) (<a href="./references#CD011301-fig-0039" title="">Analysis 10.2</a>). </p> </section> </section> <section id="CD011301-sec-0177"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0178"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment was similar with onabotulinumtoxinA 32U versus onabotulinumtoxinA 16 U at week 8 (RR 0.73; 95% CI 0.41 to 1.29, participants = 39; studies = 1) (<a href="./references#CD011301-fig-0040" title="">Analysis 10.3</a>). </p> </section> <section id="CD011301-sec-0179"> <h6 class="title">Any adverse event</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0180"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0181"> <h4 class="title">COMPARISON 11. OnabotulinumtoxinA 48 units versus 16 units for forehead lines, one cycle of treatment </h4> <p>Only one RCT (n = 40 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0182"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0183"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate, by participant assessment, was higher with onabotulinumtoxinA 48 U then onabotulinumtoxinA 16 U at week 8, but the results are uncertain due to the confidence interval including 1 (RR 1.60, 95% CI 0.63 to 4.05; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0060" title="">Analysis 17.1</a>). </p> </section> <section id="CD011301-sec-0184"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>No difference between groups was found, but the confidence interval was wide (RR 2.00; 95% CI 0.58 to 6.91, n = 40; studies = 1) (<a href="./references#CD011301-fig-0061" title="">Analysis 17.2</a>). </p> </section> </section> <section id="CD011301-sec-0185"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0186"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician's assessment, was similar with onabotulinumtoxinA 48 U and onabotulinumtoxinA 16 U at week 8 (RR 1.00; 95% CI 0.63 to 1.58, n = 40; studies = 1) (<a href="./references#CD011301-fig-0062" title="">Analysis 17.3</a>). </p> </section> <section id="CD011301-sec-0187"> <h6 class="title">Total adverse events</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0188"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0189"> <h4 class="title">COMPARISON 12. OnabotulinumtoxinA 48 units versus 32 units for forehead lines, one cycle of treatment </h4> <p>Only one RCT (n = 39 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0190"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0191"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>There was no clear difference for responder rate, by participant assessment, between doses at week 8 (RR 1.52; 95% CI 0.60 to 3.83, n = 39; studies = 1) (<a href="./references#CD011301-fig-0043" title="">Analysis 12.1</a>). </p> </section> <section id="CD011301-sec-0192"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p> No difference between groups was found but the confidence interval was wide (RR 0.47, 95% CI 0.10 to 2.30; participants = 39; studies = 1) (<a href="./references#CD011301-fig-0044" title="">Analysis 12.2</a>) </p> </section> </section> <section id="CD011301-sec-0193"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0194"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>One RCT assessed this comparison (<a href="./references#CD011301-bbs2-0012" title="CarruthersA , CarruthersJ , CohenJ .A prospective, double-blind, randomized, parallel- group, dose- ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatologic Surgery2003;29(5):461-7. [CENTRAL: CN-00437536] ">Carruthers 2003a</a>). The responder rate, by physician assessment, were similar with OnabotulinumtoxinA 48 U versus OnabotulinumtoxinA 32 U at week 8 (RR 1.37; 95% CI 0.77 to 2.43, n = 39; studies = 1) (<a href="./references#CD011301-fig-0045" title="">Analysis 12.3</a>). </p> </section> <section id="CD011301-sec-0195"> <h6 class="title">Total adverse events</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0196"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0197"> <h4 class="title">COMPARISON 13. OnabotulinumtoxinA 40 units versus placebo for forehead lines and glabellar lines, one cycle of treatment </h4> <p>Only one RCT (n = 116 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>). </p> <p>For this reason (one study), we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0198"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0199"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate, by participant assessment, was higher with onabotulinumtoxinA 40 U than placebo at week 4 (RR 6.60, 95% CI 3.44 to 12.64; participants = 116; studies = 1); at week 8 (RR 16.91, 95% CI 5.59 to 51.17; participants = 116; studies = 1); at week 12 (RR 4.73, 95% CI 2.27 to 9.84; participants = 116; studies = 1); and at week 20 (RR 6.90, 95% CI 2.17 to 21.96; participants = 116; studies = 1). </p> <p>Although, the responder rate, by participant assessment, was higher with onabotulinumtoxinA 40 U than placebo, the results are uncertain due to the wide confidence intervals: at week 16 (RR 32.09, 95% CI 4.53 to 227.29; participants = 116; studies = 1), and at week 24 (RR 15.53, 95% CI 2.12 to 113.72; participants = 116; studies = 1) (<a href="./references#CD011301-fig-0046" title="">Analysis 13.1</a>). </p> </section> <section id="CD011301-sec-0200"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0201"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0202"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment, was higher with onabotulinumtoxinA 40 U than placebo at week 16 (RR 4.49, 95% CI 2.00 to 10.08; participants = 116; studies = 1). </p> <p>The responder rate, by physician assessment, was higher with onabotulinumtoxinA 40 U than placebo at week 4 (RR 26.91, 95% CI 6.88 to 105.34; participants = 116; studies = 1); at week 8 (RR 48.65, 95% CI 6.94 to 340.90; participants = 116; studies = 1); at week 12 (RR 10.70, 95% CI 3.46 to 33.04; participants = 116; studies = 1); at week 20 (RR 20.70, 95% CI 2.87 to 149.20; participants = 116; studies = 1); and at week 24 (RR 11.39, 95% CI 1.52 to 85.36; participants = 116; studies = 1) (<a href="./references#CD011301-fig-0047" title="">Analysis 13.2</a>). However, because of the wide confidence intervals the results are very uncertain. </p> </section> <section id="CD011301-sec-0203"> <h6 class="title">Total adverse events</h6> <p>No difference between groups was found, but the confidence interval was wide (RR 1.38; 95% CI 0.79 to 2.42; participants = 116; studies = 1) (<a href="./references#CD011301-fig-0048" title="">Analysis 13.3</a>). </p> </section> <section id="CD011301-sec-0204"> <h6 class="title">Duration of treatment effect</h6> <p>The duration of the treatment effect was 16.9 weeks (118.5 days) by physician assessment and 17.8 weeks (125 days) by participant assessment in onabotulinumtoxinA 40U group. </p> </section> </section> </section> <section id="CD011301-sec-0205"> <h4 class="title">COMPARISON 14. OnabotulinumtoxinA 30 units versus placebo, one cycle of treatment, forehead lines and glabellar lines </h4> <p>Only one RCT (n = 118 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0206"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0207"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate, by participant assessment was higher with onabotulinumtoxinA 30 U group than placebo at week 4 (RR 6.25, 95% CI 3.25 to 12.01; participants = 118; studies = 1); at week 8 (RR 14.00, 95% CI 4.59 to 42.67; participants = 118; studies = 1); at week 12 (RR 4.29, 95% CI 2.05 to 8.98; participants = 118; studies = 1); at week 20 (RR 5.33, 95% CI 1.64 to 17.34; participants = 118; studies = 1); and at week 24 (RR 10.00, 95% CI 1.32 to 75.66; participants = 118; studies = 1) (<a href="./references#CD011301-fig-0049" title="">Analysis 14.1</a>). </p> <p>Although the responder rate, by participant assessment, was higher with onabotulinumtoxinA 30U group than placebo at week 16, the result is uncertain due to a large confidence interval (RR 22.00, 95% CI 3.06 to 157.95; participants = 118; studies = 1). </p> </section> <section id="CD011301-sec-0208"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>No difference between groups was found but the confidence interval was wide (RR 5.00, 95% CI 0.25 to 101.97; participants = 118; studies = 1) (<a href="./references#CD011301-fig-0050" title="">Analysis 14.2</a>) </p> </section> </section> <section id="CD011301-sec-0209"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0210"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment, was higher with onabotulinumtoxinA 30U group than placebo; however, because of the confidence interval the results is very uncertain; at week 4 (RR 24.00, 95% CI 6.11 to 94.23; participants = 118; studies = 1); at week 8 (RR 43.00, 95% CI 6.12 to 302.08; participants = 118; studies = 1); and at week 24 (RR 8.00, 95% CI 1.03 to 61.98; participants = 118; studies = 1) (<a href="./references#CD011301-fig-0051" title="">Analysis 14.3</a>). </p> <p>The responder rate, by physician assessment, was higher with onabotulinumtoxinA 30 U group than placebo at week 12 (RR 8.67, 95% CI 2.77 to 27.08; participants = 118; studies = 1); and at week 16 (RR 3.33, 95% CI 1.44 to 7.71; participants = 118; studies = 1) (<a href="./references#CD011301-fig-0051" title="">Analysis 14.3</a>). </p> </section> <section id="CD011301-sec-0211"> <h6 class="title">Total adverse events</h6> <p>No difference between groups was found, but the confidence interval was wide(RR 1.86, 95% CI 0.80 to 4.32; participants = 118; studies = 1) (<a href="./references#CD011301-fig-0052" title="">Analysis 14.4</a>). </p> </section> <section id="CD011301-sec-0212"> <h6 class="title">Duration of treatment effect</h6> <p>The duration of treatment effect was 16 weeks (113.0 days) by physician assessment and 16.5 weeks (115.5 days) by participant assessment in onabotulinumtoxinA 30u group. </p> </section> </section> </section> <section id="CD011301-sec-0213"> <h4 class="title">COMPARISON 15. OnabotulinumtoxinA 40 units versus onabotulinumtoxinA 30 units one cycle of treatment, forehead lines and glabellar lines </h4> <p>Only one RCT (n = 116 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0060" title="SolishN , RiversJK , HumphreyS , MuhnC , SomogyiC , LeiX , et al.Efficacy and safety of onabotulinumtoxina treatment of forehead lines: a multicenter, randomized, dose-ranging controlled trial. Dermatologic Surgery2016;42(3):410-9. [CENTRAL: CN-01141742] ">Solish 2016</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0214"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0215"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate, by participant assessment, were similar with onabotulinumtoxinA 40 U versus onabotulinumtoxinA 30U at week 4 (RR 1.06, 95% CI 0.92 to 1.21; participants = 116; studies = 1); at week 8 (RR 1.21, 95% CI 1.00 to 1.47; participants = 116; studies = 1); at week 12 (RR 1.10, 95% CI 0.79 to 1.55; participants = 116; studies = 1); at week 16 (RR 1.46, 95% CI 0.97 to 2.19; participants = 116; studies = 1); at week 20 (RR 1.29, 95% CI 0.75 to 2.24; participants = 116; studies = 1); and at week 24 (RR 1.55, 95% CI 0.76 to 3.17; participants = 116; studies = 1) (<a href="./references#CD011301-fig-0053" title="">Analysis 15.1</a>). </p> </section> <section id="CD011301-sec-0216"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p> No difference between groups was found, but the confidence interval was wide (RR 0.21, 95% CI 0.01 to 4.22; participants = 116; studies = 1) (<a href="./references#CD011301-fig-0054" title="">Analysis 15.2</a>). </p> </section> </section> <section id="CD011301-sec-0217"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0218"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment, were similar with onabotulinumtoxinA 40 U versus onabotulinumtoxinA 30 U at week 4 (RR 1.12, 95% CI 0.97 to 1.30; participants = 116; studies = 1); at week 8 (RR 1.13, 95% CI 0.93 to 1.38; participants = 116; studies = 1); at week 12 (RR 1.23, 95% CI 0.85 to 1.79; participants = 116; studies = 1); at week 16 (RR 1.35, 95% CI 0.85 to 2.12; participants = 116; studies = 1); at week 20 (RR 1.38, 95% CI 0.79 to 2.42; participants = 116; studies = 1); and at week 24 (RR 1.42, 95% CI 0.62 to 3.28; participants = 116; studies = 1) (<a href="./references#CD011301-fig-0055" title="">Analysis 15.3</a>). </p> </section> <section id="CD011301-sec-0219"> <h6 class="title">Total adverse events</h6> <p> No difference between groups was found, but the confidence interval was wide (RR 1.04, 95% CI 0.63 to 1.71; participants = 116; studies = 1) (<a href="./references#CD011301-fig-0056" title="">Analysis 15.4</a>). </p> </section> <section id="CD011301-sec-0220"> <h6 class="title">Duration of treatment effect</h6> <p>The duration of treatment effect was 118.5 days by investigator assessment and 125 days by participant assessment in OnbotulinumtoxinA 40 U group. The duration of treatment effect was 113.0 days by investigator assessment and 115.5 days by participant assessment in OnabotulinumtoxinA 30 U group. </p> </section> </section> </section> <section id="CD011301-sec-0221"> <h4 class="title">COMPARISON 16. OnabotulinumtoxinA 40 units versus 20 units one cycle of treatment, glabellar lines </h4> <p>Two RCTs assessed (n = 80 participants) this comparison (<a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>; <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>). </p> <section id="CD011301-sec-0222"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0223"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The meta‐analysis showed benefit in favour of onabotulinumtoxinA 40 U group at 4 weeks (RR 1.63, 95% CI 1.13 to 2.35; participants = 80; studies = 2; I² = 0%), but not at week 8 (RR 1.52, 95% CI 0.77 to 2.97; participants = 80; studies = 2; I² = 44%), or week 16 (RR 2.51, 95% CI 0.88 to 7.16; participants = 80; studies = 2; I² = 0%) (<a href="./references#CD011301-fig-0057" title="">Analysis 16.1</a>) (Figure 5). </p> </section> <section id="CD011301-sec-0224"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>Only <a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a> assessed this outcome. The rate of eyebrow ptosis was 1/20 (5%) for both doses. </p> </section> </section> <section id="CD011301-sec-0225"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0226"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The meta‐analysis showed a potential benefit in favour of onabotulinumtoxinA 40 U group at 4 weeks (RR 1.48, 95% CI 0.93 to 2.36; participants = 80; studies = 2; I² = 71%); at week 8 (RR 1.35, 95% CI 0.82 to 2.23; participants = 80; studies = 2; I² = 21%); and at 16 weeks (RR 1.34, 95% CI 0.51 to 3.53; participants = 80; studies = 2; I² = 0%) (<a href="./references#CD011301-fig-0058" title="">Analysis 16.2</a>) (Figure 5), but the difference was small and the result were not very precise. </p> </section> <section id="CD011301-sec-0227"> <h6 class="title">Total adverse events</h6> <p>No difference between groups was found, but the confidence interval was wide (RR 1.93, 95% CI 0.53 to 7.05; participants = 80; studies = 2; I² = 28%) (<a href="./references#CD011301-fig-0059" title="">Analysis 16.3</a>) (Figure 5). </p> </section> <section id="CD011301-sec-0228"> <h6 class="title">Duration of treatment effect</h6> <p>Only one RCT assessed this outcome (<a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>). The mean time of duration of treatment effect for onabotulinumtoxinA 20 U group was 17.6 weeks and 21.7 weeks for onabotulinumtoxinA 40 U group (no standard deviation (SD), P value, or 95% CIs were provided; hence, results were not provided in a forest plot). </p> </section> </section> </section> <section id="CD011301-sec-0229"> <h4 class="title">COMPARISON 17. OnabotulinumtoxinA 60 units versus 20 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 40 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0230"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0231"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0232"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0233"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0234"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by participant assessment, were higher with onabotulinumtoxinA 60 U than onabotulinumtoxinA 20 U at week 4 (RR 1.90, 95% CI 1.21 to 2.98; participants = 40; studies = 1), and at week 8 (RR 3.80, 95% CI 1.77 to 8.17; participants = 40; studies = 1). However, there was no clear or substantial difference in responder rate with onabotulinumtoxinA 60 U and onabotulinumtoxinA 20 U at week 12 (RR 2.00, 95% CI 0.72 to 5.59; participants = 40; studies = 1) at week 16 (RR 1.00, 95% CI 0.29 to 3.45; participants = 40; studies = 1); and at week 20 (RR 2.00, 95% CI 0.41 to 9.71; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0041" title="">Analysis 11.1</a>). </p> </section> <section id="CD011301-sec-0235"> <h6 class="title">Total adverse events</h6> <p>No difference between groups was found, but the confidence interval was wide (RR 1.00, 95% CI 0.07 to 14.90; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0042" title="">Analysis 11.2</a>). </p> </section> <section id="CD011301-sec-0236"> <h6 class="title">Duration of treatment effect</h6> <p>The duration of treatment effect was 17.6 weeks in onabotulinumtoxinA 20U group, and 22.8 weeks in onabotulinumtoxinA 60 U group. </p> </section> </section> </section> <section id="CD011301-sec-0237"> <h4 class="title">COMPARISON 18. OnabotulinumtoxinA 80 units versus 2 0units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 40 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0238"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0239"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate, by participant assessment, were higher with onabotulinumtoxinA 80 U than onabotulinumtoxinA 20U at week 4 (RR 3.75, 95% CI 1.51 to 9.34; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0063" title="">Analysis 18.1</a>). </p> </section> <section id="CD011301-sec-0240"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0241"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0242"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment, were higher with onabotulinumtoxinA 80 U than onabotulinumtoxinA 20 U at week 4 (RR 1.95, 95% CI 1.27 to 3.01; participants = 40; studies = 1); at week 8 (RR 3.20, 95% CI 1.45 to 7.05; participants = 40; studies = 1); and at week 12 (RR 3.50, 95% CI 1.39 to 8.80; participants = 40; studies = 1). However, the responder rate was similar with onabotulinumtoxinA 80 U and onabotulinumtoxinA 20 U at week 16 (RR 1.00, 95% CI 0.29 to 3.45; participants = 40; studies = 1), and at week 20 (RR 1.00, 95% CI 0.16 to 6.42; participants = 40; studies = 1). At week 24, the result was very uncertain (RR 5.00, 95% CI 0.26 to 98.00; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0064" title="">Analysis 18.2</a>). </p> </section> <section id="CD011301-sec-0243"> <h6 class="title">Total adverse events</h6> <p> No difference between groups was found, but the confidence interval was wide (RR 4.00, 95% CI 0.49 to 32.72; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0065" title="">Analysis 18.3</a>). </p> </section> <section id="CD011301-sec-0244"> <h6 class="title">Duration of treatment effect</h6> <p>The duration of treatment effect was 17.6 weeks in onabotulinumtoxinA 20U group and 24.2 weeks in onabotulinumtoxinA 80U. </p> </section> </section> </section> <section id="CD011301-sec-0245"> <h4 class="title">COMPARISON 19. OnabotulinumtoxinA 80 units versus 60 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 20 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0246"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0247"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0248"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0249"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0250"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment were similar with onabotulinumtoxinA 80U and onabotulinumtoxinA 60 U at week 4 (RR 1.05, 95% CI 0.92 to 1.20; participants = 40; studies = 1); at week 8 (RR 0.84, 95% CI 0.66 to 1.07; participants = 40; studies = 1); at week 12 (RR 1.75, 95% CI 0.95 to 3.22; participants = 40; studies = 1); and at week 16 (RR 1.00, 95% CI 0.29 to 3.45; participants = 40; studies = 1). At week 20 and 24, the effect sizes were less certain: (RR 0.50, 95% CI 0.10 to 2.43; participants = 40; studies = 1) (RR 5.00, 95% CI 0.26 to 98.00; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0066" title="">Analysis 19.1</a>). </p> </section> <section id="CD011301-sec-0251"> <h6 class="title">Total adverse events</h6> <p>There was no difference between groups, but the confidence interval was wide and included both an increase or a reduction at the risk of total adverse events (RR 2.00, 95% CI 0.41 to 9.71; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0067" title="">Analysis 19.2</a>). </p> </section> <section id="CD011301-sec-0252"> <h6 class="title">Duration of treatment effect</h6> <p>The duration of treatment effect was 22.8 weeks in onabotulinumtoxinA 60U group, and 24.2 weeks in onabotulinumtoxinA 80 U. </p> </section> </section> </section> <section id="CD011301-sec-0253"> <h4 class="title">COMPARISON 20. OnabotulinumtoxinA 30 units versus 10 units one cycle of treatment, glabellar lines </h4> <p>One RCT (n = 40 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>). </p> <p>For this reason (one study), we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0254"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0255"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0256"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0257"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0258"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment, were similar with onabotulinumtoxinA 30 U and onabotulinumtoxinA 10 U at week 4 (RR 1.12, 95% CI 0.91 to 1.38; participants = 40; studies = 1), but favoured the 30 U group at week 16, although with some uncertainty (RR 5.00, 95% CI 0.64 to 39.06; participants = 40; studies = 1). The responder rate, by physician assessment, were higher with onabotulinumtoxinA 30 U than onabotulinumtoxinA 10 U at week 8 (RR 2.40, 95% CI 1.04 to 5.55; participants = 40; studies = 1). </p> <p>Although the responder rate, by physician assessment, were higher with onabotulinumtoxinA 30 U than onabotulinumtoxinA 10 U at week 12, the result is uncertain because of the confidence interval (RR 9.00, 95% CI 1.25 to 64.59; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0068" title="">Analysis 20.1</a>). </p> </section> <section id="CD011301-sec-0259"> <h6 class="title">Total adverse events</h6> <p>The was no difference between groups (RR 0.25; 95% CI 0.03 to 2.05; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0069" title="">Analysis 20.2</a>). </p> </section> <section id="CD011301-sec-0260"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0261"> <h4 class="title">COMPARISON 21. OnabotulinumtoxinA 40 units versus 10 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 40 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0262"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0263"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>There was no clear or substantial difference in responder rate, by participant assessment, between onabotulinumtoxinA 40 U and onabotulinumtoxinA 10 U at week 4 (RR 1.86, 95% CI 0.94 to 3.66; participants = 40; studies = 1); at week 8 (RR 1.00, 95% CI 0.47 to 2.14; participants = 40; studies = 1); at week 12 (RR 1.75, 95% CI 0.61 to 5.05; participants = 40; studies = 1); and at week 16 (RR 1.00, 95% CI 0.16 to 6.42; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0070" title="">Analysis 21.1</a>). </p> </section> <section id="CD011301-sec-0264"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0265"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0266"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment, were similar with onabotulinumtoxinA 40 U and onabotulinumtoxinA 10 U at week 4 (RR 1.17, 95% CI 0.96 to 1.43; participants = 40; studies = 1) but the result was more uncertain at week 16 (RR 5.00, 95% CI 0.64 to 39.06; participants = 40; studies = 1). The responder rate, by physician assessment, were higher with onabotulinumtoxinA 40 U than onabotulinumtoxinA 10 U at week 8 (RR 2.80, 95% CI 1.24 to 6.30; participants = 40; studies = 1). </p> <p>Although the responder rate, by physician assessment, were higher with onabotulinumtoxinA 30u than onabotulinumtoxinA 10u at week 12, the RR is uncertain because of the wide confidence interval (RR 8.00, 95% CI 1.10 to 58.19; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0071" title="">Analysis 21.2</a>). </p> </section> <section id="CD011301-sec-0267"> <h6 class="title">Total adverse events</h6> <p>No difference between groups was found, but the confidence interval was wide (RR 1.25, 95% CI 0.39 to 3.99; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0072" title="">Analysis 21.3</a>). </p> </section> <section id="CD011301-sec-0268"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0269"> <h4 class="title">COMPARISON 22. OnabotulinumtoxinA 40 units versus 30 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 40 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0270"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0271"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate, by participant assessment, were similar with onabotulinumtoxinA 40 U and onabotulinumtoxinA 30 U at week 4 (RR 1.30, 95% CI 0.75 to 2.24; participants = 40; studies = 1); at week 8 (RR 1.00, 95% CI 0.47 to 2.14; participants = 40; studies = 1); at week 12 (RR 1.17, 95% CI 0.48 to 2.86; participants = 40; studies = 1); and at week 16 (RR 1.00, 95% CI 0.16 to 6.42; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0073" title="">Analysis 22.1</a>). </p> </section> <section id="CD011301-sec-0272"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0273"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0274"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment were similar with onabotulinumtoxinA 40 U and onabotulinumtoxinA 3 0U at week 4 (RR 1.05, 95% CI 0.92 to 1.20; participants = 40; studies = 1;, at week 8 (RR 1.17, 95% CI 0.74 to 1.85; participants = 40; studies = 1); at week 12 (RR 0.89, 95% CI 0.43 to 1.83; participants = 40; studies = 1), and at week 16 (RR 1.00, 95% CI 0.34 to 2.93; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0074" title="">Analysis 22.2</a>). </p> </section> <section id="CD011301-sec-0275"> <h6 class="title">Total adverse event</h6> <p> No difference between groups was found, but the confidence interval was wide (RR 5.00, 95% CI 0.64 to 39.06; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0075" title="">Analysis 22.3</a>). </p> </section> <section id="CD011301-sec-0276"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0277"> <h4 class="title">COMPARISON 23. OnabotulinumtoxinA 30 units versus 20 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 40 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0016" title="CarruthersA , CarruthersJ , SaidS .Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatologic Surgery2005;31(4):414-22. [PMID: 15871316]">Carruthers 2005b</a>). For this reason (one study), we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0278"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0279"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate, by participant assessment were similar with onabotulinumtoxinA 30 U and onabotulinumtoxinA 2 0U at week 4 (RR 1.11, 95% CI 0.58 to 2.14; participants = 40; studies = 1); at week 8 (RR 1.00, 95% CI 0.47 to 2.14; participants = 40; studies = 1); at week 12 (RR 1.50, 95% CI 0.50 to 4.52; participants = 40; studies = 1); and at week 16 (RR 1.00, 95% CI 0.16 to 6.42; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0076" title="">Analysis 23.1</a>). </p> </section> <section id="CD011301-sec-0280"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0281"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0282"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment, were similar with onabotulinumtoxinA 30 U and onabotulinumtoxinA 20 U at week 4 (RR 1.19, 95% CI 0.93 to 1.51; participants = 40; studies = 1); at week 8 (RR 1.00, 95% CI 0.60 to 1.66; participants = 40; studies = 1); at week 12 (RR 1.29, 95% CI 0.60 to 2.77; participants = 40; studies = 1); and at week 16 (RR 1.67, 95% CI 0.46 to 6.06; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0077" title="">Analysis 23.2</a>). </p> </section> <section id="CD011301-sec-0283"> <h6 class="title">Total adverse events</h6> <p>No difference between groups was found, but the confidence interval was wide (RR 0.25, 95% CI 0.03 to 2.05; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0078" title="">Analysis 23.3</a>). </p> </section> <section id="CD011301-sec-0284"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0285"> <h4 class="title">COMPARISON 24. OnabotulinumtoxinA 60 units versus 40 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 40 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0286"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0287"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0288"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0289"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0290"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment, were similar with onabotulinumtoxinA 60U and onabotulinumtoxinA 40 U at week 4 (RR 1.12, 95% CI 0.91 to 1.38; participants = 40; studies = 1); at week 12 (RR 1.00, 95% CI 0.47 to 2.14; participants = 40; studies = 1);at week 16 (RR 1.00, 95% CI 0.29 to 3.45; participants = 40; studies = 1); and week 20 (RR 1.00, 95% CI 0.29 to 3.45; participants = 40; studies = 1). The responder rate, by physician assessment, was higher with onabotulinumtoxinA 60 U than onabotulinumtoxinA 40 U at week 8 (RR 1.90, 95% CI 1.21 to 2.98; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0079" title="">Analysis 24.1</a>). </p> </section> <section id="CD011301-sec-0291"> <h6 class="title">Any adverse event</h6> <p>No difference between groups was found, but the confidence interval was wide (RR 0.40, 95% CI 0.09 to 1.83 participants = 40; studies = 1) (<a href="./references#CD011301-fig-0080" title="">Analysis 24.2</a>). </p> </section> <section id="CD011301-sec-0292"> <h6 class="title">Duration of treatment effect</h6> <p>The duration of treatment effect was 21.7 weeks in onabotulinumtoxinA 40U and 22.8 weeks in onabotulinumtoxinA 60 U. </p> </section> </section> </section> <section id="CD011301-sec-0293"> <h4 class="title">COMPARISON 25. OnabotulinumtoxinA 80 units versus 40 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 40 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0294"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0295"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0296"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0297"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0298"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment were similar with onabotulinumtoxinA 80 U and onabotulinumtoxinA 40 U at week 4 (RR 1.17, 95% CI 0.96 to 1.43; participants = 40; studies = 1); at week 8 (RR 1.60, 95% CI 0.98 to 2.61; participants = 40; studies = 1), at week 12 (RR 1.75, 95% CI 0.95 to 3.22; participants = 40; studies = 1); and at week 16 (RR 1.00, 95% CI 0.29 to 3.45; participants = 40; studies = 1). At week 20 (RR 0.50, 95% CI 0.10 to 2.43; participants = 40; studies = 1) and at week 24 (RR 5.00, 95% CI 0.26 to 98.00; participants = 40; studies = 1) the effect size is less certain due to wide confidence intervals and/or the inclusion of 1 in the confidence interval (<a href="./references#CD011301-fig-0081" title="">Analysis 25.1</a>). </p> </section> <section id="CD011301-sec-0299"> <h6 class="title">Total adverse event</h6> <p>No difference between groups was found, but the confidence interval was wide (RR 0.80, 95% CI 0.25 to 2.55; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0082" title="">Analysis 25.2</a>). </p> </section> <section id="CD011301-sec-0300"> <h6 class="title">Duration of treatment effect</h6> <p>The duration of treatment effect was 21.7 weeks in onabotulinumtoxinA 40 U, and 24.2 weeks in onabotulinumtoxinA 80U. </p> </section> </section> </section> <section id="CD011301-sec-0301"> <h4 class="title">COMPARISON 26. OnabotulinumtoxinA 80 units versus 60 units one cycle of treatment, glabellar lines </h4> <p>One RCT (n = 40 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0015" title="CarruthersA , CarruthersJ .Prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatologic Surgery2005;31(10):1297-303. [PMID: 16188182]">Carruthers 2005a</a>). </p> <p>For this reason (one study), we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0302"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0303"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0304"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> <section id="CD011301-sec-0305"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment, were similar with onabotulinumtoxinA 80 U and onabotulinumtoxinA 60 U at week 4 (RR 1.05, 95% CI 0.92 to 1.20; participants = 40; studies = 1) and at week 16 (RR 1.00, 95% CI 0.29 to 3.45; participants = 40; studies = 1), but was higher in the onabotulinumtoxin 60 U group at week 8 (RR 0.53, 95% CI 0.34 to 0.83; participants = 40; studies = 1). At week 12 it was higher in the onabotulinumtoxinA 80 U group, but the result is less certain due to the confidence interval including 1 (RR 1.75, 95% CI 0.95 to 3.22; participants = 40; studies = 1). At week 20 (RR 0.50, 95% CI 0.10 to 2.43; participants = 40; studies = 1) and at week 24 (RR 5.00, 95% CI 0.26 to 98.00; participants = 40; studies = 1) the effect size is uncertain due to the wide confidence intervals (<a href="./references#CD011301-fig-0083" title="">Analysis 26.1</a>). </p> </section> <section id="CD011301-sec-0306"> <h6 class="title">Total adverse events</h6> <p>No difference between groups was found, but the confidence interval was wide (RR 2.00, 95% CI 0.41 to 9.71; participants = 40; studies = 1) (<a href="./references#CD011301-fig-0084" title="">Analysis 26.2</a>). </p> </section> <section id="CD011301-sec-0307"> <h6 class="title">Duration of treatment effect</h6> <p>The duration of treatment effect was 22.8 weeks in onabotulinumA 60 U, and 24.2 weeks in onabotulinumtoxinA 80 U. </p> </section> </section> </section> <section id="CD011301-sec-0308"> <h4 class="title">COMPARISON 27. OnabotulinumtoxinA 12 units versus 7.5 units one cycle of treatment, perioral lines </h4> <p>Only one RCT (n = 60 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0024" title="CohenJL , DayanSH , CoxSE , YalamanchiliR , TardieG .OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Dermatologic Surgery2012;38(9):1497-505. [CENTRAL: CN-00969333] ">Cohen 2012</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0309"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0310"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0311"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0312"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0313"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment, were similar with onabotulinumtoxinA 12 U and onabotulinumtoxinA 7.5 U at week 4 (RR 1.27, 95% CI 0.96 to 1.69; participants = 60; studies = 1), at week 8 (RR 0.90, 95% CI 0.68 to 1.19; participants = 60; studies = 1), at week 16 (RR 1.32, 95% CI 0.78 to 2.23; participants = 60; studies = 1), and at week 20 (RR 1.23, 95% CI 0.72 to 2.12; participants = 60; studies = 1). The responder rate, by physician assessment, were higher with onabotulinumtoxinA 12U than onabotulinumtoxinA 7.5 U at week 12 (RR 2.14, 95% CI 1.27 to 3.59; participants = 60; studies = 1) (<a href="./references#CD011301-fig-0085" title="">Analysis 27.1</a>). </p> </section> <section id="CD011301-sec-0314"> <h6 class="title">Total adverse events</h6> <p>Total adverse events were higher with onabotulinumtoxinA 12 U than onabotulinumtoxinA 7.5 U (RR 1.55, 95% CI 1.00 to 2.42 participants = 60; studies = 1) (<a href="./references#CD011301-fig-0086" title="">Analysis 27.2</a>). </p> </section> <section id="CD011301-sec-0315"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0316"> <h4 class="title">COMPARISON 28. OnabotulinumtoxinA 20 units versus placebo three cycles of treatment, glabellar lines </h4> <p>Only one RCT (n = 537 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0014" title="CarruthersA , CarruthersJ , LoweNJ , MenterA , GibsonJ , NordquistM , et al.One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. Journal of Clinical Research2004;7:1-20. [CENTRAL: CN-00516138] ">Carruthers 2004</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0317"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0318"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>For the participants who received two or more onabotulinumtoxinA injections, the responder rate were significantly higher after the third cycle of treatment than after the first and second cycle of treatment (P &lt; 0.005). No numeric data were provided. </p> </section> <section id="CD011301-sec-0319"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>The number of major adverse events in the first cycle was higher in the onabotulinumtoxinA 20 U group compared with placebo, but the result is very imprecise due to the wide confidence intervals (RR 8.84, 95% CI 0.53 to 147.78; participants = 537; studies = 1) (<a href="./references#CD011301-fig-0087" title="">Analysis 28.1</a>). </p> </section> </section> <section id="CD011301-sec-0320"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0321"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>For the participants who received two or more onabotulinumtoxinA injections the responder rate were higher in the third cycle of treatment than in the first and second cycles at day 30, 60, 90, and 120 days (P &lt; 0.007). No numeric data were provided. </p> </section> <section id="CD011301-sec-0322"> <h6 class="title">Total adverse events</h6> <p>No difference between groups was found (RR 0.76, 95% CI 0.58 to 0.99; participants = 537; studies = 1) (<a href="./references#CD011301-fig-0088" title="">Analysis 28.2</a>). </p> <p>The number of adverse events across first, second and third cycle were 106/501 (21.2%) in the first cycle of BontA treatment, 17/362 (4.7%) in the second cycle of treatment, and 5/258 (2%) in the third cycle of treatment. But no numerical data related to placebo group were provided. </p> </section> <section id="CD011301-sec-0323"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0324"> <h4 class="title">COMPARISON 29. OnabotulinumtoxinA 24 units versus placebo, crow's feet lines</h4> <p>Four RCTs (n = 1675 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>). </p> <p><a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a> was a two‐phase study, so we considered only the first phase (randomised, double‐blind). </p> <section id="CD011301-sec-0325"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0326"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The meta‐analysis showed a difference in favour of onabotulinumtoxinA 24;U group at week 4 (RR 12.71, 95% CI 8.67 to 18.63; participants = 1474; studies = 3; I<sup>2</sup> = 0%), week 8 (RR 10.25, 95% CI 7.02 to 14.98; participants = 1474; studies = 3; I<sup>2</sup> = 0%); and week 12 (RR 7.70, 95% CI 4.81 to 12.33; participants = 1474; studies = 3; I<sup>2</sup> = 28%). Only <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a> showed results of onaboltulinuntoxinA versus placebo at week 20 (RR 10.33, 95% CI 3.35 to 31.89; participants = 417; studies = 1) (<a href="./references#CD011301-fig-0089" title="">Analysis 29.1</a>). </p> </section> <section id="CD011301-sec-0327"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>Two studies (<a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>) assessed this outcome. There was no difference between onabotulinumtoxinA 24 U group and placebo group (Peto OR 1.28, 95% CI 0.12 to 13.10; participants = 665; studies = 2; I<sup>2</sup> = 0%) (<a href="./references#CD011301-fig-0090" title="">Analysis 29.2</a>). </p> </section> </section> <section id="CD011301-sec-0328"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0329"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The meta‐analysis showed a difference in favour of OnabotulinumtoxinA 24U group at week 4 (RR 12.38, 95% CI 8.93 to 17.16; participants = 1675; studies = 4; I<sup>2</sup> = 0%); at week 8 (RR 10.13, 95% CI 5.34 to 19.23; participants = 1258; studies = 3; I<sup>2</sup> = 63%); at week 12 (RR 9.29, 95% CI 5.95 to 14.50; participants = 1258; studies = 3; I<sup>2</sup> = 0%); and week 16 (RR 5.46, 95% CI 3.19 to 9.32; participants = 1057; studies = 2; I² = 0%) (<a href="./references#CD011301-fig-0091" title="">Analysis 29.3</a>). </p> </section> <section id="CD011301-sec-0330"> <h6 class="title">Total adverse events</h6> <p><a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a> showed the number of adverse events per group of intervention not per cycle of treatment. Therefore, only three RCTs (<a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>) were included in the meta‐analysis. Total adverse events were similar in both groups (RR 1.17, 95% CI 0.94 to 1.45; participants = 692; studies = 2; I<sup>2</sup> = 0%) (<a href="./references#CD011301-fig-0092" title="">Analysis 29.4</a>). </p> </section> <section id="CD011301-sec-0331"> <h6 class="title">Duration of treatment effect</h6> <p>Three RCTs assessed this outcome (<a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>; <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>; <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>), but both studies described the results narratively. The duration of treatment effect for responders (none‐ mild at maximum smile) was 16.8 weeks (118 days) (physician assessment), and 16.5 (116 days) (participant assessment). The median duration of effect of treatment at day 30, responders with an improvement from baseline of at least 1 grade on the facial wrinkle scale (FWS) ‐ maximum smile, was 17.8 weeks (125 days) (physician assessment) and 20.5 weeks (144 days) (participant assessment) (<a href="./references#CD011301-bbs2-0020" title="CarruthersA , BruceS , deConinckA , ConnolyS , CoxSE , DavisPG , et al.Efficacy and safety of onabotulinumtoxinA for the treatment of crow’s feet lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2014;40(11):1181-90. [PMID: 25347451]">Carruthers 2014</a>). <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a> showed a duration of treatment effect around 95 days. And <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a> assessed the duration of onabotulinumtoxinA 24 U effect around 150‐157 by investigator assessment and 150‐157 by participant assessment. </p> </section> </section> </section> <section id="CD011301-sec-0332"> <h4 class="title">COMPARISON 30. OnabotulinumtoxinA 12 units versus placebo, crow's feet lines</h4> <p>Two RCTs (n =  657 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>, <a href="./references#CD011301-bbs2-0065" title="WuY , WangG , LiC , MaoC , LeiX , LeeE .Efficacy of onabotulinumtoxinA for treatment of crow's feet lines in Chinese subjects. Plastic and Reconstructive Surgery - Global Open2019;7(1):e2079. [PMID: 30859038]">Wu 2019</a>). <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a> was a two‐phase study, so we considered only the first phase (randomised, double‐blind). </p> <section id="CD011301-sec-0333"> <h5 class="title">Primary outcome</h5> <section id="CD011301-sec-0334"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>Neither RCT assessed this outcome.</p> </section> <section id="CD011301-sec-0335"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p><a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a> assessed this outcome and there was no difference between groups was found, but the confidence interval was wide (RR 1.36, 95% CI 0.12 to 14.76; participants = 240; studies = 1) (<a href="./references#CD011301-fig-0093" title="">Analysis 30.1</a>). </p> </section> </section> <section id="CD011301-sec-0336"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0337"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p><a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a> assessed this outcome and the results favoured onabotulinumtoxinA 12 U group at week 4 (RR 6.86, 95% CI 3.45 to 13.62; participants = 196; studies = 1); at week 8 (RR 4.29, 95% CI 2.10 to 8.76; participants = 196; studies = 1); and at week 12 (RR 5.55, 95% CI 1.68 to 18.34; participants = 196; studies = 1) (<a href="./references#CD011301-fig-0094" title="">Analysis 30.2</a>). </p> </section> <section id="CD011301-sec-0338"> <h6 class="title">Total adverse events</h6> <p>Both studies reported the total adverse events and they were similar across groups (RR 1.33. 95% CI 0.87 to 2.02; participants= 657, studies=2, I<sup>2</sup> = 0%) (<a href="./references#CD011301-fig-0095" title="">Analysis 30.3</a>). </p> </section> <section id="CD011301-sec-0339"> <h6 class="title">Duration of treatment effect</h6> <p><a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a> described the results narratively. The duration of treatment effect for responders (none‐ mild at maximum smile) was 85 days in onabotulinumtoxinA 12 U group. </p> </section> </section> </section> <section id="CD011301-sec-0340"> <h4 class="title">COMPARISON 31. OnabotulinumtoxinA 24 units versus onabotulinumtoxinA 12 units, crow's feet lines </h4> <p>One RCT (n =  294 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>). </p> <p><a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a> was a two‐phase study, we considered only the first phase (randomised, double‐blind). </p> <section id="CD011301-sec-0341"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0342"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0343"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p><a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a> assessed this outcome and there was no difference between onabotulinumtoxinA 24 U group and onabotulinumtoxinA 12 U group (RR 0.95, 95% CI 0.14 to 6.63; participants = 294; studies = 1) (<a href="./references#CD011301-fig-0096" title="">Analysis 31.1</a>). </p> </section> </section> <section id="CD011301-sec-0344"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0345"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The analysis showed a difference in favour of onabotulinumtoxinA 24 U group than onabotulinumtoxinA 12 U group at week 12 (RR 1.90, 95% CI 1.14 to 3.18; participants = 203; studies = 1); but there was a similar response between groups at week 4 (RR 1.21, 95% CI 0.97 to 1.50; participants = 203; studies = 1); and at week 8 (RR 1.36, 95% CI 0.97 to 1.90; participants = 203; studies = 1) (<a href="./references#CD011301-fig-0097" title="">Analysis 31.2</a>). </p> </section> <section id="CD011301-sec-0346"> <h6 class="title">Total adverse events</h6> <p>In <a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>, the total adverse events were similar in both groups (RR 0.86, 95% CI 0.59 to 1.25; participants = 294; studies = 1) (<a href="./references#CD011301-fig-0098" title="">Analysis 31.3</a>). </p> </section> <section id="CD011301-sec-0347"> <h6 class="title">Duration of treatment effect</h6> <p><a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a> described the results narratively. The duration of treatment effect for responders (none‐ mild at maximum smile) was 85 days in onabotulinumtoxinA 12 U group and 95 days in onabotulinumtoxinA 24 U group. </p> </section> </section> </section> <section id="CD011301-sec-0348"> <h4 class="title">COMPARISON 32. OnabotulinumtoxinA 44 units versus placebo one cycle of treatment, glabellar lines and crow's feet lines </h4> <p>Three RCTs (n = 808 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>). </p> <section id="CD011301-sec-0349"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0350"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The meta‐analysis showed a benefit with onabotulinumtoxinA 44 U at week 4 (RR 16.33, 95% CI 9.27 to 28.76; participants = 808; studies = 2; I² = 0%) (<a href="./references#CD011301-fig-0099" title="">Analysis 32.1</a>). </p> <p>Only one RCT assessed success in the following weeks (<a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>). The responder rate by participant assessment was higher with onabotulinumtxinA 44 U than placebo at week 8 (RR 8.95, 95% CI 5.03 to 15.90; participants = 611; studies = 1); at week 12 (RR 5.10, 95% CI 2.80 to 9.28; participants = 611; studies = 1); and at week 16 (RR 2.51, 95% CI 1.31 to 4.81; participants = 611; studies = 1) (<a href="./references#CD011301-fig-0099" title="">Analysis 32.1</a>). </p> <p><a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a> did not report this outcome. </p> </section> <section id="CD011301-sec-0351"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>These RCTs did not report any major event (<a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>). One RCT did not assess this outcome (<a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>). </p> </section> </section> <section id="CD011301-sec-0352"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0353"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>Two RCTs (<a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>) studied this outcome. The meta‐analysis showed benefit with onabotulinumtoxinA 44 U at week 4 (RR 11.09, 95% CI 4.12 to 29.83; n = 808; studies = 2; I² = 80%); and week 8 (RR 9.94, 95% CI 1.78 to 55.44; n = 808; studies = 2; I² = 91%). However, a less certain difference was observed at week 12 due to the wide confidence interval (RR 5.96, 95% CI 0.60 to 58.98; n = 808) (<a href="./references#CD011301-fig-0100" title="">Analysis 32.2</a>). </p> <p>One study (<a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>), assessed this outcome separately. At week 4, the responders rate (score of none or mild on the glabellar lines (G)L facial wrinkle scale (FWS) compared with the placebo group‐FWS) was 50/60 (83.3%) of participants in the onabotulinumtoxinA group, and 1/57(1.8%) in placebo group. The improvement of at least one point was 52/60 (86.7%) in the onabotulinumtoxinA group and 5/57 (8.8%) in placebo group. At week 12, 40/60 (66%) of participants in onabotulinumtoxinA group were responders. </p> </section> <section id="CD011301-sec-0354"> <h6 class="title">Total adverse events</h6> <p><a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a> and <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a> reported total adverse events; however, the authors showed the number of adverse events per group of intervention not per cycle of treatment. </p> <p>For this reason (one study), we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plot. </p> <p>One study assessed this outcome (<a href="./references#CD011301-bbs2-0055" title="RiversJK , BertucciV , McGillivrayW , MuhnC , RosenN , SolishN , et al.Subject satisfaction with onabotulinumtoxina treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure. Dermatologic Surgery2015;41(8):950-9. [CENTRAL: CN-01091229] ">Rivers 2015</a>), total adverse events were similar in both groups (RR 1.16, 95% CI 0.56 to 2.40; participants = 125; studies = 1) (<a href="./references#CD011301-fig-0101" title="">Analysis 32.3</a>). </p> </section> <section id="CD011301-sec-0355"> <h6 class="title">Duration of treatment effect</h6> <p>These RCTs did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0356"> <h4 class="title">COMPARISON 33. OnabotulinumtoxinA 44 units versus placebo two cycles of treatment, glabellar lines and crow's feet lines </h4> <p>Two RCTs (n = 808 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>; <a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>). </p> <section id="CD011301-sec-0357"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0358"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The meta‐analysis showed a benefit with onabotulinumtoxinA 44 U than placebo at week 4 (RR 10.12, 95% CI 6.36 to 16.09; participants = 808; studies = 2; I² = 0%) (<a href="./references#CD011301-fig-0102" title="">Analysis 33.1</a>). </p> <p>One RCT (<a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>) assessed responder rate at week 8 (RR 8.95, 95% CI 5.03 to 15.90; participants = 611; studies = 1), and at week 12 (RR 4.85, 95% CI 2.66 to 8.84; participants = 611; studies = 1), finding a benefit favouring onabotulinumtoxinA 44 U (<a href="./references#CD011301-fig-0102" title="">Analysis 33.1</a>). </p> </section> <section id="CD011301-sec-0359"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>Two RCTs assessed this outcome (<a href="./references#CD011301-bbs2-0045" title="Moers-CapriM , CarruthersJ , FagienS , LupoM , DelmarH , JonesD , et al.Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial. Dermatologic Surgery2015;41(1):102-12. [CENTRAL: CN-01049373] ">Moers‐Carpi 2015</a>; <a href="./references#CD011301-bbs2-0021" title="CarruthersJ , RivkinA , DonofrioL , BertucciV , SomogyiC , LeiX , et al.A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeated onabotulinumtoxinA treatments in subjects with crow's feet lines and glabellar lines. Dermatologic Surgery2015;41(6):702-11. [CENTRAL: CN-01083939] NCT01224015.Safety and efficacy study of botulinum toxin type A for the treatment of crow's feet lines and frown lines. clinicaltrials.gov/ct2/show/NCT01224015 (first received 19 October 2010). ">Carruthers 2015</a>). These RCTs did not report any major event. </p> </section> </section> <section id="CD011301-sec-0360"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0361"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The meta‐analysis showed a benefit with onabotulinumtoxinA 44 U at week 4 (RR 17.63, 95% CI 9.50 to 32.69; participants = 808; studies = 2; I² = 19%), and week 8 (RR 19.86, 95% CI 9.90 to 39.87; participants = 808; studies = 2; I² = 0%) (<a href="./references#CD011301-fig-0103" title="">Analysis 33.2</a>). </p> </section> <section id="CD011301-sec-0362"> <h6 class="title">Total adverse events</h6> <p>The meta‐analysis showed no difference between OnabotulinumtoxinA 44 U and placebo (RR 1.13, 95% CI 0.98 to 1.30; n = 808; studies = 2; I² = 0%) (<a href="./references#CD011301-fig-0104" title="">Analysis 33.3</a>). </p> </section> <section id="CD011301-sec-0363"> <h6 class="title">Duration of treatment effect</h6> <p>These RCTs did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0364"> <h4 class="title">COMPARISON 34. OnabotulinumtoxinA 24 units versus 12 units five cycles of treatment, crow's feet lines  </h4> <p>Only one RCT (n =  300 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0033" title="HariiK , KawashimaM , FuruyamaN , LeiX , HopfingerR , LeeE .Onabotulinumtoxina (botox) in the treatment of crow's feet lines in Japanese subjects. Aesthetic Plastic Surgery2017;41(5):1186-97. [PMID: 28733805]NCT01797094.BOTOX® in the treatment of upper facial lines in Japan. clinicaltrials.gov/ct2/show/NCT01797094 (first received 22 February 2013). ">Harii 2017</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0365"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0366"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The authors considered only one point of improvement as a cut‐off value. For this reason, we did not analyse this outcome. </p> </section> <section id="CD011301-sec-0367"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not show any major adverse events.</p> </section> </section> <section id="CD011301-sec-0368"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0369"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0370"> <h6 class="title">Total adverse events</h6> <p>The total adverse events rate was higher with onabotulinumtoxinA 24 U than onabotulinumtoxinA 12 U (RR 1.42, 95% CI 0.41 to 4.93; participants = 294; studies = 1) (<a href="./references#CD011301-fig-0105" title="">Analysis 34.1</a>). </p> </section> <section id="CD011301-sec-0371"> <h6 class="title"> Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0372"> <h4 class="title">COMPARISON 35. AbobotulinumtoxinA 25 units versus placebo one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 45 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0373"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0374"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0375"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus</h6> <p>This RCT did not show any major adverse event.</p> </section> </section> <section id="CD011301-sec-0376"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0377"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responders' rates, by physician assessment, were higher with abobotulinumtoxinA 25 U than placebo at week 4 (RR 7.50, 95% CI 1.09 to 51.52; participants = 45; studies = 1); at week 8(RR 17.03, 95% CI 1.09 to 265.91; participants = 45; studies = 1), at week 12 (RR 10.84, 95% CI 0.68 to 173.34; participants = 45; studies = 1); and at week 24 (RR 4.65, 95% CI 0.27 to 81.01; participants = 45; studies = 1) (<a href="./references#CD011301-fig-0106" title="">Analysis 35.1</a>). </p> </section> <section id="CD011301-sec-0378"> <h6 class="title">Total adverse events</h6> <p>This RCT showed more adverse events in abobotulinumtoxinA 25U than placebo (Peto OR 5.21, 95% CI 0.74 to 36.60; participants = 45; studies = 1) (<a href="./references#CD011301-fig-0107" title="">Analysis 35.2</a>). </p> </section> <section id="CD011301-sec-0379"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0380"> <h4 class="title">COMPARISON 36. AbobotulinumtoxinA 30 units versus placebo one cycle of treatment, glabellar lines </h4> <p>One RCT (n = 99 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plot. </p> <section id="CD011301-sec-0381"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0382"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0383"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0384"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0385"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder's rates, by physician assessment, were higher with abobotulinumtoxinA 30U than placebo at week 4: (RR 4.55, 95% CI 2.32 to 8.93; participants = 109; studies = 1) (<a href="./references#CD011301-fig-0108" title="">Analysis 36.1</a>). </p> </section> <section id="CD011301-sec-0386"> <h6 class="title">Total adverse events</h6> <p>This RCT did not report any adverse events.</p> </section> <section id="CD011301-sec-0387"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0388"> <h4 class="title">COMPARISON 37. AbobotulinumtoxinA 50 units versus placebo one cycle of treatment, glabellar lines </h4> <p>Nine RCTs (n = 1333 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>), and the results are included in <a href="./full#CD011301-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD011301-sec-0389"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0390"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The meta‐analysis (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>) showed a benefit with abobotulinumtoxinA when compared with placebo at week 4 (RR 21.22, 95% CI 7.43 to 60.56, participants = 915; studies = 5; I<sup>2</sup> = 54%, high‐certainty evidence); at week 8 (RR 39.74, 95% CI 14.04 to 112.44; participants = 714, studies = 3; I<sup>2</sup> = 0%); and week 12 (RR 28.71, 95% CI 10.12 to 81.49; participants = 724; studies = 3; I<sup>2</sup> = 0%, low‐certainty evidence) (<a href="./references#CD011301-fig-0109" title="">Analysis 37.1</a>). </p> <p>Only <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a> assessed the following weeks: 16 week (RR 10.67, 95% CI 3.44 to 33.11; participants = 300; studies = 1); and at 20 weeks (RR 5.33, 95% CI 1.67 to 16.99; participants = 300; studies = 1) (<a href="./references#CD011301-fig-0109" title="">Analysis 37.1</a>). </p> <p><a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a> did not assess this comparison, and <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a> and <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a> did not provide data. </p> </section> <section id="CD011301-sec-0391"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>A meta‐analysis (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>) showed more adverse events in abobotulinum group when compared to placebo group (RR 3.36, 95% CI 0.88 to 12.87; participants = 1294; studies = 7; I<sup>2</sup> = 0%, moderate‐certainty evidence) (<a href="./references#CD011301-fig-0110" title="">Analysis 37.2</a>). </p> <p><a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a> and <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a> did not report this outcome. </p> </section> </section> <section id="CD011301-sec-0392"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0393"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p><a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a> assessed this comparison. The meta‐analysis showed a benefit with abobotulinumtoxinA 50u than placebo at week 4 RR 15.78, 95% CI 8.75 to 28.45; participants = 1060; studies = 7; I<sup>2</sup> = 7%; moderate‐certainty evidence); at week 8 (RR 30.84, 95% CI 11.58  to 82.12; participants = 802; studies = 5; I<sup>2</sup> = 2%); at week 12 (RR 17.79, 95% CI 6.70 to 45.28; participants = 900; studies = 6; I<sup>2</sup> = 29%); and at week 16 (RR 29.88, 95% CI 6.01 to 148.52; participants = 371; studies = 2; I<sup>2</sup> = 0%) (<a href="./references#CD011301-fig-0111" title="">Analysis 37.3</a>). </p> <p> Only <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a> assessed this outcome at 20 weeks (RR 17.00, 95% CI 2.36 to 122.39; participants = 300; studies = 1) (<a href="./references#CD011301-fig-0111" title="">Analysis 37.3</a>). </p> <p>At 24 weeks in <a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>, the responder rates were 13.8% in abobotulinumtoxinA group and 0% in placebo group. We did not perform a meta‐analysis because only one RCT showed data in this period (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>). </p> </section> <section id="CD011301-sec-0394"> <h6 class="title">Total adverse events</h6> <p><a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a>; <a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a> showed data for this analysis. The total adverse events were higher with abobotulinumtoxinA than the placebo group (RR 1.25, 95% CI 1.05 to 1.49; participants = 1471; studies = 7; I<sup>2</sup> = 0%, low‐certainty evidence) (<a href="./references#CD011301-fig-0112" title="">Analysis 37.4</a>). </p> <p><a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a> did not report this outcome. </p> </section> <section id="CD011301-sec-0395"> <h6 class="title">Duration of treatment effect</h6> <p><a href="./references#CD011301-bbs2-0002" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , NiforosF , et al.Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection. Aesthetic Surgery Journal2005;25(4):365-75. [PMID: 19338833]">Ascher 2005</a> showed abobotulinumtoxinA reporting a longer duration of effect compared to placebo (MD 17.30, 95% CI 15.82 to 18.78; participants = 100; studies = 1; moderate certainty evidence) (<a href="./references#CD011301-fig-0113" title="">Analysis 37.5</a>). </p> <p><a href="./references#CD011301-bbs2-0010" title="BrandtF , SwansonN , BaumannL , HuberB .Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatologic Surgery2009;35(12):1893-901. [CENTRAL: CN-00734159] ">Brandt 2009</a> showed median duration of effect of BontA of 12 weeks (85 days). </p> <p><a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a> showed a duration of effect of 15.3 weeks (107 days) in BontA group. </p> <p><a href="./references#CD011301-bbs2-0047" title="MonheitGD , BaumannL , MaasC , RandR , DownR .Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. Dermatologic Surgery2020;46(1):61-9. ">Monheit 2019</a> showed median duration of effect of 117 days. </p> <p><a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>; <a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0046" title="MonheitG , CarruthersA , BrandtF , RandR .A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatologic Surgery2007;33(1 Spec No):S51-9. [CENTRAL: CN-00575071] ">Monheit 2007</a>; <a href="./references#CD011301-bbs2-0057" title="RzanyB , AscherB , FratilaA , MonheitGD , TalaricoS , SterryW .Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Archives of Dermatology2006;142(3):320-6. [CENTRAL: CN-00555812] ">Rzany 2006</a> and <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a> did not study this outcome. </p> </section> </section> </section> <section id="CD011301-sec-0396"> <h4 class="title">COMPARISON 38. AbobotulinumtoxinA 50 units versus 25 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 59 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0397"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0398"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0399"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus</h6> <p>This RCT did not show any major adverse events.</p> </section> </section> <section id="CD011301-sec-0400"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0401"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responders' rates, by physician assessment, were higher with abobotulinumtoxinA 50 U than abobotulinumtoxinA 25 U at week 4 (RR 1.52, 95% CI 1.00 to 2.29; participants = 59; studies = 1); at week 12 (RR 1.45, 95% CI 0.77 to 2.72; participants = 59; studies = 1), but there was no difference between abobotulinumtoxinA 50 U and abobotulinumtoxinA 25 U at week 8 (RR 1.03, 95% CI 0.65 to 1.65; participants = 59; studies = 1); and at week 24 (RR 1.03, 95% CI 0.29 to 3.75; participants = 59; studies = 1) (<a href="./references#CD011301-fig-0114" title="">Analysis 38.1</a>). </p> </section> <section id="CD011301-sec-0402"> <h6 class="title">Total adverse events</h6> <p>No difference between groups was found, but the confidence interval was wide (Peto OR 0.59, 95% CI 0.13 to 2.58; participants = 59; studies = 1) (<a href="./references#CD011301-fig-0115" title="">Analysis 38.2</a>). </p> </section> <section id="CD011301-sec-0403"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0404"> <h4 class="title">COMPARISON 39. AbobotulinumtoxinA 60 units versus placebo one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 423 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0405"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0406"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responders' rates, by participant assessment, were higher with abobotulinumtoxinA 60 U than placebo at week 4 (RR 11.48, 95% CI 6.50 to 20.29; participants = 423; studies = 1) (<a href="./references#CD011301-fig-0116" title="">Analysis 39.1</a>). </p> </section> <section id="CD011301-sec-0407"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event by units.</p> </section> </section> <section id="CD011301-sec-0408"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0409"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder's rates, by physician assessment, were higher with abobotulinumtoxinA 60 U than placebo at week 4 (RR 15.98, 95% CI 8.14 to 31.36; participants = 423; studies = 1) (<a href="./references#CD011301-fig-0117" title="">Analysis 39.2</a>). </p> </section> <section id="CD011301-sec-0410"> <h6 class="title">Total adverse events</h6> <p>This RCT did not report any adverse events by units.</p> </section> <section id="CD011301-sec-0411"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome by units.</p> </section> </section> </section> <section id="CD011301-sec-0412"> <h4 class="title">COMPARISON 40. AbobotulinumtoxinA 70 units versus placebo one cycle of treatment, glabellar lines </h4> <p>Only one RCT(n = 291 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0413"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0414"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responders' rates, by participant assessment, were higher with abobotulinumtoxinA 70 U than placebo however the confidence interval was very wide showing we are very uncertain with this result; at week 4 (RR 151.39, 95% CI 9.54 to 2402.95; participants = 291; studies = 1) (<a href="./references#CD011301-fig-0118" title="">Analysis 40.1</a>). </p> </section> <section id="CD011301-sec-0415"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major adverse events by units.</p> </section> </section> <section id="CD011301-sec-0416"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0417"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responders' rates, by physician assessment, were higher with abobotulinumtoxinA 70 U than placebo at week 4; however, the confidence interval is very wide showing uncertainty in the effect size (RR 71.36, 95% CI 10.15 to 501.56; participants = 289; studies = 1) (<a href="./references#CD011301-fig-0119" title="">Analysis 40.2</a>). </p> </section> <section id="CD011301-sec-0418"> <h6 class="title">Total adverse events</h6> <p>This RCT did not report any adverse events by units.</p> </section> <section id="CD011301-sec-0419"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome by units.</p> </section> </section> </section> <section id="CD011301-sec-0420"> <h4 class="title">COMPARISON 41. AbobotulinumtoxinA 75 units versus placebo one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 45 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0421"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0422"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0423"> <h6 class="title">Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus</h6> <p>This RCT did not show any major adverse events.</p> </section> </section> <section id="CD011301-sec-0424"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0425"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responders' rates, by physician assessment, were higher with abobotulinumtoxinA 75 U than placebo at week 4 (RR 11.50, 95% CI 1.71 to 77.18; participants = 45; studies = 1); at week 8 (RR 9.50, 95% CI 1.40 to 64.35; participants = 45; studies = 1); at week 12 (RR 16.00, 95% CI 1.02 to 250.48; participants = 45; studies = 1); and at week 24 (RR 3.61, 95% CI 0.20 to 65.73; participants = 45; studies = 1) (<a href="./references#CD011301-fig-0120" title="">Analysis 41.1</a>). </p> </section> <section id="CD011301-sec-0426"> <h6 class="title">Total adverse events</h6> <p>This RCT did not show any adverse events.</p> </section> <section id="CD011301-sec-0427"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0428"> <h4 class="title">COMPARISON 42. AbobotulinumtoxinA 75 units versus 25 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 60 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0429"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0430"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0431"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus</h6> <p>This RCT did not show any major adverse event.</p> </section> </section> <section id="CD011301-sec-0432"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0433"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responders' rates, by physician assessment, were higher with AaobotulinumtoxinA 75 U than abobotulinumtoxinA 25 U at week 4 (RR 11.50, 95% CI 2.97 to 44.51; participants = 60; studies = 1). </p> <p>Although the responders' rates, by physician assessment, were higher with abobotulinumtoxinA 75 U than abobotulinumtoxinA 25 U, the results were very uncertain because of the wide confidence intervals: at week 8 (RR 39.00, 95% CI 2.46 to 617.81; participants = 60; studies = 1); at week 12 (RR 31.00, 95% CI 1.94 to 495.61; participants = 60; studies = 1); and at week 24 (RR 7.00, 95% CI 0.38 to 129.93; participants = 60; studies = 1) (<a href="./references#CD011301-fig-0121" title="">Analysis 42.1</a>). </p> </section> <section id="CD011301-sec-0434"> <h6 class="title">Total adverse events</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0435"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0436"> <h4 class="title">COMPARISON 43. AbobotulinumtoxinA 75 units versus 50 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 60 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0001" title="AscherB , ZakineB , KestemontP , BaspeyrasM , BougaraA , SantiniJ .A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. Journal of the American Academy of Dermatology2004;51(2):223-33. [PMID: 15280841]">Ascher 2004</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0437"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0438"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not show any major adverse event.</p> </section> <section id="CD011301-sec-0439"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus</h6> <p>This RCT did not assess this outcome.</p> </section> </section> <section id="CD011301-sec-0440"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0441"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responders' rates, by physician assessment, did not show any difference with abobotulinumtoxinA 75 U or abobotulinumtoxinA 50 U at week 4 (RR 1.01, 95% CI 0.76 to 1.34; participants = 59; studies = 1); at week 8 (RR 1.15, 95% CI 0.75 to 1.76; participants = 59; studies = 1); at week 12 (RR 1.04, 95% CI 0.62 to 1.74; participants = 59; studies = 1); at week 24 (RR 0.72, 95% CI 0.18 to 2.96; participants = 59; studies = 1) (<a href="./references#CD011301-fig-0122" title="">Analysis 43.1</a>). </p> </section> <section id="CD011301-sec-0442"> <h6 class="title">Total adverse events</h6> <p>This RCT did not show any difference between AbobotulinumtoxinA 75U and AbobotulinumtoxinA 50U (Peto OR 0.12, 95% CI 0.01 to 1.22; participants = 59; studies = 1) (<a href="./references#CD011301-fig-0123" title="">Analysis 43.2</a>). </p> </section> <section id="CD011301-sec-0443"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0444"> <h4 class="title">COMPARISON 44. AbobotulinumtoxinA 80 units versus placebo one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 59 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0035" title="KaneMA , BrandtF , RohrichRJ , NarinsRS , MonheitGD , HuberMB , et al.Evaluation of variable-dose treatment with a new U.S. botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plastic and Reconstructive Surgery2009;124(5):1619-29. [CENTRAL: CN-00728882] ">Kane 2009</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0445"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0446"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responders' rates, by participant assessment, were higher with abobotulinumtoxinA 80 U than placebo at week 4; however, because of the confidence interval the results is very uncertain (RR 40.50, 95% CI 2.58 to 635.35; participants = 59; studies = 1) (<a href="./references#CD011301-fig-0124" title="">Analysis 44.1</a>). </p> </section> <section id="CD011301-sec-0447"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report major adverse events by units.</p> </section> </section> <section id="CD011301-sec-0448"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0449"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responders' rates, by physician assessment, were higher with abobotulinumtoxinA 8 0U than placebo at week 4; however, because of the confidence interval the results is very uncertain (RR 32.56, 95% CI 2.06 to 514.19; participants = 59; studies = 1) (<a href="./references#CD011301-fig-0125" title="">Analysis 44.2</a>). </p> </section> <section id="CD011301-sec-0450"> <h6 class="title">Total adverse events</h6> <p>This RCT did not report any adverse events by units.</p> </section> <section id="CD011301-sec-0451"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome by units.</p> </section> </section> </section> <section id="CD011301-sec-0452"> <h4 class="title">COMPARISON 45. AbobotulinumtoxinA 15units versus placebo one cycle of treatment, crow's feet lines </h4> <p>Only one RCT(n = 109 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0453"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0454"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0455"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0456"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0457"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responders' rates, by physician assessment, were higher with abobotulinumtoxinA 15U versus placebo at week 4 (RR 4.52, 95% CI 1.85 to 11.01; participants = 109; studies = 1) (<a href="./references#CD011301-fig-0126" title="">Analysis 45.1</a>). </p> </section> <section id="CD011301-sec-0458"> <h6 class="title">Total adverse events</h6> <p>One RCT assessed this outcome (<a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>). Adverse events frequency was 5/42 (13%) in abobotulinumtoxinA 15 U group, but no information was given for the placebo group. </p> </section> <section id="CD011301-sec-0459"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0460"> <h4 class="title">COMPARISON 46. AbobotulinumtoxinA 30 units versus placebo one cycle of treatment, crow's feet lines </h4> <p>Only one RCT (n = 108 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0461"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0462"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0463"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0464"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0465"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responders' rates, by physician assessment, were higher with abobotulinumtoxinA 30 U versus placebo week 4 (RR 6.40, 95% CI 2.70 to 15.18; participants = 108; studies = 1) (<a href="./references#CD011301-fig-0127" title="">Analysis 46.1</a>). </p> </section> <section id="CD011301-sec-0466"> <h6 class="title">Total adverse events</h6> <p>The adverse events frequency was 4/37(11%) in abobotulinumtoxinA 30U group, but no information was given for placebo. </p> </section> <section id="CD011301-sec-0467"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0468"> <h4 class="title">COMPARISON 47. AbobotulinumtoxinA 45units versus placebo one cycle of treatment, crow's feet lines </h4> <p>Only one RCT (n = 108 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0003" title="AscherB , RzanyBJ , GroverR .Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatologic Surgery2009;35(10):1478-86. [DOI: 10.1111/j.1524-4725.2009.01261.x] [PMID: 19686365]">Ascher 2009</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0469"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0470"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0471"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>One case of eyelid ptosis in AbobotulinumtoxinA 45U was reported.</p> </section> </section> <section id="CD011301-sec-0472"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0473"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responders' rates, by physician assessment, were higher with abobotulinumtoxinA 4 5U versus placebo week 4 (RR 6.20, 95% CI 2.61 to 14.74; participants = 108; studies = 1) (<a href="./references#CD011301-fig-0128" title="">Analysis 47.1</a>). </p> </section> <section id="CD011301-sec-0474"> <h6 class="title">Total adverse events</h6> <p>The adverse events frequency was 5/40 (13%) in abobotulinumtoxinA 45 U, but no information was given for the placebo group. </p> </section> <section id="CD011301-sec-0475"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0476"> <h4 class="title">COMPARISON 48. AbobotulinumtoxinA 50 units versus placebo three cycles of treatment, glabellar lines </h4> <p>Only one RCT (n = 142 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0056" title="RubinMG , DoverJ , GlogauRG , GoldbergDJ , GoldmanMP , SchlessingerJ .The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. Journal of Drugs in Dermatology2009;8(5):439-44. [CENTRAL: CN-00698408] ">Rubin 2009</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0477"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0478"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responders'rates, by participant assessment, were higher with abobotulinumtoxinA 50 U versus placebo week 4 in the third cycle (RR 8.00, 95% CI 3.92 to 16.33; participants = 142; studies = 1) (<a href="./references#CD011301-fig-0129" title="">Analysis 48.1</a>). </p> </section> <section id="CD011301-sec-0479"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0480"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0481"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responders' rates, by physician assessment, were higher with AbobotulinumtoxinA 50U versus placebo week 4 in the third cycle (RR 20.00, 95% CI 6.58 to 60.80; participants = 142; studies = 1) (<a href="./references#CD011301-fig-0130" title="">Analysis 48.2</a>). </p> </section> <section id="CD011301-sec-0482"> <h6 class="title">Total adverse events</h6> <p>No difference between groups was found, but the confidence interval was wide at week 4 in the third cycle (RR 1.29; 95% CI 0.81 to 2.05; participants = 142; studies = 1) (<a href="./references#CD011301-fig-0131" title="">Analysis 48.3</a>). </p> </section> <section id="CD011301-sec-0483"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0484"> <h4 class="title">COMPARISON 49. IncobotulinumtoxinA 20 units versus placebo one cycle of treatment, glabellar lines </h4> <p>Two RCTs (n = 547 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0019" title="CarruthersA , CarruthersJ , ColemanWP , DonofrioL , FlynnT , GoldM , et al.Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatologic Surgery2013;39(4):551-8. [PMID: 23379292]">Carruthers 2013</a>; <a href="./references#CD011301-bbs2-0031" title="HankeCW , NarinsRS , BrandtF , CohenJL , DonofrioLM , DownieJ , et al.A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatologic Surgery2013;39(6):891-9. [CENTRAL: CN-00964813] ">Hanke 2013</a>), and the results are included in <a href="./full#CD011301-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD011301-sec-0485"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0486"> <h6 class="title">Participant assessment of success by analysing scores and scales.</h6> <p>The meta analysis showed a benefit favours incobotulinumtoxinA at week 4 (RR 66.57, 95% CI 13.50 to 328.28; participants = 547; studies = 2; I² = 0%); week 8 (RR 7.35, 95% CI 4.79 to 11.29; participants = 547; studies = 2; I² = 0%); week 12 (RR 7.29, 95% CI 4.38 to 12.13; participants = 547; studies = 2; I² = 0%); and week 16 (RR 4.40, 95% CI 2.61 to 7.41; participants = 547; studies = 2; I² = 0%) (moderate‐certainty evidence) (<a href="./references#CD011301-fig-0132" title="">Analysis 49.1</a>). </p> </section> <section id="CD011301-sec-0487"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>These RCTs did not report any major event.</p> </section> </section> <section id="CD011301-sec-0488"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0489"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The meta‐analysis showed a benefit favouring incobotulinumtoxinA at week 4 (RR 134.62, 95% CI 19.05 to 951.45; participants = 547; studies = 2; I² = 0%), but the confidence interval was very wide showing uncertainty (<a href="./references#CD011301-fig-0133" title="">Analysis 49.2</a>). No studies assessed this outcome at other time points (moderate‐certainty evidence). </p> </section> <section id="CD011301-sec-0490"> <h6 class="title">Total adverse events</h6> <p>The meta‐analysis did not show any clear difference between intervention groups (RR 1.17, 95% CI 0.90 to 1.53; participants = 547; studies = 2; I² = 0%, low‐certainty evidence) (<a href="./references#CD011301-fig-0134" title="">Analysis 49.3</a>). </p> </section> <section id="CD011301-sec-0491"> <h6 class="title">Duration of treatment effect</h6> <p>These RCTs did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0492"> <h4 class="title">COMPARISON 50. IncobotulinumtoxinA 54 to 64 units versus placebo one cycles of treatment, glabellar lines, forehead lines, crow's feet lines </h4> <p>Only one RCT (n = 156 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0038" title="KerscherM , RzanyB , PragerW , TurnbullC , TrevidicP , InglefieldC .Efficacy and safety of incobotulinumtoxina in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase iii study. Dermatologic Surgery2015;41(10):1149-57. [CENTRAL: CN-01108580] ">Kerscher 2015</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0493"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0494"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0495"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>The major adverse event were higher with incotulinumtoxinA 54 U to 64  U (one unilateral blepharoptosis and the other one bilateral blepharoptosis) and placebo (dry eyes) ,but the RR is uncertain (RR 0.49; 95% CI 0.07 to 3.35; n = 156) (<a href="./references#CD011301-fig-0135" title="">Analysis 50.1</a>). </p> </section> </section> <section id="CD011301-sec-0496"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0497"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate, by physician assessment, was higher with IncobotulinumtoxinA than placebo at week 4 in glabellar lines ((GL) RR 87.81, 95% CI 5.56 to 1386.93; participants = 156; studies = 1); in forehead lines (RR 35.94, 95% CI 5.14 to 251.27; participants = 156; studies = 1); and in crow's feet lines (RR 32.54, 95% CI 4.65 to 227.82; participants = 156; studies = 1) (<a href="./references#CD011301-fig-0136" title="">Analysis 50.2</a>). However, because of the wide confidence intervals the results are very uncertain. </p> </section> <section id="CD011301-sec-0498"> <h6 class="title">Total adverse events</h6> <p>The frequency of total adverse events were similar with IncobotulinumtoxinA and placebo (RR 1.13, 95% CI 0.84 to 1.51; participants = 156; studies = 1) (<a href="./references#CD011301-fig-0137" title="">Analysis 50.3</a>). </p> </section> <section id="CD011301-sec-0499"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0500"> <h4 class="title">COMPARISON 51. HBTX‐A 10units versus placebo one cycle of treatment, glabellar lines</h4> <p>Only one RCT (n = 305 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0501"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0502"> <h6 class="title">Participant assessment of success by analysing scores and scales.</h6> <p>The responder rate, by participant assessment, was higher with HBTX‐A 10 U than placebo at week 4 (RR 14.78, 95% CI 6.74 to 32.41; participants = 305; studies = 1; at week 8 (RR 13.78, 95% CI 6.27 to 30.25; participants = 305; studies = 1); and at week 16 (RR 9.44, 95% CI 4.26 to 20.93; participants = 305; studies = 1) (<a href="./references#CD011301-fig-0138" title="">Analysis 51.1</a>). </p> </section> <section id="CD011301-sec-0503"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major adverse event.</p> </section> </section> <section id="CD011301-sec-0504"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0505"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>This RCT did not study this outcome.</p> </section> <section id="CD011301-sec-0506"> <h6 class="title">Total adverse events</h6> <p>One RCT assessed this outcome (<a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>), the total adverse events were higher with HBTX‐A 10 U than placebo (RR 4.95, 95% CI 2.33 to 10.54; participants = 305; studies = 1) (<a href="./references#CD011301-fig-0139" title="">Analysis 51.2</a>). </p> </section> <section id="CD011301-sec-0507"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0508"> <h4 class="title">COMPARISON 52. HBTX‐A 20 units versus placebo one cycle of treatment, glabellar lines</h4> <p>One RCT (n = 305 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>). </p> <p>For this reason (one study), we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0509"> <h5 class="title">Primary outcome</h5> <section id="CD011301-sec-0510"> <h6 class="title">Participant assessment of success by analysing scores and scales.</h6> <p>The responder's rate, by participant assessment, was higher with HBTX‐A 20 U than placebo at week 4 (RR 18.33, 95% CI 8.39 to 40.06; participants = 305; studies = 1); at week 8 (RR 17.00, 95% CI 7.77 to 37.19; participants = 305; studies = 1); and at week 16 (RR 15.22, 95% CI 6.95 to 33.36; participants = 305; studies = 1) (<a href="./references#CD011301-fig-0140" title="">Analysis 52.1</a>). </p> </section> <section id="CD011301-sec-0511"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major adverse event.</p> </section> </section> <section id="CD011301-sec-0512"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0513"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0514"> <h6 class="title">Total adverse events</h6> <p>The total adverse events were higher with HBTX‐A 20 U than placebo (RR 4.67; 95% CI 2.19 to 9.96; participants = 305; studies = 1) (<a href="./references#CD011301-fig-0141" title="">Analysis 52.2</a>). </p> </section> <section id="CD011301-sec-0515"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0516"> <h4 class="title">COMPARISON 53. HBTX‐A 50 units versus placebo one cycle of treatment, glabellar lines</h4> <p>One RCT (n = 190 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0049" title="NCT02493946.Efficacy and safety of botulinum toxin type A haemagglutinin complex next generation (BTX-A-HAC NG) in glabellar lines. clinicaltrials.gov/ct2/show/NCT02493946 (first received 10 July 2015). ">NCT02493946</a>). </p> <p>For this reason (one study), we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0517"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0518"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate, by participant assessment, was higher with HBTX‐A 50 U than placebo at week 4 (RR 42.68, 95% CI 6.08 to 299.41; participants = 187; studies = 1); at week 8 (RR 43.28, 95% CI 6.18 to 303.19; participants = 183; studies = 1); and at week 12 (RR 21.67, 95% CI 3.06 to 153.72; participants = 185; studies = 1) (<a href="./references#CD011301-fig-0142" title="">Analysis 53.1</a>). </p> </section> <section id="CD011301-sec-0519"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major adverse event.</p> </section> </section> <section id="CD011301-sec-0520"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0521"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate, by physician assessment, was higher with HBTX‐A 50 U than placebo at week 4 (RR 49.69; 95% CI 7.10 to 347.71, participants = 185, studies = 1); at week 8 (RR 53.52; 95% CI 7.65 to 376.34, participants = 167, studies =1); at week 12 (RR 33.17; 95% CI 4.72 to 233.16, participants = 182, studies = 1 (<a href="./references#CD011301-fig-0143" title="">Analysis 53.2</a>). </p> </section> <section id="CD011301-sec-0522"> <h6 class="title">Total adverse events</h6> <p>The total adverse event was similar with HBTX‐A 50 U and placebo (Peto OR 0.22, 95% CI 0.02 to 2.50; participants = 190, studies = 10) (<a href="./references#CD011301-fig-0144" title="">Analysis 53.3</a>). </p> </section> <section id="CD011301-sec-0523"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT reported only HBTX‐A 50 U mean duration, which was 113 days.</p> </section> </section> </section> <section id="CD011301-sec-0524"> <h4 class="title">COMPARISON 54. HBTX‐A 20 units versus 10 units one cycle of treatment, glabellar lines</h4> <p>One RCT (n = 366 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0029" title="FengZ , SunQ , HeL , WuY , XieH , ZhaoG , et al.Optimal dosage of botulinum toxin type A for treatment of glabellar lines: efficacy and safety in a clinical trial. Dermatologic Surgery2015;41(Suppl 1):S56-63. [CENTRAL: CN-01111346] ">Feng 2015</a>). </p> <p>For this reason (one study), we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0525"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0526"> <h6 class="title">Participant assessment of success by analysing scores and scales.</h6> <p>The responder rate, by participant assessment, was higher with HBTX‐A 20 U than HBTX‐A 10 U at week 4 (RR 1.24, 95% CI 1.12 to 1.37; participants = 366; studies = 1); at week 8 (RR 1.23, 95% CI 1.10 to 1.39; participants = 366; studies = 1); and at week 16 (RR 1.61, 95% CI 1.35 to 1.92; participants = 366; studies = 1) (<a href="./references#CD011301-fig-0145" title="">Analysis 54.1</a>). </p> </section> <section id="CD011301-sec-0527"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major adverse event.</p> </section> </section> <section id="CD011301-sec-0528"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0529"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0530"> <h6 class="title">Total adverse events</h6> <p>The total adverse event was similar with HBTX‐A 20 U and HBTX‐A 10 U (RR 0.94, 95% CI 0.68 to 1.31; participants = 366; studies = 1) (<a href="./references#CD011301-fig-0146" title="">Analysis 54.2</a>). </p> </section> <section id="CD011301-sec-0531"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0532"> <h4 class="title">COMPARISON 55. AbobotulinumtoxinA 50 units versus OnabotulinumtoxinA 20 units one cycle of treatment, glabellar lines </h4> <p>Two RCTs (n = 479 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0042" title="LoweP , PatnaikR , LoweN .Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study. Journal of the American Academy of Dermatology2006;55(6):975-80. [CENTRAL: CN-00573598] ">Lowe 2006</a>; <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>). The results are included in <a href="./full#CD011301-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD011301-sec-0533"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0534"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>Only  <a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a> assessed this outcome, n = 388. </p> <p>The responder rate, by participant's assessment, was similar with abobotulinumtoxinA 50 U and onabotulinumtoxinA 20 U at week 4 (RR 1.00, 95% CI 0.92 to 1.08; participants 388, study = 1, high‐certainty evidence); at week 8 (RR 0.96, 95% CI 0.88 to 1.05; participants 388, study =1 ; at week 12 (RR 0.94, 95% CI 0.81 to 1.09; participants 388, study = 1). </p> </section> <section id="CD011301-sec-0535"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p> Only one study assessed this outcome (<a href="./references#CD011301-bbs2-0048" title="NCT02450526.Dysport in the treatment of glabellar lines in Chinese subjects. clinicaltrials.gov/ct2/show/NCT02450526 (first received 21 May 2015). ">NCT02450526</a>). </p> <p>The frequency of major adverse events was higher in abobotulinumtoxinA 50 U when compared to onabotulinumtoxinA 20 U (Peto OR 2.65, 95% CI 0.77 to 9.09; participants = 433, study = 1, moderate‐certainty evidence) (<a href="./references#CD011301-fig-0148" title="">Analysis 55.2</a>). </p> </section> </section> <section id="CD011301-sec-0536"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0537"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate, by physician's assessment, was similar with abobotulinumtoxinA 50 U and onabotulinumtoxinA 20 U at week 4 (RR 1.01, 95% CI 0.95 to 1.06; participants = 388, studies = 1, high‐certainty evidence); at week 8 (RR 0.95, 95% CI 0.89 to 1.02; participants = 449, studies = 2, I<sup>2</sup> = 0% moderate‐certainty evidence); at week 12 (RR 0.92, 95% CI 0.60 to 1.40; participants = 488; studies = 2, I<sup>2</sup> = 55%); and at week 16 (RR 0.44, 95% CI 0.13 to 1.55; participants = 59; studies = 1) the RR favours the onabotulinumtoxinA 20 U, but the results are uncertain due to the confidence intervals including 1 (<a href="./references#CD011301-fig-0149" title="">Analysis 55.3</a>). </p> </section> <section id="CD011301-sec-0538"> <h6 class="title">Total adverse events</h6> <p>The frequency of total adverse events was similar with abobotulinumtoxinA 50 U and onabotulinumtoxinA 20 U (RR 1.02, 95% CI 0.67 to 1.54; participants = 492; studies = 1, moderate‐certainty evidence) (<a href="./references#CD011301-fig-0150" title="">Analysis 55.4</a>). </p> </section> <section id="CD011301-sec-0539"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0540"> <h4 class="title">COMPARISON 56. IncobotulinumtoxinA 30 units versus OnabotulinumtoxinA 20 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 224 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0541"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0542"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate, by participant assessment, was similar with IncobotulinumtoxinA 30 U and OnabotulinumtoxinA 20 U at week 4 (RR 0.90, 95% CI 0.78 to 1.04; participants = 224; studies = 1); at week 12 (RR 0.84, 95% CI 0.65 to 1.09; participants = 224; studies = 1); at week 14 (RR 0.93, 95% CI 0.68 to 1.29; participants = 224; studies = 1); and at week 16 (RR 0.94, 95% CI 0.63 to 1.40; participants = 224; studies = 1) (<a href="./references#CD011301-fig-0151" title="">Analysis 56.1</a>). </p> </section> <section id="CD011301-sec-0543"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0544"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0545"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate, by physician assessment, was similar with IncobotulinumtoxinA 30 U and onabotulinumtoxinA 20 U at week 4 (RR 0.98, 95% CI 0.93 to 1.04; participants = 224; studies = 1); at week 12 (RR 0.90, 95% CI 0.77 to 1.04; participants = 224; studies = 1); at week 14 (RR 0.96, 95% CI 0.79 to 1.16; participants = 224; studies = 1); and at week 16 (RR 0.90, 95% CI 0.70 to 1.16; participants = 224; studies = 1) (<a href="./references#CD011301-fig-0152" title="">Analysis 56.2</a>). </p> </section> <section id="CD011301-sec-0546"> <h6 class="title">Total adverse events</h6> <p>One RCT assessed this outcome (<a href="./references#CD011301-bbs2-0044" title="Moers-CapriM , DirschkaT , Feller-HepptG , HiltonsS , HoffmannK , Philipp-DormstonWG , et al.A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. Journal of Cosmetic and Laser Therapy2012;14(6):296-303. [CENTRAL: CN-00967309] ">Moers‐Carpi 2012</a>); the total adverse events were higher with incobotulinumtoxinA 30 U compared with onabotulinumtoxinA 20 U, but the result is uncertain due to the low number of events (two events versus one event) (RR 1.96, 95% CI 0.20 to 19.03, participants = 224; studies = 1 (<a href="./references#CD011301-fig-0153" title="">Analysis 56.3</a>). </p> </section> <section id="CD011301-sec-0547"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0548"> <h4 class="title">COMPARISON 57. IncobotulinumtoxinA 24 units versus onabotulinumtoxinA 24 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 381 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0059" title="SattlerG , CallanderMJ , GrablowitzD , WalkerT , BeeEK , RzanyB , et al.Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatologic Surgery2010;36(Suppl 4):2146-54. [CENTRAL: CN-00778835] ">Satler 2010</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. Results are also shown in <a href="./full#CD011301-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD011301-sec-0549"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0550"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0551"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>Ptosis was reported in one participant in onabotulinumtoxinA group (OR 0.02 95% CI 0.00 to 1.77; participants = 381; studies = 1, very low‐certainty evidence) (<a href="./references#CD011301-fig-0154" title="">Analysis 57.1</a>). </p> </section> </section> <section id="CD011301-sec-0552"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0553"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate, by physician assessment, was similar with incobotulinumtoxinA 24 U and onabotulinumtoxinA 24 U at week 4 (RR 1.01, 95% CI 0.96 to 1.05; participants = 381; studies = 1); and at week 12 (RR 1.02, 95% CI 0.91 to 1.15; participants = 381; studies = 1) (moderate‐certainty evidence) (<a href="./references#CD011301-fig-0155" title="">Analysis 57.2</a>). </p> </section> <section id="CD011301-sec-0554"> <h6 class="title">Total adverse events</h6> <p>There was only one adverse event in the onabotulinumtoxinA 24 U group and zero events in the IncobotulinumtoxinA 24 U group (OR 0.02, 95% CI 0.00 to 1.77; participants = 381; studies = 1) (very low‐certainty evidence) (<a href="./references#CD011301-fig-0156" title="">Analysis 57.3</a>). </p> </section> <section id="CD011301-sec-0555"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0556"> <h4 class="title">COMPARISON 58. IncobotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment, glabellar lines </h4> <p>Two RCTs (n = 250 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>; <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>). </p> <section id="CD011301-sec-0557"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0558"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>These RCTs did not assess this outcome.</p> </section> <section id="CD011301-sec-0559"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p><a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a> did not report any major adverse event. One RCT studied this outcome (<a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>). No difference between groups (Peto OR 0.14, 95% CI 0.01 to 2.26; participants = 250; studies = 1) (<a href="./references#CD011301-fig-0157" title="">Analysis 58.1</a>). </p> </section> </section> <section id="CD011301-sec-0560"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0561"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p><a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a> did not assess this outcome. </p> <p>Only one RCT studied this outcome (<a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>). The responder rate, by independent observer assessment, was similar with incobotulinumtoxinA 20 U and onabotulinumtoxinA 20 U at week 4 (RR 0.98, 95% CI 0.92 to 1.04; participants = 250; studies = 1); at week 8 (RR 0.97, 95% CI 0.88 to 1.06; participants = 250; studies = 1); at week 12 (RR 0.97, 95% CI 0.85 to 1.12; participants = 250; studies = 1); and at week 16 (RR 0.98, 95% CI 0.80 to 1.20; participants = 250; studies = 1) (<a href="./references#CD011301-fig-0158" title="">Analysis 58.2</a>). </p> <p>The responder rate, by physician assessment, was similar with incobotulinumtoxinA 20 U and onabotulinumtoxinA 20 U at week 4 (RR 0.97, 95% CI 0.93 to 1.01; participants = 250; studies = 1); at week 8 (RR 0.96, 95% CI 0.90 to 1.03; participants = 250; studies = 1); at week 12 (RR 1.00, 95% CI 0.88 to 1.13; participants = 250; studies = 1); and at week 16 (RR 0.93, 95% CI 0.77 to 1.11; participants = 250; studies = 1) (<a href="./references#CD011301-fig-0159" title="">Analysis 58.3</a>). </p> </section> <section id="CD011301-sec-0562"> <h6 class="title">Total adverse events</h6> <p><a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a> did not report total adverse events. One RCT studied this outcome (<a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a>). The frequency of total adverse events was similar with incobotulinumtoxinA 20 U and onabotulinumtoxinA 20 U (RR 1.05, 95% CI 0.41 to 2.71; participants = 250; studies = 1) (<a href="./references#CD011301-fig-0160" title="">Analysis 58.4</a>). </p> </section> <section id="CD011301-sec-0563"> <h6 class="title">Duration of treatment effect</h6> <p>One RCT assessed this outcome by gender (<a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>). The duration of treatment effect was 20.8 weeks (146.12 days) for female and 17.3 weeks (121.14 days) for male in incobotulinumtoxinA group.The duration of treatment effect was 20 weeks (140.65 days for female and 16.6 weeks (116.61 days) for male) in onabotulinumtoxinA group. After 180 days, four in the incobotulinumtoxinA group, and two in onabotulinumtoxinA, still showed an effect. All of these participants were botulinum toxin treatment naïve, and all had mild glabellar frown lines at baseline. </p> <p><a href="./references#CD011301-bbs2-0036" title="KaneMA , GoldMH , ColemanWP , JonesDH , TanghettiEA , AlsterTS , et al.A randomized, double-blind trial to investigate the equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for glabellar frown lines. Dermatologic Surgery2015;41(11):1310-9. [CENTRAL: CN-01105599] ">Kane 2015</a> did not study this outcome. </p> </section> </section> </section> <section id="CD011301-sec-0564"> <h4 class="title">COMPARISON 59. NewBontA [Medytox®] 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 291 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0041" title="LeeWS , Won CH, HuhCH , KangH , KimBJ , LeeJH , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blinded, active controlled multicenter study. Toxicon2013;68:116. [EMBASE: 71313875]">Lee 2013</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0565"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0566"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0567"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0568"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0569"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The responder rate, by physician assessment, was similar with NewBontA 20U and onabotulinumtoxinA 20 U (RR 0.99, 95% CI 0.94 to 1.05; participants = 291; studies = 1) (<a href="./references#CD011301-fig-0161" title="">Analysis 59.1</a>). </p> </section> <section id="CD011301-sec-0570"> <h6 class="title">Total adverse events</h6> <p>This RCT did not report any adverse event.</p> </section> <section id="CD011301-sec-0571"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0572"> <h4 class="title">COMPARISON 60. NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 314 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0573"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0574"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>One RCT assessed this outcome (<a href="./references#CD011301-bbs2-0062" title="WonCH , LeeHM , LeeWS , KangH , KimBJ , KimWS , et al.Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active- controlled multicenter study. Dermatologic Surgery2013;39(1 Pt 2):171-8. [CENTRAL: CN-00841439] ">Won 2013</a>) where the responder rate, by participant assessment, was similar with NewBontA 20 U and onabotulinumtoxinA 20 U at week 4 (RR 0.94, 95% CI 0.87 to 1.02; participants = 314; studies = 1); at week 8 (RR 0.96, 95% CI 0.88 to 1.04; participants = 314; studies = 1); at week 12 (RR 1.02, 95% CI 0.90 to 1.14; participants = 314; studies = 1); and at week 16 (RR 1.07, 95% CI 0.92 to 1.24; participants = 314; studies = 1) (<a href="./references#CD011301-fig-0162" title="">Analysis 60.1</a>). </p> </section> <section id="CD011301-sec-0575"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>The frequency of eyelid was similar with NewBontA 20U and onabotulinumtoxinA 20 U (RR 0.86, 95% CI 0.30 to 2.51; participants = 313; studies = 1) (<a href="./references#CD011301-fig-0163" title="">Analysis 60.2</a>). </p> </section> </section> <section id="CD011301-sec-0576"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0577"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate, by physician assessment, was similar with NewBontA 20 U and onabotulinumtoxinA 20 U at week 4 (RR 0.99, 95% CI 0.94 to 1.05; participants = 314; studies = 1); at week 8 (RR 1.01, 95% CI 0.92 to 1.10; participants = 314; studies = 1); at week 12 (RR 1.06, 95% CI 0.93 to 1.22; participants = 314; studies = 1); and at week 16 (RR 0.95, 95% CI 0.75 to 1.20; participants = 314; studies = 1) (<a href="./references#CD011301-fig-0164" title="">Analysis 60.3</a>). </p> </section> <section id="CD011301-sec-0578"> <h6 class="title">Total adverse events</h6> <p>The frequency of adverse events was similar with NewBontA 20 U and onabotulinumtoxinA 20 U (RR 1.21, 95% CI 0.82 to 1.78; participants = 313; studies = 1) (<a href="./references#CD011301-fig-0165" title="">Analysis 60.4</a>). </p> </section> <section id="CD011301-sec-0579"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0580"> <h4 class="title">COMPARISON 61. NewBontA [Neuronox®] 24 units versus OnabotulinumtoxinA 24 units one cycle of treatment, crow's feet lines </h4> <p>Only one RCT (n = 220 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0581"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0582"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>One RCT assessed this outcome (<a href="./references#CD011301-bbs2-0023" title="CheonHI , JungN , WonCH , KimBJ , LeeYW .Efficacy and safety of prabotulinumtoxin A and onabotulinumtoxin A for crow's feet A phase 3, multicenter, randomized, double-blind, split-face study. Dermatologic Surgery2019;45(12):1610-9. [PMID: 30893169]">Cheon 2019</a>). The responder rate, by participant assessment, was similar with NewBontA 24 U and onabotulinumtoxinA 24 U at week 4 (RR 1.01, 95% CI 0.89 to 1.15; participants = 220; studies = 1); at week 8 (RR 0.93, 95% CI 0.83 to 1.03; participants = 220; studies = 1); at week 12 (RR 1.02, 95% CI 0.90 to 1.16; participants = 220; studies = 1); at week 16 (RR 0.84, 95% CI 0.70 to 1.01; participants = 220; studies = 1) (<a href="./references#CD011301-fig-0166" title="">Analysis 61.1</a>). </p> </section> <section id="CD011301-sec-0583"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>No difference between groups (Peto OR 7.39, 95% CI 0.15 to 372.38); participants = 220; studies = 1) (<a href="./references#CD011301-fig-0167" title="">Analysis 61.2</a>). </p> </section> </section> <section id="CD011301-sec-0584"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0585"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate, by physician assessment, was similar with NewBontA 24U 24 U and onabotulinumtoxinA 24 U at week 4 (RR 1.00, 95% CI 0.89 to 1.13; participants = 220; studies = 1); at week 8 (RR 0.98, 95% CI 0.86 to 1.11; participants = 220; studies = 1); at week 12 (RR 1.08, 95% CI 0.88 to 1.32; participants = 220; studies = 1); at week 16 (RR 1.14, 95% CI 0.83 to 1.56; participants = 220; studies = 1) (<a href="./references#CD011301-fig-0168" title="">Analysis 61.3</a>). </p> </section> <section id="CD011301-sec-0586"> <h6 class="title">Total adverse events</h6> <p>The frequency of adverse events was similar with NewBontA 24Us and onabotulinumtoxinA 24 U (RR 0.97, 95% CI 0.65 to 1.45; participants = 220; studies = 1) (<a href="./references#CD011301-fig-0169" title="">Analysis 61.4</a>). </p> </section> <section id="CD011301-sec-0587"> <h6 class="title">Duration of treatment effect</h6> <p>The median duration of the treatment effect was similar in both groups (112 days after week 4). </p> </section> </section> </section> <section id="CD011301-sec-0588"> <h4 class="title">COMPARISON 62. Liquid BontA (MT10109L) 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 159 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0040" title="KimJE , SongEJ , ChoiGS , LewBL , SimWY , KangH .The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plastic and Reconstructive Surgery2015;135(3):732-41. [CENTRAL: CN-01076800] ">Kim 2015</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0589"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0590"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate, by participant assessment, was similar with NewBontA 20 U and onabotulinumtoxinA 20 U at week 4 (RR 0.97, 95% CI 0.88 to 1.07; participants = 159; studies = 1); at week 10 (RR 0.90, 95% CI 0.79 to 1.02; participants = 159; studies = 1); and at week 16 (RR 1.04, 95% CI 0.84 to 1.28; participants = 159; studies = 1) (<a href="./references#CD011301-fig-0170" title="">Analysis 62.1</a>). </p> </section> <section id="CD011301-sec-0591"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0592"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0593"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate, by physician assessment, was similar with NewBontA 20 U and onabotulinumtoxinA 20 U at week 4 (RR 0.99, 95% CI 0.88 to 1.12; participants = 159; studies = 1). The responder rate was higher with NewBontA 20 U than onabotulinumtoxinA 20 U at week 16 (RR 1.54, 95% CI 1.12 to 2.12; participants = 156; studies = 1) (<a href="./references#CD011301-fig-0171" title="">Analysis 62.2</a>). </p> </section> <section id="CD011301-sec-0594"> <h6 class="title">Total adverse events</h6> <p>The total adverse events were similar with NewBontA 20U and onabotulinumtoxinA 20 U (RR 1.27, 95% CI 0.69 to 2.32; participants = 156; studies = 1) (<a href="./references#CD011301-fig-0172" title="">Analysis 62.3</a>). </p> </section> <section id="CD011301-sec-0595"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0596"> <h4 class="title">COMPARISON 63. NewBontA [Prosigne®] 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 157 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0025" title="CostaA , Talarico-FilhoS , ArrudaLH , PecoraCS , OrtolanDG , MonteiroEO , et al.Multicenter, prospective, comparative, randomized, double-blind clinical study comparing two botulinum toxin type A formulations registered in Brazil for the treatment of glabellar wrinkles [Estudo clínico multicêntrico, prospectivo, comparativo, randomizado e duplo cego, entre duas formulações de toxina botulínica tipo A registradas no Brasil para o tratamento das rugas da glabela]. Surgical and Cosmetic Dermatology2016;8(1):33-40. ">Costa 2016</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0597"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0598"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0599"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0600"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0601"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was higher in the onabotulinumtoxinA 20 U group at week 12 (RR 0.49, 95% CI 0.21 to 1.19; participants = 157; studies = 1) (<a href="./references#CD011301-fig-0173" title="">Analysis 63.1</a>). </p> </section> </section> <section id="CD011301-sec-0602"> <h5 class="title">Total adverse events</h5> <p>This RCT did not assess this outcome.</p> <section id="CD011301-sec-0603"> <h6 class="title">Duration of treatment effect</h6> <p>The duration of treatment effect was 12 weeks (84.5 ± 38.8 days) for NewBontA 20U (Prosigne®), and 12.8 weeks (89.9 ± 41.1 days) for OnabotulinumtoxinA 20 U assessed by three independent observers. The duration of treatment effect by physician assessment was 10.9 weeks: 76.8 ± 46.6 days for NewBontA 20 U (Prosigne®), and 12.5 weeks (88.1 ± 43.6 days) for onabotulinumtoxinA 20 U. </p> </section> </section> </section> <section id="CD011301-sec-0604"> <h4 class="title">COMPARISON 64. CBFC26 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 249 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0039" title="KimBJ , KwonHH , ParkSY , MinSU , YoonJY , ParkYM , et al.Double-blind, randomized non-inferiority trial of a novel botulinum toxin a processed from the strain cbfc26, compared with onabotulinumtoxin a in the treatment of glabellar lines. Journal of the European Academy of Dermatology and Venereology : JEADV2014;28(12):1761-7. [CENTRAL: CN-01118064] ">Kim 2014</a>). Hence, we were unable to undertake a meta‐analysis and only present results in a forest plot for visual representation. </p> <section id="CD011301-sec-0605"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0606"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant assessment was higher with NewBontA 20 U than onabotulinumtoxinA 20 U at week 4 (RR 1.22, 95% CI 1.10 to 1.35; participants = 249; studies = 1); and at week 8 (RR 1.14, 95% CI 1.01 to 1.29; participants = 249; studies = 1). The responder rate was similar with NewBontA 20 U and onabotulinumtoxinA 20 U at week 12 (RR 1.08, 95% CI 0.91 to 1.28; participants = 249; studies = 1); and at week 16 (RR 1.15, 95% CI 0.92 to 1.44; participants = 249; studies = 1) (<a href="./references#CD011301-fig-0174" title="">Analysis 64.1</a>). </p> </section> <section id="CD011301-sec-0607"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>The major adverse events were higher with NewBontA 20 U than onabotulinumtoxinA 20 U, but the result is uncertain due to the wide confidence interval (RR 2.04, 95% CI 0.52 to 8.01; participants = 271; studies = 1) (<a href="./references#CD011301-fig-0175" title="">Analysis 64.2</a>). </p> </section> </section> <section id="CD011301-sec-0608"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0609"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was similar with NewBontA 20 U and onabotulinumtoxinA 20 U at week 4 (RR 1.09, 95% CI 0.99 to 1.21; participants = 249; studies = 1); at week 8 (RR 1.09, 95% CI 0.92 to 1.29; participants = 249; studies = 1); at week 12 (RR 1.21, 95% CI 0.96 to 1.51; participants = 249; studies = 1); and at week 16 (RR 1.26, 95% CI 0.94 to 1.68; participants = 249; studies = 1) (<a href="./references#CD011301-fig-0176" title="">Analysis 64.3</a>). </p> </section> <section id="CD011301-sec-0610"> <h6 class="title">Total adverse events</h6> <p>The total adverse events were similar with NewBontA 20 U andoonabotulinumtoxinA 20 U (RR 0.86, 95% CI 0.60 to 1.24; participants = 249; studies = 1) (<a href="./references#CD011301-fig-0177" title="">Analysis 64.4</a>). </p> </section> <section id="CD011301-sec-0611"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0612"> <h4 class="title">COMPARISON 65. Liquid AbobotulinumtoxinA 20 units versus placebo one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 71 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0613"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0614"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant assessment was similar with liquid abobotulinumtoxinA 20 U and placebo at week 4 (RR 66.81, 95% CI 4.25 to 1050.36, participants = 71; studies = 1); at week 8 (RR 42.14, 95% CI 2.65 to 670.89), participants = 71; studies = 1); at week 12 (RR 44.19, 95% CI 2.78 to 702.51 participants = 71; studies = 1); at week 16 (RR 27.75, 95% CI 1.71 to 449.60, participants = 71; studies = 1) (<a href="./references#CD011301-fig-0178" title="">Analysis 65.1</a>). </p> </section> <section id="CD011301-sec-0615"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>There was no difference between groups (Peto OR 7.60, 95% CI  0.15 to 383.33, participants = 71; studies = 1) (<a href="./references#CD011301-fig-0179" title="">Analysis 65.2</a>). </p> </section> </section> <section id="CD011301-sec-0616"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0617"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was similar with liquid abobotulinumtoxinA 20 U and placebo at week 4 (RR 66.81, 95% CI 4.25 to 1050.36; participants = 71; studies = 1); at week 8 (RR 58.58, 95% CI 3.71 to 923.86, participants = 71, studies = 1); at week 12 (RR 40.08, 95% CI 2.51 to 639.27, participants = 71, studies = 1); at week 16 (RR 19.53, 95% CI 1.18 to 323.24, participants = 71, studies = 1) (<a href="./references#CD011301-fig-0180" title="">Analysis 65.3</a>). </p> </section> <section id="CD011301-sec-0618"> <h6 class="title">Total adverse events</h6> <p>There was no difference between groups (RR 1.23, 95% CI 0.41 to 3.68, participants = 71; studies = 1) (<a href="./references#CD011301-fig-0181" title="">Analysis 65.4</a>). </p> </section> <section id="CD011301-sec-0619"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0620"> <h4 class="title">COMPARISON 66. Liquid AbobotulinumtoxinA 50 units versus placebo one cycle of treatment, glabellar lines </h4> <p>Two RCTs (n = 255 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>; <a href="./references#CD011301-bbs2-0005" title="AscherB , RzanyB , KestemontP , HiltonS , HeckmannM , BodokhI , et al.Liquid formulation of abobotulinumtoxinA: A 6-month, phase 3, double-blind,randomized, placebo-controlled study of a single treatment, ready-to-use toxin for moderate-to-severe glabellar lines. Aesthetic Surgery Journal2020;40(1):93-104. [PMID: 30893430]NCT02353871.Efficacy and safety of clostridium botulinum toxin type A to improve appearance of moderate to severe glabellar lines (BTX-A-HAC NG). clinicaltrials.gov/ct2/show/NCT02353871 (first received 3 February 2015). ">Ascher 2020</a>).  </p> <section id="CD011301-sec-0621"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0622"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant's assessment was higher than placebo at week 4 (RR 46.95, 95% CI 9.57 to 230.36, participants = 255, studies = 2); at week 8 (RR 41.87, 95% CI 8.52 to 205.88, participants = 253, studies = 2), at week 12 (RR 24.61, 95% CI 4.97 to 121.91, participants= 253, studies =2); at week 16 (RR 6.54, 95% CI 1.70 to 25.15, participants= 254, studies =2), at week 20 (RR 3.35, 95% CI 1.71 to 6.58, participants= 183, studies =1) (see <a href="./references#CD011301-fig-0182" title="">Analysis 66.1</a>). </p> </section> <section id="CD011301-sec-0623"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>No difference between groups (Peto OR 4.39, 95% CI 0.07 to 289.31, participants = 256, studies = 2, <a href="./references#CD011301-fig-0183" title="">Analysis 66.2</a>). </p> </section> </section> <section id="CD011301-sec-0624"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0625"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was higher than placebo at week 4 (RR 16.73, 95% CI 2.84 to 98.58, participants = 255, studies = 2); at week 8 (RR 48.98, 95% CI 9.99 to 240.21, participants = 255, studies = 2); at week 12 (RR 35.93, 95% CI 7.30 to 176.90, participants = 255, studies = 2); at week 16 (RR 21.25, 95% CI 2.95 to 152.88, participants = 255, studies = 2); and at week 20 (RR 25.86, 95% CI 1.60 to 417.34, participants = 184, studies = 1) (see <a href="./references#CD011301-fig-0184" title="">Analysis 66.3</a>). </p> </section> <section id="CD011301-sec-0626"> <h6 class="title">Total adverse events</h6> <p>There was no difference between the groups (RR 1.11, 95% CI 0.72 to1.71, participants = 255, studies = 2). </p> </section> <section id="CD011301-sec-0627"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0628"> <h4 class="title">COMPARISON 67. Liquid AbobotulinumtoxinA 75 units versus placebo one cycle of treatment, glabellar lines </h4> <p>One RCT (n = 71 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>). </p> <section id="CD011301-sec-0629"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0630"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant's assessment was higher with liquid abobotulinumtoxinA 7 5U than placebo at week 4 (RR 60.64, 95% CI 3.85 to 955.48, participants = 71, studies = 1); at week 8 (RR 62.69, 95% CI 3.98 to 987.11, participants = 71, studies = 1); at week 12 (RR 44.19, 95% CI 2.78 to 702.51, participants = 71, studies = 1); at week 16 (RR 35.97, 95% CI 2.25 to 576.04, participants = 71, studies = 1) (<a href="./references#CD011301-fig-0186" title="">Analysis 67.1</a>). </p> </section> <section id="CD011301-sec-0631"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>There was no difference between groups (Peto 7.83, 95% CI 0.48 to 127.75, participants = 71, studies = 1) (<a href="./references#CD011301-fig-0187" title="">Analysis 67.2</a>). </p> </section> </section> <section id="CD011301-sec-0632"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0633"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was higher with liquid abobotulinumtoxinA 20 U and placebo at week (RR 64.75, 95% CI 4.12 to 1018.73; participants = 71; studies = 1); at week 8 (RR 60.64, 95% CI 3.85 to 955.48, participants = 71, studies = 1); at week 12 (RR 56.53 95% CI 3.58 to 892.24, participants =  71, studies = 1); at week 16 (RR 42.14 95% CI2.65 to 670.89, participants = 71, studies = 1) (<a href="./references#CD011301-fig-0188" title="">Analysis 67.3</a>). </p> </section> <section id="CD011301-sec-0634"> <h6 class="title">Total adverse events</h6> <p>There was no difference between groups (RR 0.82 95% CI 0.24 to 2.81, participants =  71, studies = 1) (<a href="./references#CD011301-fig-0189" title="">Analysis 67.4</a>). </p> </section> <section id="CD011301-sec-0635"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0636"> <h4 class="title">COMPARISON 68. Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines </h4> <p>One RCT (n = 70 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>). </p> <section id="CD011301-sec-0637"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0638"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant's assessment was similar with Liquid Abobotulinumtoxin 20 U and Liquid abobotulinumtoxin 50 U at week 4 (RR 1.07, 95% CI 0.90 to 1.26, participants = 70,studies = 1); at week 8 (RR 1.05, 95% CI 0.69 to 1.60, participant s = 70, studies = 1); at week 12 (RR 1.31, 95% CI 0.84 to 2.06, participants =  70, studies = 1); at week 16 (RR 1.08, 95% CI 0.58 to 2.03, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0190" title="">Analysis 68.1</a>). </p> </section> <section id="CD011301-sec-0639"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>There was no difference between groups (Peto OR 7.39, 95% CI 0.15 to 372.38, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0191" title="">Analysis 68.2</a>). </p> </section> </section> <section id="CD011301-sec-0640"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0641"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by participant's assessment was similar with Liquid abobotulinumtoxin 20 U and Liquid abobotulinumtoxin 50 U at week 4 (RR 1.07, 95% CI 0.90 to 1.26; participants = 70; studies = 1); at week 12 (RR 1.19, 95% CI 0.74 to 1.90, participants = 70, studies = 1); at week 16 (RR 0.75, 95% CI 0.36 to 1.55, participants = 70, studies = 1).   </p> <p>The responder rate by participant's assessment was higher with Liquid abobotulinumtoxin 50 U and Liquid abobotulinumtoxin 20 U at week 8 (R 1.47, 95% CI 1.04 to 2.08, participants =70, studies = 1) (<a href="./references#CD011301-fig-0192" title="">Analysis 68.3</a>). </p> </section> <section id="CD011301-sec-0642"> <h6 class="title">Total adverse events  </h6> <p>There was no difference between groups (RR 1.50, 95% CI 0.46 to 4.86, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0193" title="">Analysis 68.4</a>). </p> </section> <section id="CD011301-sec-0643"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0644"> <h4 class="title">COMPARISON 69. Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines </h4> <p>One RCT (n = 70 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>). </p> <section id="CD011301-sec-0645"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0646"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant's assessment was similar with Liquid abobotulinumtoxin 20 U and Liquid abobotulinumtoxin 75 U at week 4 (RR 1.10, 95% CI 0.92 to 1.32, participants = 70, studies = 1); at week 8 (RR 0.67, 95% CI 0.49 to 0.92, participants = 70, studies = 1); at week 12 (RR 0.95, 95% CI 0.66 to 1.38, participants = 70, studies = 1); at week 16 (RR 0.76, 95% CI 0.44 to 1.32, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0194" title="">Analysis 69.1</a>). </p> </section> <section id="CD011301-sec-0647"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>There was no difference between groups (Peto OR 0.50, 95% CI 0.05 to 5.00, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0195" title="">Analysis 69.2</a>). </p> </section> </section> <section id="CD011301-sec-0648"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0649"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was similar with Liquid abobotulinumtoxin 20 U and Liquid abobotulinumtoxin 75 U at week 4 (RR 1.03, 95% CI 0.88 to 1.21; participants = 70; studies = 1); at week 8 (RR 0.97, 95% CI 0.77 to 1.21, participants = 70, studies = 1); at week 12 (RR 0.70, 95% CI 0.49 to 1.00, participants = 70, studies = 1); at week 16 (RR 0.55, 95% CI 0.29 to 1.06, participants =  70, studies = 1) (<a href="./references#CD011301-fig-0196" title="">Analysis 69.3</a>). </p> </section> <section id="CD011301-sec-0650"> <h6 class="title">Total adverse events</h6> <p>There was no difference between groups (RR 2.50, 95% CI 0.87 to 7.22, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0197" title="">Analysis 69.4</a>). </p> </section> <section id="CD011301-sec-0651"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0652"> <h4 class="title">COMPARISON 70. Liquid AbobotulinumtoxinA 50 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines </h4> <p>One RCT (n = 70 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>). </p> <section id="CD011301-sec-0653"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0654"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant's assessment was similar with liquid abobotulinumtoxin 50 U and Liquid abobotulinumtoxin 75 U at week 4 (RR 1.00, 95% CI 0.83 to 1.21 participants = 70, studies = 1; at week 8 (RR 0.63, 0.88 95% CI 0.45 to 0.88, participants = 70, studies = 1); at week 12 (RR 0.76, 95% CI 0.49 to 1.20, participants = 70, studies = 1); at week 16 (RR 0.71, 95% CI 0.40 to 1.25, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0198" title="">Analysis 70.1</a>). </p> </section> <section id="CD011301-sec-0655"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>There was no difference between groups (Peto 0.13, 95% CI 0.01 to 2.14, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0199" title="">Analysis 70.2</a>). </p> </section> </section> <section id="CD011301-sec-0656"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0657"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was similar with Liquid abobotulinumtoxin 50 U and Liquid abobotulinumtoxin 75 U at week 4 (RR 0.97, 95% CI 0.81 to 1.16; participants = 70; studies = 1), at week 8 (RR 0.66, 95% CI 0.47 to 0.92, participants = 70, studies = 1); at week 12 (RR 0.59, 95% CI 0.40 to 0.89, participants = 70, studies = 1); at week 16 (RR 0.60, 95% CI 0.35 to 1.03, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0200" title="">Analysis 70.3</a>). </p> </section> <section id="CD011301-sec-0658"> <h6 class="title">Total adverse events</h6> <p>There was no difference between groups (RR 1.00, 95% CI 0.27 to 3.69, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0201" title="">Analysis 70.4</a>). </p> </section> <section id="CD011301-sec-0659"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0660"> <h4 class="title">COMPARISON 71. Liquid AbobotulinumtoxinA 20 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines </h4> <p>One RCT (n = 70 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>). </p> <section id="CD011301-sec-0661"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0662"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant's assessment was similar with Liquid abobotulinumtoxin 20 U and Liquid abobotulinumtoxin 50 U at week 4 (RR 1.10, 95% CI 0.92 to 1.32, participants = 70, studies = 1); at week 8 (RR 0.91, 95% CI 0.62 to 1.33 participants = 70, studies = 1); at week 12 (RR 1.50, 95% CI 0.92 to 2.44, participants = 70, studies = 1); at week 16 (RR 0.93, 95% CI 0.51 to 1.68, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0202" title="">Analysis 71.1</a>). </p> </section> <section id="CD011301-sec-0663"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>There was no difference between groups (Peto OR 7.39, 95% CI 0.15 to 372.38, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0203" title="">Analysis 71.2</a>). </p> </section> </section> <section id="CD011301-sec-0664"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0665"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was similar with Liquid abobotulinumtoxin 20 U and Liquid abobotulinumtoxin 50 U at week (RR 1.1, 95% CI 0.96 to 1.46; participants = 70; studies = 1); at week 8 (RR 1.00, 95% CI 0.79 to 1.26, participants = 70, studies = 1); at week 12 (RR 1.00, 95% CI 0.65 to 1.54, participants = 70, studies = 1); at week 16 (RR 0.69, 95% CI 0.34 to 1.41, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0204" title="">Analysis 71.3</a>). </p> </section> <section id="CD011301-sec-0666"> <h6 class="title">Total adverse events</h6> <p>There was no difference between groups (RR 3.00, 95% CI 0.65 to 13.86), participants = 70, studies = 1) (<a href="./references#CD011301-fig-0205" title="">Analysis 71.4</a>). </p> </section> <section id="CD011301-sec-0667"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0668"> <h4 class="title">COMPARISON 72. Liquid AbobotulinumtoxinA 75 units versus AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines </h4> <p>One RCT (n = 70 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0004" title="AscherB , KestemontP , BoineauD , BodokhI , SteinA , HeckmannM , et al.Liquid formulation of abobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial. Aesthetic Surgery Journal2018;38(2):183-91. [PMID: 28200002]">Ascher 2018</a>). </p> <section id="CD011301-sec-0669"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0670"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant's assessment was similar with Liquid abobotulinumtoxin 75 U and abobotulinumtoxin 50 U at week 4 (RR 1.00, 95% CI 0.81 to 1.24, participants = 70, studies = 1); at week 12 (RR 1.57, 95% CI 0.97 to 2.54, participants = 70, studies = 1); at week 16 (RR 1.70, 95% CI 0.91 to 3.18, participants = 70, studies = 1). </p> <p>The responder rate by participant's assessment was higher with Liquid abobotulinumtoxin 75 U than abobotulinumtoxin 50 U at week 8 (RR 1.36, 95% CI 1.02 to 1.82, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0206" title="">Analysis 72.1</a>). </p> </section> <section id="CD011301-sec-0671"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>There was no difference between groups (Peto OR 7.61, 95% CI 0.47 to 124.15, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0207" title="">Analysis 72.2</a>). </p> </section> </section> <section id="CD011301-sec-0672"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0673"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was similar with Liquid abobotulinumtoxin 75 U and abobotulinumtoxin 50 U at week 4 (RR 1.15, 95% CI 0.93 to 1.43 participants = 70; studies = 1); at week 8 (RR 1.04, 95% CI 0.83 to 1.30, participants = 70, studies = 1); at week 12 (RR 1.42, 95% CI 1.00 to 2.02), participants = 70, studies = 1); at week 16 (RR 1.54, 95% CI 0.92 to 2.58, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0208" title="">Analysis 72.3</a>). </p> </section> <section id="CD011301-sec-0674"> <h6 class="title">Total adverse events</h6> <p>There was no difference between groups (RR 2.00, 95% CI 0.39 to 10.22, participants = 70, studies = 1) (<a href="./references#CD011301-fig-0209" title="">Analysis 72.4</a>). </p> </section> <section id="CD011301-sec-0675"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0676"> <h4 class="title">Comparison 73. DaxibotulinumtoxinA 60 units versus placebo one cycle of treatment, glabellar lines </h4> <p>One RCT (n = 76 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>). </p> <section id="CD011301-sec-0677"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0678"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant assessment was higher with daxibotulinumtoxinA 60 U and placebo at week 4 (RR 52.29, 95% CI 3.31 to 825.07; participants = 76; studies = 1); at week 16 (RR 18.00, 95% CI 1.09 to 296.56; participants = 76; studies = 1); and at week 24 (RR 6.00, 95% CI 0.32 to 112.32; participants = 76; studies = 1) (<a href="./references#CD011301-fig-0210" title="">Analysis 73.1</a>). </p> </section> <section id="CD011301-sec-0679"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>No difference between groups (Peto 7.71, 95% CI 0.43 to 138.48; participants = 76; studies = 1) (<a href="./references#CD011301-fig-0211" title="">Analysis 73.2</a>). </p> </section> </section> <section id="CD011301-sec-0680"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0681"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was higher with daxibotulinumtoxinA 60 U and placebo at week 4 (RR 69.43, 95% CI 4.42 to 1089.43; participants = 76; studies = 1); at week 8 (RR 55.71, 95% CI 3.54 to 877.94; participants = 76; studies = 1); at week 12 (RR 31.71, 95% CI 1.98 to 507.90; participants = 76; studies = 1); at week 16 (RR 14.57, 95% CI 0.87 to 243.78; participants = 76; studies = 1); at week 20 (RR 14.57, 95% CI 0.87 to 243.78; participants = 76; studies = 1); and at week 24 (RR 4.29, 95% CI 0.21 to 86.39; participants = 76; studies = 1). Although, the effect sizes are uncertain due to the very large confidence interval, which includes 1 at week 16, week 20 and week 24 (<a href="./references#CD011301-fig-0212" title="">Analysis 73.3</a>). </p> </section> <section id="CD011301-sec-0682"> <h6 class="title">Total adverse events</h6> <p>The total adverse events was higher in daxibotulinumtoxinA 60 U group than in placebo group (RR 2.89, 95% CI 1.23 to 6.75; participants = 107; studies = 1) (<a href="./references#CD011301-fig-0213" title="">Analysis 73.4</a>) </p> </section> <section id="CD011301-sec-0683"> <h6 class="title">Duration of treatment effect</h6> <p>The duration of effect of daxibotulinumtoxinA 60 U was 22.5 weeks and 0.4 weeks for placebo group (MD 22.10, 95% CI 20.24 to 23.96; participants = 76; studies = 1) (<a href="./references#CD011301-fig-0214" title="">Analysis 73.5</a>). </p> </section> </section> </section> <section id="CD011301-sec-0684"> <h4 class="title">COMPARISON 74. DaxibotulinumtoxinA 40 units versus placebo one cycle of treatment, glabellar lines </h4> <p>Two RCTs (n = 683 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a>; <a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>). Results are also shown in <a href="./full#CD011301-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD011301-sec-0685"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0686"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant assessment was higher with daxibotulinumtoxinA 40 U and placebo at week 4 (RR 21.10, 95% CI 11.31 to 39.34; participants = 683; studies = 2; I<sup>2</sup> = 0%, moderate‐certainty evidence); at week 8 (RR 15.75, 95% CI 8.85 to 28.03; participants = 609; studies = 1); at week 12 (RR 24.51, 95% CI 11.12 to 54.05; participants = 609; studies = 1); at week 16 (RR 12.74, 95% CI 6.80 to 23.89; participants = 683; studies = 2; I<sup>2</sup> = 0%); at week 20 (RR 13.60, 95% CI 6.13 to 30.18; participants = 609; studies = 1); and at week 24 (RR 3.09, 95% CI 0.13 to 73.21; participants = 683; studies = 2; I<sup>2</sup> = 0%). (<a href="./references#CD011301-fig-0215" title="">Analysis 74.1</a>) </p> </section> <section id="CD011301-sec-0687"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>These RCTs did not show any major event.</p> </section> </section> <section id="CD011301-sec-0688"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0689"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was higher with daxibotulinumtoxinA 40 U and placebo at week 4 (RR 23.40, 95% CI 12.56 to 43.61; participants = 683; studies = 2; I<sup>2</sup> = 0%, moderate‐certainty evidence); at week 8 (RR 18.09, 95% CI 10.30 to 31.78; participants = 683; studies = 2; I<sup>2</sup> = 0%); at week 12 (RR 29.46, 95% CI 13.79 to 62.94; participants = 683; studies = 2; I<sup>2</sup> = 0%); at week 16 (RR 16.84, 95% CI 9.01 to 31.47; participants = 683; studies = 2; I<sup>2</sup> = 0%); at week 20 (RR 18.06, 95% CI 8.42 to 38.76; participants = 683; studies = 2; I<sup>2</sup> = 0%); and at week 24 (RR 15.33, 95% CI 6.06 to 38.78; participants = 683; studies = 2; I<sup>2</sup> = 0%) (<a href="./references#CD011301-fig-0216" title="">Analysis 74.2</a>). </p> </section> <section id="CD011301-sec-0690"> <h6 class="title">Total adverse events</h6> <p>The risk of any adverse events was higher in daxibotulinumtoxinA group (RR 2.23, 95% CI 1.46 to 3.40; participants = 716; studies = 2; I<sup>2</sup> = 0%, moderate‐certainty evidence) (<a href="./references#CD011301-fig-0217" title="">Analysis 74.3</a>). </p> </section> <section id="CD011301-sec-0691"> <h6 class="title">Duration of treatment effect</h6> <p>One RCT assesses this outcome (<a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>).The duration of treatment effect was 23.2 weeks for daxibotulinumtoxinA 60 U and 0.4 weeks for placebo group (MD 22.80, 95% CI 20.74 to 24.86; participants = 74; studies = 1) (<a href="./references#CD011301-fig-0218" title="">Analysis 74.4</a>). </p> <p><a href="./references#CD011301-bbs2-0009" title="BertucciV , SolishN , Kaufman-JanetteJ , YoelinS , ShambanA , SchlessingerJ , et al.DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Journal of the American Academy of Dermatology2020;82(4):838-45. [PMID: 31791824]CarruthersJD , FagienS , JosephJH , HumphreySD , BiesmanBS , GallagherCJ , et al.DaxibotulinumtoxinA for injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plastic and Reconstructive Surgery2020;145(1):45-58. [PMID: 31609882]">Bertucci 2020</a> pre‐specified 24 weeks as duration of treatment effect. </p> </section> </section> </section> <section id="CD011301-sec-0692"> <h4 class="title">COMPARISON 75. DaxibotulinumtoxinA 20 units versus placebo one cycle of treatment, glabellar lines </h4> <p>One RCT (n = 69 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>). </p> <section id="CD011301-sec-0693"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0694"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant assessment was higher with daxibotulinumtoxinA 20 U and placebo at week 4 (RR 50.40, 95% CI 3.19 to 797.13; participants = 69; studies = 1); at week 16 (RR 11.31, 95% CI 0.65 to 197.06; participants = 69; studies = 1); at week 24 (RR 3.09, 95% CI 0.13 to 73.21; participants = 69; studies = 1), although the effect size is uncertain due to the very large confidence interval (<a href="./references#CD011301-fig-0219" title="">Analysis 75.1</a>). </p> </section> <section id="CD011301-sec-0695"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0696"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0697"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was higher with daxibotulinumtoxinA 20 U and placebo at week 4 (RR 60.69, 95% CI 3.86 to 955.19; participants = 69; studies = 1); at week 8 (RR 33.94, 95% CI 2.12 to 544.26; participants = 69; studies = 1); at week 12 (RR 21.60, 95% CI 1.32 to 354.72; participants = 69; studies = 1); at week 16 (RR 15.43, 95% CI 0.92 to 260.05; participants = 69; studies = 1); at week 20 (RR 9.26, 95% CI 0.52 to 165.65; participants = 83; studies = 1); at week 24 (RR 7.20, 95% CI 0.39 to 134.36; participants = 69; studies = 1), although the effect size is uncertain due to the very large confidence interval (<a href="./references#CD011301-fig-0220" title="">Analysis 75.2</a>). </p> </section> <section id="CD011301-sec-0698"> <h6 class="title">Total adverse events</h6> <p>The total adverse events was higher in daxibotulinumtoxinA 40 U group than in placebo group (RR 2.17, 95% CI 0.89 to 5.28; participants = 108; studies = 1) (<a href="./references#CD011301-fig-0221" title="">Analysis 75.3</a>). </p> </section> <section id="CD011301-sec-0699"> <h6 class="title">Duration of treatment effect</h6> <p>The duration of treatment effect of daxibotulinumtoxinA 60 U was 20.8 weeks and 0.4 weeks for placebo group (MD 20.40, 95% CI 18.56 to 22.24; participants = 69; studies = 1) (<a href="./references#CD011301-fig-0222" title="">Analysis 75.4</a>). </p> </section> </section> </section> <section id="CD011301-sec-0700"> <h4 class="title">COMPARISON 76. DaxibotulinumtoxinA 60 units versus OnabotulimtoxinA 20units one cycle of treatment, glabellar lines </h4> <p>One RCT (n = 83 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>). </p> <section id="CD011301-sec-0701"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0702"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant assessment was higher with daxibotulinumtoxinA 60 U and onabotulinumtoxinA 20 U at week 4(RR 1.14, 95% CI 0.85 to 1.52; participants = 83; ; studies = 1); and at week 16 (RR 2.05, 95% CI 0.77 to 5.48; participants = 83; studies = 1); but similar at week 24 (RR 2.05, 95% CI 0.77 to 5.48; participants = 83; studies = 1) (<a href="./references#CD011301-fig-0223" title="">Analysis 76.1</a>). </p> </section> <section id="CD011301-sec-0703"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>No difference between groups (Peto OR 3.62, 95% CI 0.60 to 21.86; participants = 83; studies = 1) (<a href="./references#CD011301-fig-0224" title="">Analysis 76.2</a>). </p> </section> </section> <section id="CD011301-sec-0704"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0705"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was higher with daxibotulinumtoxinA 60 U and onabotulinumtoxinA 20 U at week 8 (RR 1.49, 95% CI 1.07 to 2.07; participants = 83; studies = 1); but a  similar response at week 4 (RR 1.24, 95% CI 1.05 to 1.46); participants = 83; studies = 1); at week 12 (RR 0.97, 95% CI 0.60 to 1.57; participants = 83; studies = 1); at week 16 (RR 2.05, 95% CI 0.67 to 6.28; participants = 83; studies = 1); at week 20 (RR 1.02, 95% CI 0.15 to 6.9; participants = 83; studies = 1); and at week 24 (RR 1.02, 95% CI 0.15 to 6.93; participants = 83; studies = 1) (<a href="./references#CD011301-fig-0225" title="">Analysis 76.3</a>). </p> </section> <section id="CD011301-sec-0706"> <h6 class="title">Total adverse events</h6> <p>There was no difference between total adverse events between groups (RR 1.15, 95% CI 0.65 to 2.07; participants = 107; studies = 1) (<a href="./references#CD011301-fig-0226" title="">Analysis 76.4</a>). </p> </section> <section id="CD011301-sec-0707"> <h6 class="title">Duration of treatment effect</h6> <p>There was no difference of duration of treatment between groups (MD 3.70, 95% CI 0.91 to 6.49; participants = 83; studies = 1) (<a href="./references#CD011301-fig-0227" title="">Analysis 76.5</a>). </p> </section> </section> </section> <section id="CD011301-sec-0708"> <h4 class="title">COMPARISON 77. DaxibotulinumtoxinA 40 units versus OnabotulimtoxinA 20 units one cycle of treatment, glabellar lines </h4> <p>One RCT (n = 250 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>). </p> <section id="CD011301-sec-0709"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0710"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant assessment was similar between daxibotulinumtoxinA 40 U and onabotulinumtoxinA 20 U at week 4(RR 0.88, 95% CI 0.61 to 1.25; participants = 81; studies = 1); at week 16 (RR 2.15, 95% CI 0.81 to 5.74; participants = 81; studies = 1); and at week 24 (RR 1.08, 95% CI 0.16 to 7.28; participants = 81; studies = 1) (<a href="./references#CD011301-fig-0228" title="">Analysis 77.1</a>). </p> </section> <section id="CD011301-sec-0711"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>There was no difference between groups (Peto OR 0.15, 95% CI 0.00 to 7.35; participants = 81; studies = 1) (<a href="./references#CD011301-fig-0229" title="">Analysis 77.2</a>). </p> </section> </section> <section id="CD011301-sec-0712"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0713"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was higher with daxibotulinumtoxinA 40 U and onabotulinumtoxinA 20 U at week 4(RR 1.21, 95% CI 1.01 to 1.44; participants = 81; studies = 1); at week 8 (RR 1.42, 95% CI 1.01 to 2.00; participants = 81; studies = 1); at week 16 (RR 3.77, 95% CI 1.36 to 10.48; participants = 81; studies = 1); but similar at week 12 (RR 0.96, 95% CI 0.59 to 1.57; participants = 81; studies = 1); at week 20 (RR 2.87, 95% CI 0.82 to 10.06; participants = 81; studies = 1); and at week 24 (RR 2.15, 95% CI 0.42 to 11.11; participants = 81; studies = 1) (<a href="./references#CD011301-fig-0230" title="">Analysis 77.3</a>). </p> </section> <section id="CD011301-sec-0714"> <h6 class="title">Total adverse events</h6> <p>There was no difference between total adverse events between groups (RR 0.95, 95% CI 0.51 to 1.77; participants = 107; studies = 1) (<a href="./references#CD011301-fig-0231" title="">Analysis 77.4</a>). </p> </section> <section id="CD011301-sec-0715"> <h6 class="title">Duration of treatment effect</h6> <p>The duration of treatment effect was similar in the daxibotulinumtoxinA 40 U group and OnabotulinumtoxinA 20 U group (MD 4.40, 95% CI 1.47 to 7.33; participants = 81; studies = 1) ( <a href="./references#CD011301-fig-0232" title="">Analysis 77.5</a>). </p> </section> </section> </section> <section id="CD011301-sec-0716"> <h4 class="title">COMPARISON 78. DaxibotulinumtoxinA 20 units versus onabotulimtoxinA 20units one cycle of treatment, glabellar lines </h4> <p>One RCT (n = 76 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0022" title="CarruthersJ , SolishN , HumphreyS , RosenN , MuhnC , BertucciV , et al.Injectable daxibotulinumtoxinA for the treatment of glabellar lines: a phase 2, randomized, dose-ranging, double-blind, multicenter comparison with onabotulinumtoxinA and placebo. Dermatologic Surgery2017;43(11):1321-31. [PMID: 28614091]NCT02303002.Efficacy and safety of botulinum toxin type A for injection to treat glabellar lines. clinicaltrials.gov/ct2/show/NCT02303002 (first received 27 November 2014). ">Carruthers 2017</a>). </p> <section id="CD011301-sec-0717"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0718"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant assessment showed no difference between daxibotulinumtoxinA 20 U and onabotulinumtoxinA 20 U at week 4 (RR 1.10, 95% CI 0.80 to 1.50; participants = 76; studies = 1); at week 16 (RR 1.24, 95% CI 0.39 to 3.92; participants = 76; studies = 1); and at week 24(RR 0.25, 95% CI 0.01 to 4.95; participants = 76; studies = 1) (<a href="./references#CD011301-fig-0233" title="">Analysis 78.1</a>). </p> </section> <section id="CD011301-sec-0719"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>There was no difference between groups (Peto OR 0.16, 95% CI 0.00 to 8.43; participants = 76; studies = 1) (<a href="./references#CD011301-fig-0234" title="">Analysis 78.2</a>). </p> </section> </section> <section id="CD011301-sec-0720"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0721"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was similar with daxibotulinumtoxinA 20 U and onabotulinumtoxinA 20 U at week 4 (RR 1.09, 95% CI 0.88 to 1.34; participants = 76; studies = 1); at week 8 (RR 0.90, 95% CI 0.57 to 1.42; participants = 76; studies = 1); at week 12 (RR 1.24, 95% CI 0.58 to 2.62; participants = 76; studies = 1); at week 16 (RR 2.16, 95% CI 0.69 to 6.77; participants = 76; studies = 1); at week 20 (RR 1.65, 95% CI 0.40 to 6.86; participants = 76; studies = 1); and at week 24 (RR 1.85, 95% CI 0.33 to 10.46; participants = 76; studies = 1) (<a href="./references#CD011301-fig-0235" title="">Analysis 78.3</a>). </p> </section> <section id="CD011301-sec-0722"> <h6 class="title">Total adverse events</h6> <p>There was no difference between daxibotulinumtoxinA 20U and onabotulinumtoxinA 20 U (RR 0.87, 95% CI 0.46 to 1.64; participants = 108; studies = 1) (<a href="./references#CD011301-fig-0236" title="">Analysis 78.4</a>). </p> </section> <section id="CD011301-sec-0723"> <h6 class="title">Duration of treatment effect</h6> <p>The duration of treatment effect was similar between of daxibotulinumtoxinA 20U and onabotulinumtoxinA 20 U (MD 2.00, 95% CI ‐0.78 to 4.78; participants = 76; studies = 1) (<a href="./references#CD011301-fig-0237" title="">Analysis 78.5</a>). </p> </section> </section> </section> <section id="CD011301-sec-0724"> <h4 class="title">COMPARISON 79. PrabotulinumtoxinA 20 units versus placebo one cycle of treatment, glabellar lines </h4> <p>Three RCTs (n = 948 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>; <a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>). </p> <section id="CD011301-sec-0725"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0726"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant assessment was higher withdaxibotulinumtoxinA 20 U than placebo at week 4 (RR 18.34, 95% CI 9.68 to 34.76; participants = 930; studies = 3; I<sup>2</sup> = 0%). (<a href="./references#CD011301-fig-0238" title="">Analysis 79.1</a>). </p> <p>Two RCTs (<a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>) showed this outcome at week 8, 12 and 16, but the authors did not separate participant and physician assessment scores. </p> </section> <section id="CD011301-sec-0727"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>There was no difference between prabotulinumtoxinA 20U and placebo (RR 0.60, 95% CI 0.06 to 5.65; participants = 939; studies = 3; I<sup>2</sup> = 0%) (<a href="./references#CD011301-fig-0239" title="">Analysis 79.2</a>). </p> </section> </section> <section id="CD011301-sec-0728"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0729"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was similar with prabotulinumtoxinA 20 U and placebo at week 4 (RR 23.96, 95% CI 9.35 to 61.40; participants = 929; studies = 3; I<sup>2</sup> = 26%) (<a href="./references#CD011301-fig-0240" title="">Analysis 79.3</a>). </p> <p>Two RCTs (<a href="./references#CD011301-bbs2-0007" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019a</a>; <a href="./references#CD011301-bbs2-0008" title="BeerKR , ShambanAT , AvelarRL , GrossJE , JonkerA .Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results From 2 identical phase III studies. Dermatologic Surgery2019;45(11):1381-93. [PMID: 30893162]">Beer 2019b</a>) showed this outcome at weeks 8, 12, and 16, but the authors did not separate participant and physician assessment scores. </p> </section> <section id="CD011301-sec-0730"> <h6 class="title">Total adverse events</h6> <p>There was no difference between prabotulinumtoxinA 20 U and placebo (RR 1.14, 95% CI 0.91 to 1.43; participants = 948; studies = 3; I<sup>2</sup> = 0%) (<a href="./references#CD011301-fig-0241" title="">Analysis 79.4</a>). </p> </section> <section id="CD011301-sec-0731"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0732"> <h4 class="title">COMPARISON 80. PrabotulinumtoxinA 20 units versus OnabotulimtoxinA 20 units one cycle of treatment, glabellar lines </h4> <p>Two RCTs (n = 759 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0058" title="RzanyBJ , AscherB , AvelarRL , BergdahlJ , BertucciV , BodokhI , et al.A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects. Aesthetic Surgery Journal 2019 Apr 5 [Epub ahead of print]. [CENTRAL: CN-01941776] [DOI: 10.1093/asj/sjz110]">Rzany 2019</a>; <a href="./references#CD011301-bbs2-0063" title="WonCH , KimHK , KimBJ , KangH , HongJP , LeeSY , et al.Comparative trial of a novel botulinum neurotoxin type A versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. International Journal of Dermatology2015;54(2):227-34. [CENTRAL: CN-01048870] ">Won 2015</a>). </p> <section id="CD011301-sec-0733"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0734"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The responder rate by participant assessment was higher with daxibotulinumtoxinA 20 U than onabotulinumtoxinA 20 U at week 4 (RR 1.04, 95% CI 1.00 to 1.09; participants = 749; studies = 2; I<sup>2</sup> = 0%) (<a href="./references#CD011301-fig-0242" title="">Analysis 80.1</a>). </p> </section> <section id="CD011301-sec-0735"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>There was no difference between prabotulinumtoxinA 20 U and onabotulinumtoxinA (Peto OR 2.75, 95% CI 0.38 to 19.61; participants = 491; studies = 1) (<a href="./references#CD011301-fig-0243" title="">Analysis 80.2</a>). </p> </section> </section> <section id="CD011301-sec-0736"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0737"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate by physician assessment was similar with prabotulinumtoxinA 20 U and onabotulinumtoxinA at week 4 (RR 1.04, 95% CI 0.94 to 1.14; participants = 483; studies = 1) (<a href="./references#CD011301-fig-0244" title="">Analysis 80.3</a>). </p> </section> <section id="CD011301-sec-0738"> <h6 class="title">Total adverse events</h6> <p>There was no difference between prabotulinumtoxinA 20U and onabotulinumtoxinA (RR 0.91, 95% CI 0.74 to 1.13; participants = 759; studies = 2; I<sup>2</sup> = 0%) (<a href="./references#CD011301-fig-0245" title="">Analysis 80.4</a>). </p> </section> <section id="CD011301-sec-0739"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0740"> <h4 class="title">COMPARISON 81. OnabotulinumtoxinA 9 units versus hyaluronic acid [JUVEDERM ULTRA ® and/or JUVEDERM ULTRA PLUS®] one cycle of treatment, lips and perioral lines </h4> <p>Only one RCT (n = 60 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>). Therefore, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0741"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0742"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This did not assess this outcome.</p> </section> <section id="CD011301-sec-0743"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0744"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0745"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The authors showed a significant difference among the groups (data not shown). No numeric data were provided. </p> </section> <section id="CD011301-sec-0746"> <h6 class="title">Total adverse events</h6> <p>The total adverse events were higher with onabotulinumtoxinA than hyaluronic acid, but the result is uncertain due to the wide confidence interval (RR 2.00, 95% CI 0.40 to 10.11; participants = 60; studies = 1) (<a href="./references#CD011301-fig-0246" title="">Analysis 81.1</a>). </p> </section> <section id="CD011301-sec-0747"> <h6 class="title">Duration of treatment effect</h6> <p>The mean duration of treatment effect by physician assessment at maximum contraction of each treatment were: 9.9 weeks (69.3 ± 11.0 days) for onabotulinumtoxinA group; 15.5 weeks (108.9 ± 12 days) 24 g/mL cohesive gel group. </p> </section> </section> </section> <section id="CD011301-sec-0748"> <h4 class="title">COMPARISON 82. OnabotulinumtoxinA 9 units associated with hyaluronic acid [JUVEDERM ULTRA ® and/or JUVEDERM ULTRA PLUS®] versus onabotulinumtoxinA 9 units one cycle of treatment, lips and perioral lines </h4> <p>Only one RCT (n = 60 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>). Hence, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0749"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0750"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0751"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0752"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0753"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The authors showed a significant difference among the groups (data not shown). No numerical data were provided. </p> </section> <section id="CD011301-sec-0754"> <h6 class="title">Total adverse events</h6> <p>The frequency of adverse events was similar with onabotulinumtoxinA and onabotulinumtoxinA associated with filler (RR 0.75, 95% CI 0.18 to 3.07; participants = 60; studies = 1) (<a href="./references#CD011301-fig-0247" title="">Analysis 82.1</a>). </p> </section> <section id="CD011301-sec-0755"> <h6 class="title">Duration of treatment effect</h6> <p>The mean duration of treatment effect by investigator assessment at maximum contraction were 15.2 weeks (106.6 ± 10.6 days) in the BontA plus 24‐mg/mL cohesive gel and 9.9 weeks (69.3 ± 11.0 days) for onabotulinumtoxinA. </p> </section> </section> </section> <section id="CD011301-sec-0756"> <h4 class="title">COMPARISON 83. Hyaluronic acid versus OnabotulinumtoxinA 9 units associated with hyaluronic acid [JUVEDERM ULTRA ® and/or JUVEDERM ULTRA PLUS®] one cycle of treatment, lips and perioral lines </h4> <p>Only one RCT (n = 60 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0018" title="CarruthersA , CarruthersJ , MonheitGD , DavisPG , TardieG .Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatologic Surgery2010;36(Suppl 4):2121-34. [PMID: 21134044]">Carruthers 2010</a>). For this reason, we were not able to undertake a meta‐analysis, and only a visual representation of the results is shown in the forest plots. </p> <section id="CD011301-sec-0757"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0758"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0759"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>This RCT did not report any major event.</p> </section> </section> <section id="CD011301-sec-0760"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0761"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The authors showed a significant difference among the groups. No numeric data were provided. </p> </section> <section id="CD011301-sec-0762"> <h6 class="title">Total adverse events</h6> <p>no difference between groups (RR 0.67; 95% CI 0.12 to 3.71, participants = 60; studies = 1) (<a href="./references#CD011301-fig-0248" title="">Analysis 83.1</a>). </p> </section> <section id="CD011301-sec-0763"> <h6 class="title">Duration of treatment effect</h6> <p>The mean duration of treatment effect by investigator assessment at maximum contraction were 15.2 (106.6 ± 10.6 days) in the onabotulinumtoxinA plus 24‐mg/mL cohesive gel group, and 15.5 weeks (108.9 ± 12 days) in 24‐mg/mL cohesive gel. </p> </section> </section> </section> <section id="CD011301-sec-0764"> <h4 class="title">COMPARISON 84. IncobotulinumtoxinA 21 units versus AbobotulinumtoxinA 63 units, one cycle of treatment, glabellar lines </h4> <p>Only one RCT (n = 120 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>). </p> <section id="CD011301-sec-0765"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0766"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0767"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>No serious adverse events were reported.</p> </section> </section> <section id="CD011301-sec-0768"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0769"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The authors showed a significant difference among the groups. No numerical data were provided. </p> </section> <section id="CD011301-sec-0770"> <h6 class="title">Total adverse events</h6> <p>Two participants reported mild bruising, which resolved within 2 to 3 days (the authors did not provide this results by intervention group) (very low‐certainty evidence). </p> </section> <section id="CD011301-sec-0771"> <h6 class="title">Duration of treatment</h6> <p>For females, the mean duration of treatment effect was 146.12 days for incobotulinumtoxinA versus 139.69 days for abobotulinumtoxinA. For males, these results were 121.14 and 115.81, respectively (no SD or P value were provided). </p> </section> </section> </section> <section id="CD011301-sec-0772"> <h4 class="title">COMPARISON 85. AbobotulinumtoxinA 50 units versus OnabotulinumtoxinA 18 units one cycle of treatment, glabellar and crow's feet lines </h4> <p>One RCT (n = 85 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0037" title="KassirR , KolluruA , KassirM .Triple-blind, prospective, internally controlled comparative study between AbobotulinumtoxinA and OnabotulinumtoxinA for the treatment of facial rhytids. Dermatology and Therapy2013;3(2):179-89. [CENTRAL: CN-00993785] ">Kassir 2013</a>). This was a split‐face study design, so the results are described narratively. </p> <section id="CD011301-sec-0773"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0774"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0775"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>One participant in the abobotulinumtoxinA group reported ptosis.</p> </section> </section> <section id="CD011301-sec-0776"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0777"> <h6 class="title">Physician assessment of success by analysing scores and scales </h6> <p>The responder rate for glabellar lines, by physician assessment, was similar with abobotulinumtoxinA 30 U compared to onabotulinumtoxinA 8 U from week 4 to week 16. </p> <p>The responder rate for crow's feet lines, by physician assessment, was similar with AbobotulinumtoxinA 30U and onabotulinumtoxinA 10 U from week 4 to week 16. </p> </section> <section id="CD011301-sec-0778"> <h6 class="title">Total adverse events</h6> <p>This RCT did not assess this outcome.</p> </section> <section id="CD011301-sec-0779"> <h6 class="title">Duration of treatment</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0780"> <h4 class="title">COMPARISON 86. AbobotulinumtoxinA 30 units versus OnabotulinumtoxinA 10 units one cycle of treatment, crow's feet lines </h4> <p>One RCT (n = 90 participants) assessed this comparison (<a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>). </p> <section id="CD011301-sec-0781"> <h5 class="title">Primary outcomes</h5> <section id="CD011301-sec-0782"> <h6 class="title">Participant assessment of success by analysing scores and scales</h6> <p>The score (Merz scale) rate by participant assessment was higher with abobotulinumtoxinA treatment (2.34) than onabotulinumtoxinA (2.13), P = 0.03 at week 4. </p> </section> <section id="CD011301-sec-0783"> <h6 class="title">Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</h6> <p>No major adverse events were reported.</p> </section> </section> <section id="CD011301-sec-0784"> <h5 class="title">Secondary outcomes</h5> <section id="CD011301-sec-0785"> <h6 class="title">Physician assessment of success by analysing scores and scales</h6> <p>The score (Merz scale) rate by participant assessment was higher with abobotulinumtoxinA treatment (2.60) than onabotulinumtoxinA (2.33), P = 0.01 at week 4. </p> </section> <section id="CD011301-sec-0786"> <h6 class="title">Total adverse events</h6> <p>One patient from onabotulinumtoxinA group showed a bruise.</p> </section> <section id="CD011301-sec-0787"> <h6 class="title">Duration of treatment effect</h6> <p>This RCT did not assess this outcome.</p> </section> </section> </section> <section id="CD011301-sec-0788"> <h4 class="title">COMPARISONS WITHOUT USABLE DATA</h4> <p>We were unable to collect usable data on the following comparisons, because the studies did not collect or report relevant data: </p> <p> <ul id="CD011301-list-0039"> <li> <p>AbobotulinumtoxinA different doses comparison (full face treatment): one RCT (n = 90, <a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>). The doses compared were too similar and did not allow any validate comparisons (no clinical relevance). Moreover, there was dose overlap among the dose range (<a href="./references#CD011301-bbs2-0034" title="HexselD , BrumC , PortoMD , SoirefmannM , SiegaC , Schilling-SouzaJ , et al.Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy. Journal of Drugs in Dermatology2013;12(12):1356-62. [CENTRAL: CN-00961073] ">Hexsel 2013</a>). </p> </li> <li> <p>OnabotulinumtoxinA versus facial cream (Strivectin®) one cycle of treatment (glabellar lines): one RCT (n = 32, <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>). </p> </li> <li> <p>OnabotulinumtoxinA versus facial cream (Wrinklerelax™) one cycle of treatment (glabellar lines): one RCT (n = 31, <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>). </p> </li> <li> <p>OnabotulinumtoxinA versus facial cream (Hydroderm™) one cycle of treatment (glabellar lines): one RCT (n = 31, <a href="./references#CD011301-bbs2-0006" title="BeerKR .Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids. Dermatologic Surgery2006;32(2):184-97. [DOI: 10.1111/j.1524-4725.2006.32036.x] [PMID: 16442037]">Beer 2006</a>). </p> </li> <li> <p>OnabotulinumtoxinA 25 units versus abobotulinumtoxinA 62.5 units one cycle of treatment (glabellar lines, crow's feet, and forehead lines (split‐face)): One RCT (n = 53, <a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>). </p> </li> <li> <p>OnabotulinumtoxinA 20 units versus abobotulinumtoxinA 50 units one cycle of treatment (crow's feet lines): one RCT (n = 90, <a href="./references#CD011301-bbs2-0050" title="NettarKD , YuKC , BapnaS , BoscardinJ , MaasCS .An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2011;13(6):380-6. [CENTRAL: CN-00814326] YuKC , NettarKD , BapnaS , BoscardinWJ , MaasCS .Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Archives of Facial Plastic Surgery2012;14(3):198-204. [CENTRAL: CN-00840586] ">Nettar 2011</a>). </p> </li> <li> <p>OnabotulinumtoxinA 7.5 units versus incobotulinumtoxinA 7.5 units one cycle of treatment (crow's feet lines): one RCT (n = 56, <a href="./references#CD011301-bbs2-0052" title="LeeJH , ParkJH , LeeSK , HanKH , KimSD , YoonCS , et al.Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. Journal of Dermatological Treatment2014;25(4):326-30. [CENTRAL: CN-00986202] ">Park 2014</a>). </p> </li> <li> <p>AbobotulinumtoxinA 63 units versus onabotulinumtoxinA 32 units one cycle of treatment (glabellar lines): one RCT (n = 119, <a href="./references#CD011301-bbs2-0054" title="RapplT , ParviziD , FriedlH , WiednerM , MayS , KranzelbinderB , et al.Onset and duration of effect of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in the treatment of glabellar frown lines: a randomized, double-blind study. Clinical, Cosmetic and Investigational Dermatology2013;6:211-9. [CENTRAL: CN-00914061] ">Rappl 2013</a>). </p> </li> <li> <p>OnabotulinumtoxinA 25 units versus onabotulinumtoxinA 25 units associated to collagen one cycle of treatment (glabellar lines): One RCT (n = 45, <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>). </p> </li> <li> <p>OnabotulinumtoxinA 25 units versus collagen one cycle of treatment (glabellar lines): one RCT (n = 42, <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>). </p> </li> <li> <p>OnabotulinumtoxinA 25 units associated with collagen versus collagen one cycle of treatment (glabellar lines): one RCT (n = 45, <a href="./references#CD011301-bbs2-0053" title="PatelMP , TalmorM , NolanWB .Botox and collagen for glabellar furrows: advantages of combination therapy. Annals of Plastic Surgery2004;52(5):442-7. [CENTRAL: CN-00489363] ">Patel 2004</a>). </p> </li> <li> <p>OnabotulinumtoxinA units not shown versus abobotulinumtoxin units not shown one cycle of treatment of glabellar lines and frontal lines, split‐face study: one study (<a href="./references#CD011301-bbs2-0030" title="FirozB , PilatoT , ZhouW .A randomized, double blind, split-face comparison of Botox verses dysport for glabellar and forehead lines. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB21. [EMBASE: 70703936]">Firoz 2012</a>). </p> </li> <li> <p>OnabotulinumtoxinA 25 units versus abobotulinumtoxin 62.5 units one cycle of treatment of glabellar lines, periorbital lines and frontal lines (<a href="./references#CD011301-bbs2-0043" title="MichaelsBM , CsankGA , RybGE , EkoFN , RubinA .Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthetic Surgery Journal2012;32(1):96-102. [CENTRAL: CN-00832322] ">Michaels 2012</a>). </p> </li> </ul> </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011301-sec-0789" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011301-sec-0789"></div> <section id="CD011301-sec-0790"> <h3 class="title" id="CD011301-sec-0790">Summary of main results</h3> <p>We included 65 randomised controlled trials (RCTs), involving 14,919 randomised participants. Here we summarise the results for the main comparisons that assessed the treatment of the facial region glabellar lines. </p> <p><a href="./full#CD011301-tbl-0001">summary of findings Table 1</a>: based on moderate‐certainty evidence, onabotulinumtoxinA‐20 units (U) probably has a higher success rate than placebo when measured at four weeks by participants or physicians. OnabotulinumtoxinA‐20 U probably increased the risk of major adverse events compared to placebo (moderate‐certainty evidence), but there may be no difference between groups in any adverse events (low‐certainty evidence). Adverse events were collected over the duration of these studies, which ranged from four weeks to 24 weeks. </p> <p><a href="./full#CD011301-tbl-0002">summary of findings Table 2</a>: abobotulinumtoxinA‐50 U showed a higher success rate than placebo at week four by participant assessment (high‐certainty evidence), and abobotulinumtoxinA‐50 U probably has a higher success rate by physician assessment (moderate‐certainty evidence). Compared to placebo, abobotulinumtoxinA‐50 U probably increases the occurrence of major adverse effects(moderate‐certainty evidence; collected in studies of four to 12 weeks duration) and may increase the occurrence of any adverse events (low‐certainty evidence; collected in studies of four to 16 weeks duration). </p> <p><a href="./full#CD011301-tbl-0003">summary of findings Table 3</a>: there is probably a higher success rate with incobotulinumtoxinA‐20 U than placebo at week four by both participant assessment (moderate‐certainty evidence) and physician assessment (moderate‐certainty evidence). Major adverse events were not observed (moderate‐certainty evidence), and there may be no difference between groups in any adverse events (low‐certainty evidence; collected in studies of four to 16 weeks duration). </p> <p><a href="./full#CD011301-tbl-0004">summary of findings Table 4</a>: there is no difference in the participant‐assessed or physician‐assessed success rate between abobotulinumtoxinA‐50 U and onabotulinumtoxinA‐20 U at four weeks (high‐certainty evidence). AbobotulinumtoxinA‐50 U probably increases the occurrence of major adverse events compared to onabotulinumtoxinA‐20 U (moderate‐certainty evidence), but there is probably no difference in any adverse events (moderate‐certainty evidence; collected in studies of four to 12 weeks duration). </p> <p><a href="./full#CD011301-tbl-0005">summary of findings Table 5</a>: there may be no difference in the success rate between incobotulinumtoxinA‐24 U and onabotulinumtoxinA‐24 U at four weeks (by physician assessment; low‐certainty evidence). Participant assessment was not measured. Ptosis was reported in one participant in the onabotulinumtoxinA group, but the certainty of this evidence is very low, so we are uncertain of the risk of adverse events (collected in studies of four to 12 weeks duration). </p> <p><a href="./full#CD011301-tbl-0006">summary of findings Table 6</a>: daxibotulinumtoxinA 40 U probably has a higher success rate than placebo when assessed at four weeks by either participants or physicians (moderate‐certainty evidence). Major adverse events were not observed. There may be an increase in any adverse events with daxibotulinumtoxinA than with placebo (moderate‐certainty evidence; collected in studies of four to 24 weeks duration). </p> <p>Adverse events: ptosis was the main major adverse event. Botulinum toxin type A (BontA) are associated with a risk of strabismus or eyelid sensory disorders. </p> </section> <section id="CD011301-sec-0791"> <h3 class="title" id="CD011301-sec-0791">Overall completeness and applicability of evidence</h3> <p>Analysing the data, some ethnicities (Middle East, Latin America) and males are underrepresented. More than 80% of the total number of study participants were female. Ethnicity and anatomic characteristics such as skin width, oily skin, the skeletal structure can potentially impact on outcomes for BontA treatment. In general, men have stronger muscles than women, and this fact could interfere in the relationship between the units of BontA needed to treat and duration of effect. </p> <p>Our review aimed to assess treatment of any type of facial wrinkle, but almost two‐thirdsof studies assessed treatment of the glabella region (43/65 studies). The other types of wrinkles assessed in this review: crow's feet lines: seven RCTs;<b> </b>forehead lines: two RCTs; forehead lines and crow's feet lines: one RCT; upper lines (glabellar lines, crow's feet lines, and forehead lines): three RCTs; forehead lines and glabellar lines: three RCTs; crow's feet lines and glabellar lines: three RCTs; full face: one RCT; perioral area: two RCTs. </p> <p>Most of the studies that treated glabellar lines included moderate‐to‐severe glabellar lines according to Facial Wrinkle Scale score (FWS)or Glabellar Lines Severity Scale (GLSS). The studies that assessed others regions did not show details about wrinkle severity. In clinical practice, physicians treat mild‐to‐moderate glabellar lines. </p> <p>The main commercial BontA treatments were addressed in the included studies. These included onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, HBTX‐A, NewBontA (Medytox®, Neuronox®, Prosigne®), liquid BontA (MT101109L), daxibotulinumtoxinA (DWP450), praxibotulinumtoxinA, liquid BontA (Ipsen), and CBFC26. However, these treatments were not assessed by equal numbers of studies. Half of the studies assessed onabotulinumtoxinA, with 71% of the rest of the studies assessing abobotulinumtoxinA or incobotulinumtoxinA. Some types of BontA (e.g. liquid BontA (MT101109L)) were only assessed by single studies, or two studies (HBTXA). </p> <p>The mean study duration was 20.75 weeks ± 11.7 (range: 1 to 52 weeks).</p> <p>There was huge variation in doses, number of cycles, and duration of follow‐up. These factors precluded data pooling and compromised the robustness of evidence. We assessed the following comparisons: BontA versus placebo, at least one cycle of treatment (36 studies); BontA at different doses, one cycle of treatment (21 studies); BontA versus placebo, at least two cycles of treatment (11 studies); BontA versus facial cream (one study); BontA associated to fillers (two studies). Eighty‐three per cent of the studies assessed a single cycle of treatment, and as BontA has a temporary effect on wrinkles, the single cycle does not reflect the need for repeated treatments. Some studies administered much higher doses than those recommended by two different consensus groups (<a href="./references#CD011301-bbs2-0106" title="CarruthersJD , GlogauRG , BlitzerAS , Facial Aesthetics Consensus Group Faculty.Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies-consensus recommendations. Plastic &amp; Reconstructive Surgery2008;121(5 Suppl):5S-30S. [MEDLINE: 18449026]">Carruthers 2008a</a>; <a href="./references#CD011301-bbs2-0133" title="SundaramH , SignoriniM , LiewnS , Trindade de AlmeidaAR , WuY , BrazAV , et al.Global aesthetics consensus: botulinum toxin type A—evidence-based review emerging concepts, and consensus recommendations for aesthetic use, including updates on complications. Plastic and Reconstructive Surgery2016;137(3):518e-29e. [PMID: 26910696]">Sundaram 2016</a>). </p> <p>The most common comparator was placebo (36 studies). An active control was used in 19 studies. There were eight dose‐ranging studies of onabotulinumtoxinA, and a small number of studies compared against fillers. Direct comparisons of different BontA treatments were lacking. OnabotulinumtoxinA and abobotulinumtoxinA were the most common BontA comparators (seven studies each), followed by incobotulinumtoxinA (five studies). OnabotulinumtoxinA was compared with abobotulinumtoxinA (five studies), onabotulinumtoxinA was compared with incobotulinumtoxinA (four studies), and the following were compared in single studies against onabotulinumtoxinA: liquid BontA (MT101109L), New BontA (Medytox®), and Neuronox. </p> <p>Duration of treatment was the least‐reported outcome of interest (21 studies). Physician assessment of success was more often reported (49 studies) than participant assessment of success (35 studies). Seventy‐one per cent of studies assessed major adverse events, and 78% evaluated the occurrence of any adverse events. However, long‐term adverse effects were not measured. </p> <p>Unfortunately, there was disparity in the definition of outcome tools, inhibiting pooling. </p> <p>Most of the studies had pharmaceutical support with no description about the role of the research development, planning, conduct, statistical analysis and reporting. </p> </section> <section id="CD011301-sec-0792"> <h3 class="title" id="CD011301-sec-0792">Quality of the evidence</h3> <p>As presented in the summary of findings tables, the certainty of the body of evidence obtained for each outcome was usually rated as very low, low or moderate certainty. Only three effect sizes were rated as high certainty. Most outcomes were downgraded for study limitations. Such limitations included an unclear/high risk of bias of selection bias from random sequence generation and allocation concealment, and unclear/high risk of performance or detection bias from blinding of participants, study personnel and outcome assessors. Many outcomes were also downgraded for imprecision as the estimates had wide confidence intervals which crossed the null effect. </p> <p>Moreover, the studies were poorly reported, and patient double count was difficult to detect. Design study complexity was another obstacle to data collection. </p> </section> <section id="CD011301-sec-0793"> <h3 class="title" id="CD011301-sec-0793">Potential biases in the review process</h3> <p>This review followed strictly all the recommendations of the <i>Cochrane Handbook</i> (<a href="./references#CD011301-bbs2-0122" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s).Cochrane Handbook for Systematic Review of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Higgins 2020</a>) on searching, study selection, data collection, and data analysis to avoid bias. </p> <p>Strengths of this review include a wide and recently updated literature search. The limitations of this review include no assessment of publication bias through funnel plot analysis because there were less than 10 studies included in each meta‐analysis. </p> <p>We changed some items from protocol to the review as a tentative measure to decrease potential bias: minimal number of participants for included studies from 20 to 50; we assessed the responder rates only during 'muscle contraction', rather than 'at rest', as: for clinical practice this last approach was less relevant, and at label, BontA was indicated for hyperdynamic facial wrinkles; and we did meta‐analysis only in parallel group studies; we did not include split face studies in this analysis. </p> <p>The 24 studies in '<a href="./references#CD011301-bbs1-0003" title="">Studies awaiting classification</a>' may alter the conclusions of the review once assessed. </p> </section> <section id="CD011301-sec-0794"> <h3 class="title" id="CD011301-sec-0794">Agreements and disagreements with other studies or reviews</h3> <p>In general, all systematic reviews (SRs) showed similar results.</p> <p> <ul id="CD011301-list-0040"> <li> <p>The majority of the studies injected onabotulinumtoxinA, followed by abbobotulinumtoxinA and incobotulinumtoxinA. </p> </li> <li> <p>The most frequent facial region was glabellar lines, crow's feet lines and forehead lines. </p> </li> <li> <p>The frequency of adverse effects is similar between BontA and placebo, except for the occurrence of blepharoptosis. Blepharoptosis is higher in the BontA groups than the placebo groups. </p> </li> </ul> </p> <p>Ghadia and colleagues (<a href="./references#CD011301-bbs2-0118" title="GadhiaK , WalmsleyAD .Facial aesthetics: is botulinum toxin treatment effective and safe? A systematic review of randomised controlled trials. British Dental Journal2009;207(5):E-9. [PMID: 19749689]">Ghadia 2009</a>) analysed 11 articles (1063 participants). The primary endpoint was the efficacy of BontA in facial wrinkles, and the secondary endpoint was safety. This systematic review studied the effect of treatment of onabotulinumtoxinA and abobotulinumtoxinA. The age ranged from 31 to 59 years, whereas in our systematic review, age range was broader (18 to 65 years). Regarding efficacy, we found similar results to Ghadia and colleagues: BontA in facial wrinkles was more effective than the placebo group, but because of a high level of heterogeneity this conclusion was uncertain. In <a href="./references#CD011301-bbs2-0118" title="GadhiaK , WalmsleyAD .Facial aesthetics: is botulinum toxin treatment effective and safe? A systematic review of randomised controlled trials. British Dental Journal2009;207(5):E-9. [PMID: 19749689]">Ghadia 2009</a>, the overall quality of evidence was considered good (Jadad scale). In our systematic review, we largely showed a range from very low‐ to moderate‐certainty evidence according to GRADE pro GDT (<a href="./references#CD011301-bbs2-0120" title="McMaster University (developed by Evidence Prime)GRADEpro GDT.Hamilton (ON): McMaster University (developed by Evidence Prime), 2021. Available at gradepro.org.">GRADEpro GDT</a>). </p> <p>Cavallini and colleagues studied 35 articles, 8787 participants (<a href="./references#CD011301-bbs2-0111" title="CavalliniM , CirilloP , FundaroSP , QuartucciS , SitoC , SitoG , et al.Safety of botulinum toxin A in aesthetic treatments: a systematic review of clinical studies. Dermatologic Surgery2014;40(5):525-36. [PMID: 24575858]">Cavallini 2014</a>). In this systematic review, the authors only considered onabotulinumtoxinA, abobotulinumtoxinA, and incobotulinumtoxinA, and analysed only safety outcomes(<a href="./references#CD011301-bbs2-0111" title="CavalliniM , CirilloP , FundaroSP , QuartucciS , SitoC , SitoG , et al.Safety of botulinum toxin A in aesthetic treatments: a systematic review of clinical studies. Dermatologic Surgery2014;40(5):525-36. [PMID: 24575858]">Cavallini 2014</a>). Because of limited search on the most common BontA brands, this review also limited their results (<a href="./references#CD011301-bbs2-0111" title="CavalliniM , CirilloP , FundaroSP , QuartucciS , SitoC , SitoG , et al.Safety of botulinum toxin A in aesthetic treatments: a systematic review of clinical studies. Dermatologic Surgery2014;40(5):525-36. [PMID: 24575858]">Cavallini 2014</a>). </p> <p>Jia and colleagues reported another systematic review of adverse events. The authors limited their search strategy to articles in the English language, some BontA (onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, and HBTX‐A), and some regions (glabellar and crow’s feet lines). This systematic review studied 34 articles, 42,405 participants (<a href="./references#CD011301-bbs2-0125" title="JiaZ , LuH , YangX , JinX , WuR , ZhaoJ , et al.Adverse events of botulinum toxin type A in facial rejuvenation: a systematic review and meta-analysis. Aesthetic Plastic Surgery2016;40(5):769-77. [PMID: 27495260]">Jia 2016</a>). The meta‐analysis was different, because they used a fixed‐effect analysis, whereas our systematic review used random‐effects analysis, In general, both systematic reviews agreed that BontA was safe for glabellar and crow’s feet lines (<a href="./references#CD011301-bbs2-0125" title="JiaZ , LuH , YangX , JinX , WuR , ZhaoJ , et al.Adverse events of botulinum toxin type A in facial rejuvenation: a systematic review and meta-analysis. Aesthetic Plastic Surgery2016;40(5):769-77. [PMID: 27495260]">Jia 2016</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011301-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011301-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Illustration of injection sites in glabellar region. Copyright [2020] [Cristina Pires Camargo]Reproduced with permission" data-id="CD011301-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-FIG-02.jpg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-FIG-02.jpg" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Illustration of injection sites in glabellar region. Copyright [2020] [Cristina Pires Camargo]Reproduced with permission </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-FIG-02.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011301-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011301-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: OnabotulinumtoxinA 10units versus placebo, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: OnabotulinumtoxinA 10units versus placebo, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: OnabotulinumtoxinA 10units versus placebo, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: OnabotulinumtoxinA 10units versus placebo, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: OnabotulinumtoxinA 10units versus placebo, Outcome 3: Total adverse events" data-id="CD011301-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: OnabotulinumtoxinA 10units versus placebo, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: OnabotulinumtoxinA 20 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: OnabotulinumtoxinA 20 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: OnabotulinumtoxinA 20 units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: OnabotulinumtoxinA 20 units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: OnabotulinumtoxinA 20 units versus placebo one cycle of treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: OnabotulinumtoxinA 20 units versus placebo one cycle of treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: OnabotulinumtoxinA 20 units versus placebo one cycle of treatment in glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: OnabotulinumtoxinA 20 units versus placebo one cycle of treatment in glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: OnabotulinumtoxinA 20 units versus placebo one cycle of treatment in glabellar lines, Outcome 5: Duration of treatment (weeks)" data-id="CD011301-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: OnabotulinumtoxinA 20 units versus placebo one cycle of treatment in glabellar lines, Outcome 5: Duration of treatment (weeks) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: OnabotulinumtoxinA 20units versus 10 units one treatment glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: OnabotulinumtoxinA 20units versus 10 units one treatment glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: OnabotulinumtoxinA 20units versus 10 units one treatment glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: OnabotulinumtoxinA 20units versus 10 units one treatment glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: OnabotulinumtoxinA 20units versus 10 units one treatment glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: OnabotulinumtoxinA 20units versus 10 units one treatment glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: OnabotulinumtoxinA 20units versus 10 units one treatment glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: OnabotulinumtoxinA 20units versus 10 units one treatment glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: OnabotulinumtoxinA 64units versus placebo one cycle of treatment, upper wrinkles, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: OnabotulinumtoxinA 64units versus placebo one cycle of treatment, upper wrinkles, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: OnabotulinumtoxinA 64units versus placebo one cycle of treatment, upper wrinkles, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus" data-id="CD011301-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: OnabotulinumtoxinA 64units versus placebo one cycle of treatment, upper wrinkles, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: OnabotulinumtoxinA 64units versus placebo one cycle of treatment, upper wrinkles, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: OnabotulinumtoxinA 64units versus placebo one cycle of treatment, upper wrinkles, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: OnabotulinumtoxinA 64units versus placebo one cycle of treatment, upper wrinkles, Outcome 4: Total adverse events" data-id="CD011301-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: OnabotulinumtoxinA 64units versus placebo one cycle of treatment, upper wrinkles, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: OnabotulinumtoxinA 40units versus placebo one cycle of treatment, upper wrinkles, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: OnabotulinumtoxinA 40units versus placebo one cycle of treatment, upper wrinkles, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: OnabotulinumtoxinA 40units versus placebo one cycle of treatment, upper wrinkles, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: OnabotulinumtoxinA 40units versus placebo one cycle of treatment, upper wrinkles, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: OnabotulinumtoxinA 40units versus placebo one cycle of treatment, upper wrinkles, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: OnabotulinumtoxinA 40units versus placebo one cycle of treatment, upper wrinkles, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: OnabotulinumtoxinA 40units versus placebo one cycle of treatment, upper wrinkles, Outcome 4: Total adverse events" data-id="CD011301-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: OnabotulinumtoxinA 40units versus placebo one cycle of treatment, upper wrinkles, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: OnabotulinumtoxinA 64units versus OnabotulinumoxinA 40U one cycle of treatment, upper wrinkles, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: OnabotulinumtoxinA 64units versus OnabotulinumoxinA 40U one cycle of treatment, upper wrinkles, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: OnabotulinumtoxinA 64units versus OnabotulinumoxinA 40U one cycle of treatment, upper wrinkles, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: OnabotulinumtoxinA 64units versus OnabotulinumoxinA 40U one cycle of treatment, upper wrinkles, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: OnabotulinumtoxinA 64units versus OnabotulinumoxinA 40U one cycle of treatment, upper wrinkles, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: OnabotulinumtoxinA 64units versus OnabotulinumoxinA 40U one cycle of treatment, upper wrinkles, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: OnabotulinumtoxinA 64units versus OnabotulinumoxinA 40U one cycle of treatment, upper wrinkles, Outcome 4: Total adverse events" data-id="CD011301-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: OnabotulinumtoxinA 64units versus OnabotulinumoxinA 40U one cycle of treatment, upper wrinkles, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: OnabotulinumtoxinA 64units versus 32 units one cycle of treatment upper wrinkles, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: OnabotulinumtoxinA 64units versus 32 units one cycle of treatment upper wrinkles, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: OnabotulinumtoxinA 64units versus 32 units one cycle of treatment upper wrinkles, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: OnabotulinumtoxinA 64units versus 32 units one cycle of treatment upper wrinkles, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: OnabotulinumtoxinA 64units versus 32 units one cycle of treatment upper wrinkles, Outcome 3: Total adverse events" data-id="CD011301-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: OnabotulinumtoxinA 64units versus 32 units one cycle of treatment upper wrinkles, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: OnabotulinumtoxinA 96 units versus 32 units one cycle of treatment upper wrinkles, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: OnabotulinumtoxinA 96 units versus 32 units one cycle of treatment upper wrinkles, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: OnabotulinumtoxinA 96 units versus 32 units one cycle of treatment upper wrinkles, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: OnabotulinumtoxinA 96 units versus 32 units one cycle of treatment upper wrinkles, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: OnabotulinumtoxinA 96 units versus 32 units one cycle of treatment upper wrinkles, Outcome 3: Total adverse events" data-id="CD011301-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: OnabotulinumtoxinA 96 units versus 32 units one cycle of treatment upper wrinkles, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: OnabotulinumtoxinA 96 units versus 64 units one cycle of treatment upper wrinkles, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: OnabotulinumtoxinA 96 units versus 64 units one cycle of treatment upper wrinkles, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: OnabotulinumtoxinA 96 units versus 64 units one cycle of treatment upper wrinkles, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: OnabotulinumtoxinA 96 units versus 64 units one cycle of treatment upper wrinkles, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: OnabotulinumtoxinA 96 units versus 64 units one cycle of treatment upper wrinkles, Outcome 3: Total adverse events" data-id="CD011301-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: OnabotulinumtoxinA 96 units versus 64 units one cycle of treatment upper wrinkles, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: OnabotulinumtoxinA 32 units versus 16 units one cycle of treatment forehead lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: OnabotulinumtoxinA 32 units versus 16 units one cycle of treatment forehead lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: OnabotulinumtoxinA 32 units versus 16 units one cycle of treatment forehead lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: OnabotulinumtoxinA 32 units versus 16 units one cycle of treatment forehead lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: OnabotulinumtoxinA 32 units versus 16 units one cycle of treatment forehead lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: OnabotulinumtoxinA 32 units versus 16 units one cycle of treatment forehead lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-011.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: OnabotulinumtoxinA 60 units versus 20 units one cycle of treatment glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-011.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-011.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11: OnabotulinumtoxinA 60 units versus 20 units one cycle of treatment glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-011.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-011.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 11: OnabotulinumtoxinA 60 units versus 20 units one cycle of treatment glabellar lines, Outcome 2: Total adverse events" data-id="CD011301-fig-0042" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-011.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-011.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11: OnabotulinumtoxinA 60 units versus 20 units one cycle of treatment glabellar lines, Outcome 2: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-011.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-012.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: OnabotulinumtoxinA 48 units versus 32 units one cycle of treatment forehead lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0043" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-012.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-012.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12: OnabotulinumtoxinA 48 units versus 32 units one cycle of treatment forehead lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-012.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-012.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: OnabotulinumtoxinA 48 units versus 32 units one cycle of treatment forehead lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0044" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-012.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-012.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12: OnabotulinumtoxinA 48 units versus 32 units one cycle of treatment forehead lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-012.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-012.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 12: OnabotulinumtoxinA 48 units versus 32 units one cycle of treatment forehead lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0045" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-012.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-012.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12: OnabotulinumtoxinA 48 units versus 32 units one cycle of treatment forehead lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-012.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-013.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: OnabotulinumtoxinA 40 units versus placebo one cycle of treatment for forehead lines and glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0046" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-013.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-013.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13: OnabotulinumtoxinA 40 units versus placebo one cycle of treatment for forehead lines and glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-013.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-013.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: OnabotulinumtoxinA 40 units versus placebo one cycle of treatment for forehead lines and glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0047" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-013.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-013.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13: OnabotulinumtoxinA 40 units versus placebo one cycle of treatment for forehead lines and glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-013.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-013.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 13: OnabotulinumtoxinA 40 units versus placebo one cycle of treatment for forehead lines and glabellar lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0048" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-013.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-013.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13: OnabotulinumtoxinA 40 units versus placebo one cycle of treatment for forehead lines and glabellar lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-013.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-014.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: OnabotulinumtoxinA 30 units versus placebo one cycle of treatment for forehead lines and glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0049" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-014.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-014.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14: OnabotulinumtoxinA 30 units versus placebo one cycle of treatment for forehead lines and glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-014.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-014.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: OnabotulinumtoxinA 30 units versus placebo one cycle of treatment for forehead lines and glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0050" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-014.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-014.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14: OnabotulinumtoxinA 30 units versus placebo one cycle of treatment for forehead lines and glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-014.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-014.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: OnabotulinumtoxinA 30 units versus placebo one cycle of treatment for forehead lines and glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0051" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-014.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-014.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14: OnabotulinumtoxinA 30 units versus placebo one cycle of treatment for forehead lines and glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-014.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-014.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 14: OnabotulinumtoxinA 30 units versus placebo one cycle of treatment for forehead lines and glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0052" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-014.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-014.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14: OnabotulinumtoxinA 30 units versus placebo one cycle of treatment for forehead lines and glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-014.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-015.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: OnabotulinumtoxinA 40 units versus OnabotulinumonabotulinumtoxinA 30 units one cycle of treatment for forehead lines and glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0053" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-015.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-015.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15: OnabotulinumtoxinA 40 units versus OnabotulinumonabotulinumtoxinA 30 units one cycle of treatment for forehead lines and glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-015.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-015.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: OnabotulinumtoxinA 40 units versus OnabotulinumonabotulinumtoxinA 30 units one cycle of treatment for forehead lines and glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0054" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-015.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-015.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15: OnabotulinumtoxinA 40 units versus OnabotulinumonabotulinumtoxinA 30 units one cycle of treatment for forehead lines and glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-015.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-015.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: OnabotulinumtoxinA 40 units versus OnabotulinumonabotulinumtoxinA 30 units one cycle of treatment for forehead lines and glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0055" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-015.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-015.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15: OnabotulinumtoxinA 40 units versus OnabotulinumonabotulinumtoxinA 30 units one cycle of treatment for forehead lines and glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-015.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-015.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 15: OnabotulinumtoxinA 40 units versus OnabotulinumonabotulinumtoxinA 30 units one cycle of treatment for forehead lines and glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0056" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-015.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-015.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15: OnabotulinumtoxinA 40 units versus OnabotulinumonabotulinumtoxinA 30 units one cycle of treatment for forehead lines and glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-015.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-016.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: OnabotulinumtoxinA 40 units versus 20 units one treatment glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0057" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-016.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-016.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16: OnabotulinumtoxinA 40 units versus 20 units one treatment glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-016.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-016.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: OnabotulinumtoxinA 40 units versus 20 units one treatment glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0058" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-016.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-016.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16: OnabotulinumtoxinA 40 units versus 20 units one treatment glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-016.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-016.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 16: OnabotulinumtoxinA 40 units versus 20 units one treatment glabellar lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0059" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-016.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-016.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16: OnabotulinumtoxinA 40 units versus 20 units one treatment glabellar lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-016.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-017.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: OnabotulinumtoxinA 48 units versus 16 units one cycle of treatment forehead lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0060" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-017.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-017.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17: OnabotulinumtoxinA 48 units versus 16 units one cycle of treatment forehead lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-017.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-017.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: OnabotulinumtoxinA 48 units versus 16 units one cycle of treatment forehead lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0061" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-017.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-017.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17: OnabotulinumtoxinA 48 units versus 16 units one cycle of treatment forehead lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-017.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-017.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 17: OnabotulinumtoxinA 48 units versus 16 units one cycle of treatment forehead lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0062" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-017.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-017.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17: OnabotulinumtoxinA 48 units versus 16 units one cycle of treatment forehead lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-017.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-018.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: OnabotulinumtoxinA 80 units versus 20 units one cycle of treatment glabellar lines, Outcome 1: Participant assessment, maximum contraction (responder rate)" data-id="CD011301-fig-0063" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-018.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-018.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18: OnabotulinumtoxinA 80 units versus 20 units one cycle of treatment glabellar lines, Outcome 1: Participant assessment, maximum contraction (responder rate) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-018.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-018.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: OnabotulinumtoxinA 80 units versus 20 units one cycle of treatment glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0064" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-018.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-018.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18: OnabotulinumtoxinA 80 units versus 20 units one cycle of treatment glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-018.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-018.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 18: OnabotulinumtoxinA 80 units versus 20 units one cycle of treatment glabellar lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0065" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-018.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-018.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.3</div> <div class="figure-caption"> <p>Comparison 18: OnabotulinumtoxinA 80 units versus 20 units one cycle of treatment glabellar lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-018.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-019.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: OnabotulinumtoxinA 80 units versus 60 units one cycle of treatment glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0066" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-019.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-019.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19: OnabotulinumtoxinA 80 units versus 60 units one cycle of treatment glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-019.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-019.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 19: OnabotulinumtoxinA 80 units versus 60 units one cycle of treatment glabellar lines, Outcome 2: Total adverse events" data-id="CD011301-fig-0067" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-019.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-019.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19: OnabotulinumtoxinA 80 units versus 60 units one cycle of treatment glabellar lines, Outcome 2: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-019.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-020.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: OnabotulinumtoxinA 30 units versus 10 units one cycle of treatment glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0068" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-020.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-020.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20: OnabotulinumtoxinA 30 units versus 10 units one cycle of treatment glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-020.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-020.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 20: OnabotulinumtoxinA 30 units versus 10 units one cycle of treatment glabellar lines, Outcome 2: Total adverse events" data-id="CD011301-fig-0069" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-020.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-020.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20: OnabotulinumtoxinA 30 units versus 10 units one cycle of treatment glabellar lines, Outcome 2: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-020.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-021.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: OnabotulinumtoxinA 40 units versus 10 units one cycle of treatment glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0070" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-021.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-021.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21: OnabotulinumtoxinA 40 units versus 10 units one cycle of treatment glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-021.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-021.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: OnabotulinumtoxinA 40 units versus 10 units one cycle of treatment glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0071" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-021.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-021.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.2</div> <div class="figure-caption"> <p>Comparison 21: OnabotulinumtoxinA 40 units versus 10 units one cycle of treatment glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-021.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-021.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 21: OnabotulinumtoxinA 40 units versus 10 units one cycle of treatment glabellar lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0072" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-021.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-021.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.3</div> <div class="figure-caption"> <p>Comparison 21: OnabotulinumtoxinA 40 units versus 10 units one cycle of treatment glabellar lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-021.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-022.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: OnabotulinumtoxinA 40 units versus 30 units one cycle of treatment glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0073" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-022.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-022.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22: OnabotulinumtoxinA 40 units versus 30 units one cycle of treatment glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-022.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-022.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: OnabotulinumtoxinA 40 units versus 30 units one cycle of treatment glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0074" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-022.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-022.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22: OnabotulinumtoxinA 40 units versus 30 units one cycle of treatment glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-022.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-022.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 22: OnabotulinumtoxinA 40 units versus 30 units one cycle of treatment glabellar lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0075" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-022.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-022.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.3</div> <div class="figure-caption"> <p>Comparison 22: OnabotulinumtoxinA 40 units versus 30 units one cycle of treatment glabellar lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-022.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-023.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: OnabotulinumtoxinA 30 units versus 20 units one cycle of treatment glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0076" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-023.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-023.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23: OnabotulinumtoxinA 30 units versus 20 units one cycle of treatment glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-023.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-023.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: OnabotulinumtoxinA 30 units versus 20 units one cycle of treatment glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0077" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-023.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-023.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.2</div> <div class="figure-caption"> <p>Comparison 23: OnabotulinumtoxinA 30 units versus 20 units one cycle of treatment glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-023.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-023.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 23: OnabotulinumtoxinA 30 units versus 20 units one cycle of treatment glabellar lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0078" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-023.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-023.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.3</div> <div class="figure-caption"> <p>Comparison 23: OnabotulinumtoxinA 30 units versus 20 units one cycle of treatment glabellar lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-023.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-024.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 24: OnabotulinumtoxinA 60 units versus 40 units one cycle of treatment glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0079" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-024.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-024.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.1</div> <div class="figure-caption"> <p>Comparison 24: OnabotulinumtoxinA 60 units versus 40 units one cycle of treatment glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-024.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-024.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 24: OnabotulinumtoxinA 60 units versus 40 units one cycle of treatment glabellar lines, Outcome 2: Total adverse events" data-id="CD011301-fig-0080" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-024.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-024.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.2</div> <div class="figure-caption"> <p>Comparison 24: OnabotulinumtoxinA 60 units versus 40 units one cycle of treatment glabellar lines, Outcome 2: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-024.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-025.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 25: OnabotulinumtoxinA 80 units versus 40 units one cycle of treatment glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0081" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-025.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-025.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.1</div> <div class="figure-caption"> <p>Comparison 25: OnabotulinumtoxinA 80 units versus 40 units one cycle of treatment glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-025.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-025.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 25: OnabotulinumtoxinA 80 units versus 40 units one cycle of treatment glabellar lines, Outcome 2: Total adverse events" data-id="CD011301-fig-0082" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-025.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-025.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.2</div> <div class="figure-caption"> <p>Comparison 25: OnabotulinumtoxinA 80 units versus 40 units one cycle of treatment glabellar lines, Outcome 2: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-025.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-026.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 26: OnabotulinumtoxinA 80units versus 60units one cycle of treatment glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0083" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-026.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-026.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.1</div> <div class="figure-caption"> <p>Comparison 26: OnabotulinumtoxinA 80units versus 60units one cycle of treatment glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-026.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-026.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 26: OnabotulinumtoxinA 80units versus 60units one cycle of treatment glabellar lines, Outcome 2: Total adverse events" data-id="CD011301-fig-0084" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-026.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-026.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.2</div> <div class="figure-caption"> <p>Comparison 26: OnabotulinumtoxinA 80units versus 60units one cycle of treatment glabellar lines, Outcome 2: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-026.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-027.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 27: OnabotulinumtoxinA 12 units versus 7.5 units one cycle of treatment perioral lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0085" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-027.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-027.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.1</div> <div class="figure-caption"> <p>Comparison 27: OnabotulinumtoxinA 12 units versus 7.5 units one cycle of treatment perioral lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-027.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-027.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 27: OnabotulinumtoxinA 12 units versus 7.5 units one cycle of treatment perioral lines, Outcome 2: Total adverse events" data-id="CD011301-fig-0086" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-027.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-027.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.2</div> <div class="figure-caption"> <p>Comparison 27: OnabotulinumtoxinA 12 units versus 7.5 units one cycle of treatment perioral lines, Outcome 2: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-027.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-028.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 28: OnabotulinumtoxinA 20units versus placebo in glabellar lines three cycles of treatment, Outcome 1: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0087" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-028.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-028.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.1</div> <div class="figure-caption"> <p>Comparison 28: OnabotulinumtoxinA 20units versus placebo in glabellar lines three cycles of treatment, Outcome 1: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-028.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-028.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 28: OnabotulinumtoxinA 20units versus placebo in glabellar lines three cycles of treatment, Outcome 2: Total adverse events" data-id="CD011301-fig-0088" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-028.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-028.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.2</div> <div class="figure-caption"> <p>Comparison 28: OnabotulinumtoxinA 20units versus placebo in glabellar lines three cycles of treatment, Outcome 2: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-028.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-029.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 29: OnabotulinumtoxinA24 units versus placebo one treatment in crow's feet lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0089" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-029.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-029.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.1</div> <div class="figure-caption"> <p>Comparison 29: OnabotulinumtoxinA24 units versus placebo one treatment in crow's feet lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-029.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-029.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 29: OnabotulinumtoxinA24 units versus placebo one treatment in crow's feet lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0090" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-029.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-029.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.2</div> <div class="figure-caption"> <p>Comparison 29: OnabotulinumtoxinA24 units versus placebo one treatment in crow's feet lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-029.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-029.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 29: OnabotulinumtoxinA24 units versus placebo one treatment in crow's feet lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0091" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-029.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-029.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.3</div> <div class="figure-caption"> <p>Comparison 29: OnabotulinumtoxinA24 units versus placebo one treatment in crow's feet lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-029.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-029.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 29: OnabotulinumtoxinA24 units versus placebo one treatment in crow's feet lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0092" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-029.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-029.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.4</div> <div class="figure-caption"> <p>Comparison 29: OnabotulinumtoxinA24 units versus placebo one treatment in crow's feet lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-029.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-030.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 30: OnabotulinumtoxinA 12 units versus placebo one treatment in crow's feet lines, Outcome 1: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0093" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-030.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-030.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.1</div> <div class="figure-caption"> <p>Comparison 30: OnabotulinumtoxinA 12 units versus placebo one treatment in crow's feet lines, Outcome 1: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-030.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-030.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 30: OnabotulinumtoxinA 12 units versus placebo one treatment in crow's feet lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0094" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-030.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-030.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.2</div> <div class="figure-caption"> <p>Comparison 30: OnabotulinumtoxinA 12 units versus placebo one treatment in crow's feet lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-030.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-030.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 30: OnabotulinumtoxinA 12 units versus placebo one treatment in crow's feet lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0095" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-030.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-030.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.3</div> <div class="figure-caption"> <p>Comparison 30: OnabotulinumtoxinA 12 units versus placebo one treatment in crow's feet lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-030.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-031.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 31: OnabotulinumtoxinA 24 units versus OnabotulinumtoxinA 12 units one treatment in crow's feet lines, Outcome 1: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0096" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-031.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-031.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.1</div> <div class="figure-caption"> <p>Comparison 31: OnabotulinumtoxinA 24 units versus OnabotulinumtoxinA 12 units one treatment in crow's feet lines, Outcome 1: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-031.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-031.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 31: OnabotulinumtoxinA 24 units versus OnabotulinumtoxinA 12 units one treatment in crow's feet lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0097" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-031.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-031.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.2</div> <div class="figure-caption"> <p>Comparison 31: OnabotulinumtoxinA 24 units versus OnabotulinumtoxinA 12 units one treatment in crow's feet lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-031.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-031.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 31: OnabotulinumtoxinA 24 units versus OnabotulinumtoxinA 12 units one treatment in crow's feet lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0098" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-031.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-031.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.3</div> <div class="figure-caption"> <p>Comparison 31: OnabotulinumtoxinA 24 units versus OnabotulinumtoxinA 12 units one treatment in crow's feet lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-031.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-032.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 32: OnabotulinumtoxinA 44 units versus placebo one treatments in glabellar lines and crow's feet lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0099" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-032.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-032.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.1</div> <div class="figure-caption"> <p>Comparison 32: OnabotulinumtoxinA 44 units versus placebo one treatments in glabellar lines and crow's feet lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-032.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-032.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 32: OnabotulinumtoxinA 44 units versus placebo one treatments in glabellar lines and crow's feet lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0100" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-032.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-032.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.2</div> <div class="figure-caption"> <p>Comparison 32: OnabotulinumtoxinA 44 units versus placebo one treatments in glabellar lines and crow's feet lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-032.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-032.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 32: OnabotulinumtoxinA 44 units versus placebo one treatments in glabellar lines and crow's feet lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0101" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-032.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-032.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.3</div> <div class="figure-caption"> <p>Comparison 32: OnabotulinumtoxinA 44 units versus placebo one treatments in glabellar lines and crow's feet lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-032.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-033.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 33: OnabotulinumtoxinA 44 units versus placebo two cycles of treatments in crow's feet lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0102" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-033.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-033.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.1</div> <div class="figure-caption"> <p>Comparison 33: OnabotulinumtoxinA 44 units versus placebo two cycles of treatments in crow's feet lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-033.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-033.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 33: OnabotulinumtoxinA 44 units versus placebo two cycles of treatments in crow's feet lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0103" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-033.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-033.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.2</div> <div class="figure-caption"> <p>Comparison 33: OnabotulinumtoxinA 44 units versus placebo two cycles of treatments in crow's feet lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-033.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-033.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 33: OnabotulinumtoxinA 44 units versus placebo two cycles of treatments in crow's feet lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0104" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-033.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-033.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.3</div> <div class="figure-caption"> <p>Comparison 33: OnabotulinumtoxinA 44 units versus placebo two cycles of treatments in crow's feet lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-033.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-034.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 34: OnabotulinumtoxinA 24 units versus 12 units five cycles of treatment in crow's feet lines, Outcome 1: Total adverse events" data-id="CD011301-fig-0105" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-034.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-034.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.1</div> <div class="figure-caption"> <p>Comparison 34: OnabotulinumtoxinA 24 units versus 12 units five cycles of treatment in crow's feet lines, Outcome 1: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-034.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-035.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 35: AbobotulinumtoxinA 25 units versus placebo one cycle of treatment, glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0106" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-035.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-035.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 35.1</div> <div class="figure-caption"> <p>Comparison 35: AbobotulinumtoxinA 25 units versus placebo one cycle of treatment, glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-035.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-035.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 35: AbobotulinumtoxinA 25 units versus placebo one cycle of treatment, glabellar lines, Outcome 2: Total adverse events" data-id="CD011301-fig-0107" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-035.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-035.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 35.2</div> <div class="figure-caption"> <p>Comparison 35: AbobotulinumtoxinA 25 units versus placebo one cycle of treatment, glabellar lines, Outcome 2: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-035.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-036.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 36: AbobotulinumtoxinA 30 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0108" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-036.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-036.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 36.1</div> <div class="figure-caption"> <p>Comparison 36: AbobotulinumtoxinA 30 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-036.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-037.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 37: AbobotulinumtoxinA 50 units versus placebo one treatment glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0109" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-037.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-037.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.1</div> <div class="figure-caption"> <p>Comparison 37: AbobotulinumtoxinA 50 units versus placebo one treatment glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-037.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-037.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 37: AbobotulinumtoxinA 50 units versus placebo one treatment glabellar lines, Outcome 2: Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0110" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-037.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-037.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.2</div> <div class="figure-caption"> <p>Comparison 37: AbobotulinumtoxinA 50 units versus placebo one treatment glabellar lines, Outcome 2: Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-037.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-037.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 37: AbobotulinumtoxinA 50 units versus placebo one treatment glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0111" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-037.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-037.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.3</div> <div class="figure-caption"> <p>Comparison 37: AbobotulinumtoxinA 50 units versus placebo one treatment glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-037.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-037.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 37: AbobotulinumtoxinA 50 units versus placebo one treatment glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0112" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-037.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-037.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.4</div> <div class="figure-caption"> <p>Comparison 37: AbobotulinumtoxinA 50 units versus placebo one treatment glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-037.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-037.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 37: AbobotulinumtoxinA 50 units versus placebo one treatment glabellar lines, Outcome 5: Duration of treatment (days)" data-id="CD011301-fig-0113" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-037.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-037.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 37.5</div> <div class="figure-caption"> <p>Comparison 37: AbobotulinumtoxinA 50 units versus placebo one treatment glabellar lines, Outcome 5: Duration of treatment (days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-037.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-038.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 38: AbobotulinumtoxinA 50 units versus 25 units one cycle of treatment, glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0114" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-038.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-038.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 38.1</div> <div class="figure-caption"> <p>Comparison 38: AbobotulinumtoxinA 50 units versus 25 units one cycle of treatment, glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-038.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-038.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 38: AbobotulinumtoxinA 50 units versus 25 units one cycle of treatment, glabellar lines, Outcome 2: Total adverse events" data-id="CD011301-fig-0115" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-038.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-038.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 38.2</div> <div class="figure-caption"> <p>Comparison 38: AbobotulinumtoxinA 50 units versus 25 units one cycle of treatment, glabellar lines, Outcome 2: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-038.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-039.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 39: AbobotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0116" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-039.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-039.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 39.1</div> <div class="figure-caption"> <p>Comparison 39: AbobotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-039.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-039.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 39: AbobotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0117" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-039.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-039.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 39.2</div> <div class="figure-caption"> <p>Comparison 39: AbobotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-039.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-040.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 40: AbobotulinumtoxinA 70 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0118" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-040.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-040.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 40.1</div> <div class="figure-caption"> <p>Comparison 40: AbobotulinumtoxinA 70 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-040.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-040.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 40: AbobotulinumtoxinA 70 units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0119" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-040.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-040.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 40.2</div> <div class="figure-caption"> <p>Comparison 40: AbobotulinumtoxinA 70 units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-040.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-041.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 41: AbobotulinumtoxinA 75 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0120" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-041.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-041.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 41.1</div> <div class="figure-caption"> <p>Comparison 41: AbobotulinumtoxinA 75 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-041.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-042.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 42: AbobotulinumtoxinA 75 units versus 25 units one cycle of treatment in glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0121" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-042.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-042.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 42.1</div> <div class="figure-caption"> <p>Comparison 42: AbobotulinumtoxinA 75 units versus 25 units one cycle of treatment in glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-042.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-043.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 43: AbobotulinumtoxinA 75 units versus 50 units one cycle of treatment in glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0122" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-043.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-043.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 43.1</div> <div class="figure-caption"> <p>Comparison 43: AbobotulinumtoxinA 75 units versus 50 units one cycle of treatment in glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-043.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-043.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 43: AbobotulinumtoxinA 75 units versus 50 units one cycle of treatment in glabellar lines, Outcome 2: Total adverse events" data-id="CD011301-fig-0123" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-043.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-043.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 43.2</div> <div class="figure-caption"> <p>Comparison 43: AbobotulinumtoxinA 75 units versus 50 units one cycle of treatment in glabellar lines, Outcome 2: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-043.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-044.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 44: AbobotulinumtoxinA 80 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0124" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-044.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-044.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 44.1</div> <div class="figure-caption"> <p>Comparison 44: AbobotulinumtoxinA 80 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-044.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-044.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 44: AbobotulinumtoxinA 80 units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0125" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-044.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-044.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 44.2</div> <div class="figure-caption"> <p>Comparison 44: AbobotulinumtoxinA 80 units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-044.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-045.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 45: AbobotulinumtoxinA 15 units versus placebo one cycle of treatment crow's feet lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0126" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-045.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-045.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 45.1</div> <div class="figure-caption"> <p>Comparison 45: AbobotulinumtoxinA 15 units versus placebo one cycle of treatment crow's feet lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-045.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-046.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 46: AbobotulinumtoxinA 30 units versus placebo one cycle of treatment crow's feet lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0127" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-046.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-046.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 46.1</div> <div class="figure-caption"> <p>Comparison 46: AbobotulinumtoxinA 30 units versus placebo one cycle of treatment crow's feet lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-046.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-047.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 47: AbobotulinumtoxinA 45 units versus placebo one cycle of treatment crow's feet lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0128" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-047.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-047.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 47.1</div> <div class="figure-caption"> <p>Comparison 47: AbobotulinumtoxinA 45 units versus placebo one cycle of treatment crow's feet lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-047.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-048.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 48: AbobotulinumtoxinA 50 units versus placebo, three cycles of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0129" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-048.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-048.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 48.1</div> <div class="figure-caption"> <p>Comparison 48: AbobotulinumtoxinA 50 units versus placebo, three cycles of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-048.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-048.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 48: AbobotulinumtoxinA 50 units versus placebo, three cycles of treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0130" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-048.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-048.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 48.2</div> <div class="figure-caption"> <p>Comparison 48: AbobotulinumtoxinA 50 units versus placebo, three cycles of treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-048.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-048.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 48: AbobotulinumtoxinA 50 units versus placebo, three cycles of treatment in glabellar lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0131" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-048.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-048.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 48.3</div> <div class="figure-caption"> <p>Comparison 48: AbobotulinumtoxinA 50 units versus placebo, three cycles of treatment in glabellar lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-048.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-049.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 49: IncobotulinumtoxinA 20 units versus placebo one treatment glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0132" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-049.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-049.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 49.1</div> <div class="figure-caption"> <p>Comparison 49: IncobotulinumtoxinA 20 units versus placebo one treatment glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-049.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-049.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 49: IncobotulinumtoxinA 20 units versus placebo one treatment glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0133" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-049.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-049.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 49.2</div> <div class="figure-caption"> <p>Comparison 49: IncobotulinumtoxinA 20 units versus placebo one treatment glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-049.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-049.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 49: IncobotulinumtoxinA 20 units versus placebo one treatment glabellar lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0134" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-049.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-049.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 49.3</div> <div class="figure-caption"> <p>Comparison 49: IncobotulinumtoxinA 20 units versus placebo one treatment glabellar lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-049.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-050.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 50: IncobotulinumtoxinA 54 to 64units versus placebo one cycles of treatment glabellar lines, forehead liens, crow's feet lines, Outcome 1: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0135" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-050.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-050.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 50.1</div> <div class="figure-caption"> <p>Comparison 50: IncobotulinumtoxinA 54 to 64units versus placebo one cycles of treatment glabellar lines, forehead liens, crow's feet lines, Outcome 1: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-050.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-050.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 50: IncobotulinumtoxinA 54 to 64units versus placebo one cycles of treatment glabellar lines, forehead liens, crow's feet lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0136" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-050.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-050.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 50.2</div> <div class="figure-caption"> <p>Comparison 50: IncobotulinumtoxinA 54 to 64units versus placebo one cycles of treatment glabellar lines, forehead liens, crow's feet lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-050.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-050.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 50: IncobotulinumtoxinA 54 to 64units versus placebo one cycles of treatment glabellar lines, forehead liens, crow's feet lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0137" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-050.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-050.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 50.3</div> <div class="figure-caption"> <p>Comparison 50: IncobotulinumtoxinA 54 to 64units versus placebo one cycles of treatment glabellar lines, forehead liens, crow's feet lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-050.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-051.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 51: HBTX‐A 10 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0138" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-051.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-051.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 51.1</div> <div class="figure-caption"> <p>Comparison 51: HBTX‐A 10 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-051.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-051.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 51: HBTX‐A 10 units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Total adverse events" data-id="CD011301-fig-0139" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-051.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-051.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 51.2</div> <div class="figure-caption"> <p>Comparison 51: HBTX‐A 10 units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-051.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-052.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 52: HBTX‐A 20 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0140" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-052.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-052.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 52.1</div> <div class="figure-caption"> <p>Comparison 52: HBTX‐A 20 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-052.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-052.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 52: HBTX‐A 20 units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Total adverse events" data-id="CD011301-fig-0141" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-052.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-052.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 52.2</div> <div class="figure-caption"> <p>Comparison 52: HBTX‐A 20 units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-052.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-053.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 53: HBTX‐A 50 units versus placebo one cycle of treatment, glabellar lines, Outcome 1:  Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0142" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-053.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-053.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 53.1</div> <div class="figure-caption"> <p>Comparison 53: HBTX‐A 50 units versus placebo one cycle of treatment, glabellar lines, Outcome 1:  Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-053.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-053.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 53: HBTX‐A 50 units versus placebo one cycle of treatment, glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0143" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-053.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-053.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 53.2</div> <div class="figure-caption"> <p>Comparison 53: HBTX‐A 50 units versus placebo one cycle of treatment, glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-053.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-053.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 53: HBTX‐A 50 units versus placebo one cycle of treatment, glabellar lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0144" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-053.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-053.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 53.3</div> <div class="figure-caption"> <p>Comparison 53: HBTX‐A 50 units versus placebo one cycle of treatment, glabellar lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-053.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-054.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 54: HBTX‐A 20 units versus 10 units one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0145" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-054.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-054.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 54.1</div> <div class="figure-caption"> <p>Comparison 54: HBTX‐A 20 units versus 10 units one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-054.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-054.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 54: HBTX‐A 20 units versus 10 units one cycle of treatment in glabellar lines, Outcome 2: Total adverse events" data-id="CD011301-fig-0146" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-054.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-054.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 54.2</div> <div class="figure-caption"> <p>Comparison 54: HBTX‐A 20 units versus 10 units one cycle of treatment in glabellar lines, Outcome 2: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-054.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-055.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 55: AbobotulinumtoxinA 50 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 1: Participant assessment success by analysing scores and scales" data-id="CD011301-fig-0147" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-055.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-055.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 55.1</div> <div class="figure-caption"> <p>Comparison 55: AbobotulinumtoxinA 50 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 1: Participant assessment success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-055.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-055.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 55: AbobotulinumtoxinA 50 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 2: Major adverse events " data-id="CD011301-fig-0148" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-055.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-055.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 55.2</div> <div class="figure-caption"> <p>Comparison 55: AbobotulinumtoxinA 50 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 2: Major adverse events  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-055.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-055.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 55: AbobotulinumtoxinA 50 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0149" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-055.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-055.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 55.3</div> <div class="figure-caption"> <p>Comparison 55: AbobotulinumtoxinA 50 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-055.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-055.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 55: AbobotulinumtoxinA 50 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0150" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-055.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-055.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 55.4</div> <div class="figure-caption"> <p>Comparison 55: AbobotulinumtoxinA 50 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-055.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-056.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 56: IncobotulinumtoxinA 30 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0151" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-056.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-056.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 56.1</div> <div class="figure-caption"> <p>Comparison 56: IncobotulinumtoxinA 30 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-056.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-056.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 56: IncobotulinumtoxinA 30 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0152" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-056.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-056.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 56.2</div> <div class="figure-caption"> <p>Comparison 56: IncobotulinumtoxinA 30 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-056.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-056.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 56: IncobotulinumtoxinA 30 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0153" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-056.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-056.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 56.3</div> <div class="figure-caption"> <p>Comparison 56: IncobotulinumtoxinA 30 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-056.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-057.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 57: IncobotulinumtoxinA 24 units versus OnabotulinumtoxinA 24 units one treatment in glabellar lines, Outcome 1: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0154" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-057.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-057.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 57.1</div> <div class="figure-caption"> <p>Comparison 57: IncobotulinumtoxinA 24 units versus OnabotulinumtoxinA 24 units one treatment in glabellar lines, Outcome 1: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-057.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-057.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 57: IncobotulinumtoxinA 24 units versus OnabotulinumtoxinA 24 units one treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0155" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-057.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-057.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 57.2</div> <div class="figure-caption"> <p>Comparison 57: IncobotulinumtoxinA 24 units versus OnabotulinumtoxinA 24 units one treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-057.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-057.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 57: IncobotulinumtoxinA 24 units versus OnabotulinumtoxinA 24 units one treatment in glabellar lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0156" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-057.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-057.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 57.3</div> <div class="figure-caption"> <p>Comparison 57: IncobotulinumtoxinA 24 units versus OnabotulinumtoxinA 24 units one treatment in glabellar lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-057.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-058.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 58: IncobotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 1: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0157" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-058.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-058.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 58.1</div> <div class="figure-caption"> <p>Comparison 58: IncobotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 1: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-058.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-058.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 58: IncobotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales ‐ injector" data-id="CD011301-fig-0158" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-058.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-058.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 58.2</div> <div class="figure-caption"> <p>Comparison 58: IncobotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales ‐ injector </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-058.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0159"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-058.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 58: IncobotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales ‐ independent observer" data-id="CD011301-fig-0159" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-058.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-058.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 58.3</div> <div class="figure-caption"> <p>Comparison 58: IncobotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales ‐ independent observer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0159">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-058.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0160"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-058.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 58: IncobotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0160" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-058.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-058.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 58.4</div> <div class="figure-caption"> <p>Comparison 58: IncobotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0160">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-058.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0161"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-059.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 59: NewBontA [Medytox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 1: Physician assessment, maximum contraction (responder rate)" data-id="CD011301-fig-0161" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-059.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-059.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 59.1</div> <div class="figure-caption"> <p>Comparison 59: NewBontA [Medytox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 1: Physician assessment, maximum contraction (responder rate) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0161">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-059.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0162"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-060.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 60: NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0162" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-060.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-060.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 60.1</div> <div class="figure-caption"> <p>Comparison 60: NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0162">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-060.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0163"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-060.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 60: NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0163" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-060.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-060.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 60.2</div> <div class="figure-caption"> <p>Comparison 60: NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0163">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-060.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0164"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-060.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 60: NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0164" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-060.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-060.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 60.3</div> <div class="figure-caption"> <p>Comparison 60: NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0164">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-060.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0165"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-060.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 60: NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0165" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-060.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-060.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 60.4</div> <div class="figure-caption"> <p>Comparison 60: NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0165">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-060.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0166"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-061.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 61: NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in crow’s feet lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0166" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-061.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-061.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 61.1</div> <div class="figure-caption"> <p>Comparison 61: NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in crow’s feet lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0166">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-061.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0167"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-061.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 61: NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in crow’s feet lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0167" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-061.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-061.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 61.2</div> <div class="figure-caption"> <p>Comparison 61: NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in crow’s feet lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0167">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-061.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0168"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-061.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 61: NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in crow’s feet lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0168" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-061.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-061.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 61.3</div> <div class="figure-caption"> <p>Comparison 61: NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in crow’s feet lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0168">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-061.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0169"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-061.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 61: NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in crow’s feet lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0169" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-061.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-061.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 61.4</div> <div class="figure-caption"> <p>Comparison 61: NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in crow’s feet lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0169">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-061.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0170"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-062.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 62: Liquid BontA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0170" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-062.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-062.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 62.1</div> <div class="figure-caption"> <p>Comparison 62: Liquid BontA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0170">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-062.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0171"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-062.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 62: Liquid BontA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0171" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-062.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-062.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 62.2</div> <div class="figure-caption"> <p>Comparison 62: Liquid BontA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0171">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-062.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0172"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-062.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 62: Liquid BontA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0172" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-062.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-062.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 62.3</div> <div class="figure-caption"> <p>Comparison 62: Liquid BontA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0172">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-062.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0173"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-063.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 63: NewBontA (Prosigne®) 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0173" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-063.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-063.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 63.1</div> <div class="figure-caption"> <p>Comparison 63: NewBontA (Prosigne®) 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 1: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0173">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-063.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0174"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-064.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 64: CBFC26 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0174" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-064.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-064.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 64.1</div> <div class="figure-caption"> <p>Comparison 64: CBFC26 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0174">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-064.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0175"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-064.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 64: CBFC26 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0175" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-064.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-064.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 64.2</div> <div class="figure-caption"> <p>Comparison 64: CBFC26 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0175">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-064.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0176"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-064.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 64: CBFC26 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0176" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-064.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-064.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 64.3</div> <div class="figure-caption"> <p>Comparison 64: CBFC26 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0176">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-064.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0177"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-064.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 64: CBFC26 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0177" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-064.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-064.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 64.4</div> <div class="figure-caption"> <p>Comparison 64: CBFC26 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0177">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-064.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0178"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-065.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 65: Liquid AbobotulinumtoxinA 20 units versus placebo one treatment in glabellar lines, Outcome 1:  Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0178" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-065.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-065.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 65.1</div> <div class="figure-caption"> <p>Comparison 65: Liquid AbobotulinumtoxinA 20 units versus placebo one treatment in glabellar lines, Outcome 1:  Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0178">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-065.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0179"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-065.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 65: Liquid AbobotulinumtoxinA 20 units versus placebo one treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0179" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-065.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-065.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 65.2</div> <div class="figure-caption"> <p>Comparison 65: Liquid AbobotulinumtoxinA 20 units versus placebo one treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0179">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-065.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0180"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-065.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 65: Liquid AbobotulinumtoxinA 20 units versus placebo one treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0180" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-065.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-065.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 65.3</div> <div class="figure-caption"> <p>Comparison 65: Liquid AbobotulinumtoxinA 20 units versus placebo one treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0180">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-065.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0181"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-065.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 65: Liquid AbobotulinumtoxinA 20 units versus placebo one treatment in glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0181" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-065.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-065.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 65.4</div> <div class="figure-caption"> <p>Comparison 65: Liquid AbobotulinumtoxinA 20 units versus placebo one treatment in glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0181">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-065.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0182"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-066.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 66: Liquid AbobotulinumtoxinA 50 units versus placebo one treatment in glabellar lines, Outcome 1: Participant assessment success by analysing scores and scales" data-id="CD011301-fig-0182" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-066.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-066.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 66.1</div> <div class="figure-caption"> <p>Comparison 66: Liquid AbobotulinumtoxinA 50 units versus placebo one treatment in glabellar lines, Outcome 1: Participant assessment success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0182">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-066.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0183"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-066.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 66: Liquid AbobotulinumtoxinA 50 units versus placebo one treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0183" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-066.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-066.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 66.2</div> <div class="figure-caption"> <p>Comparison 66: Liquid AbobotulinumtoxinA 50 units versus placebo one treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0183">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-066.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0184"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-066.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 66: Liquid AbobotulinumtoxinA 50 units versus placebo one treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0184" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-066.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-066.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 66.3</div> <div class="figure-caption"> <p>Comparison 66: Liquid AbobotulinumtoxinA 50 units versus placebo one treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0184">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-066.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0185"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-066.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 66: Liquid AbobotulinumtoxinA 50 units versus placebo one treatment in glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0185" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-066.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-066.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 66.4</div> <div class="figure-caption"> <p>Comparison 66: Liquid AbobotulinumtoxinA 50 units versus placebo one treatment in glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0185">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-066.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0186"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-067.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 67: Liquid AbobotulinumtoxinA 75 units versus placebo one treatment in glabellar lines, Outcome 1:  Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0186" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-067.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-067.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 67.1</div> <div class="figure-caption"> <p>Comparison 67: Liquid AbobotulinumtoxinA 75 units versus placebo one treatment in glabellar lines, Outcome 1:  Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0186">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-067.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0187"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-067.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 67: Liquid AbobotulinumtoxinA 75 units versus placebo one treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0187" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-067.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-067.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 67.2</div> <div class="figure-caption"> <p>Comparison 67: Liquid AbobotulinumtoxinA 75 units versus placebo one treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0187">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-067.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0188"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-067.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 67: Liquid AbobotulinumtoxinA 75 units versus placebo one treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0188" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-067.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-067.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 67.3</div> <div class="figure-caption"> <p>Comparison 67: Liquid AbobotulinumtoxinA 75 units versus placebo one treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0188">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-067.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0189"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-067.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 67: Liquid AbobotulinumtoxinA 75 units versus placebo one treatment in glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0189" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-067.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-067.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 67.4</div> <div class="figure-caption"> <p>Comparison 67: Liquid AbobotulinumtoxinA 75 units versus placebo one treatment in glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0189">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-067.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0190"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-068.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 68: Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0190" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-068.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-068.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 68.1</div> <div class="figure-caption"> <p>Comparison 68: Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0190">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-068.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0191"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-068.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 68: Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0191" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-068.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-068.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 68.2</div> <div class="figure-caption"> <p>Comparison 68: Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0191">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-068.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0192"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-068.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 68: Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0192" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-068.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-068.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 68.3</div> <div class="figure-caption"> <p>Comparison 68: Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0192">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-068.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0193"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-068.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 68: Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0193" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-068.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-068.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 68.4</div> <div class="figure-caption"> <p>Comparison 68: Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0193">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-068.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0194"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-069.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 69: Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0194" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-069.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-069.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 69.1</div> <div class="figure-caption"> <p>Comparison 69: Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0194">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-069.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0195"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-069.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 69: Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0195" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-069.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-069.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 69.2</div> <div class="figure-caption"> <p>Comparison 69: Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0195">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-069.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0196"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-069.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 69: Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0196" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-069.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-069.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 69.3</div> <div class="figure-caption"> <p>Comparison 69: Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0196">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-069.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0197"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-069.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 69: Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0197" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-069.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-069.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 69.4</div> <div class="figure-caption"> <p>Comparison 69: Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0197">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-069.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0198"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-070.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 70: Liquid AbobotulinumtoxinA 50 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines, Outcome 1:  Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0198" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-070.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-070.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 70.1</div> <div class="figure-caption"> <p>Comparison 70: Liquid AbobotulinumtoxinA 50 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines, Outcome 1:  Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0198">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-070.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0199"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-070.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 70: Liquid AbobotulinumtoxinA 50 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0199" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-070.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-070.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 70.2</div> <div class="figure-caption"> <p>Comparison 70: Liquid AbobotulinumtoxinA 50 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0199">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-070.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0200"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-070.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 70: Liquid AbobotulinumtoxinA 50 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0200" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-070.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-070.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 70.3</div> <div class="figure-caption"> <p>Comparison 70: Liquid AbobotulinumtoxinA 50 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0200">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-070.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0201"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-070.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 70: Liquid AbobotulinumtoxinA 50 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0201" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-070.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-070.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 70.4</div> <div class="figure-caption"> <p>Comparison 70: Liquid AbobotulinumtoxinA 50 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0201">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-070.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0202"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-071.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 71: Liquid AbobotulinumtoxinA 20 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 1:  Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0202" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-071.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-071.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 71.1</div> <div class="figure-caption"> <p>Comparison 71: Liquid AbobotulinumtoxinA 20 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 1:  Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0202">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-071.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0203"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-071.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 71: Liquid AbobotulinumtoxinA 20 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0203" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-071.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-071.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 71.2</div> <div class="figure-caption"> <p>Comparison 71: Liquid AbobotulinumtoxinA 20 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0203">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-071.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0204"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-071.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 71: Liquid AbobotulinumtoxinA 20 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0204" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-071.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-071.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 71.3</div> <div class="figure-caption"> <p>Comparison 71: Liquid AbobotulinumtoxinA 20 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0204">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-071.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0205"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-071.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 71: Liquid AbobotulinumtoxinA 20 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0205" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-071.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-071.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 71.4</div> <div class="figure-caption"> <p>Comparison 71: Liquid AbobotulinumtoxinA 20 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0205">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-071.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0206"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-072.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 72: Liquid AbobotulinumtoxinA 75 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0206" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-072.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-072.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 72.1</div> <div class="figure-caption"> <p>Comparison 72: Liquid AbobotulinumtoxinA 75 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0206">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-072.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0207"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-072.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 72: Liquid AbobotulinumtoxinA 75 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0207" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-072.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-072.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 72.2</div> <div class="figure-caption"> <p>Comparison 72: Liquid AbobotulinumtoxinA 75 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0207">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-072.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0208"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-072.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 72: Liquid AbobotulinumtoxinA 75 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0208" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-072.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-072.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 72.3</div> <div class="figure-caption"> <p>Comparison 72: Liquid AbobotulinumtoxinA 75 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0208">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-072.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0209"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-072.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 72: Liquid AbobotulinumtoxinA 75 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0209" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-072.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-072.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 72.4</div> <div class="figure-caption"> <p>Comparison 72: Liquid AbobotulinumtoxinA 75 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0209">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-072.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0210"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-073.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 73: DaxibotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participants assessment of success by analysing scores and scales" data-id="CD011301-fig-0210" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-073.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-073.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 73.1</div> <div class="figure-caption"> <p>Comparison 73: DaxibotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participants assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0210">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-073.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0211"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-073.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 73: DaxibotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0211" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-073.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-073.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 73.2</div> <div class="figure-caption"> <p>Comparison 73: DaxibotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0211">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-073.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0212"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-073.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 73: DaxibotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0212" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-073.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-073.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 73.3</div> <div class="figure-caption"> <p>Comparison 73: DaxibotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0212">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-073.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0213"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-073.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 73: DaxibotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0213" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-073.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-073.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 73.4</div> <div class="figure-caption"> <p>Comparison 73: DaxibotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0213">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-073.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0214"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-073.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 73: DaxibotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines, Outcome 5: Duration of treatment" data-id="CD011301-fig-0214" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-073.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-073.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 73.5</div> <div class="figure-caption"> <p>Comparison 73: DaxibotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines, Outcome 5: Duration of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0214">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-073.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0215"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-074.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 74: DaxibotulinumtoxinA 40 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0215" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-074.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-074.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 74.1</div> <div class="figure-caption"> <p>Comparison 74: DaxibotulinumtoxinA 40 units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0215">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-074.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0216"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-074.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 74: DaxibotulinumtoxinA 40 units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0216" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-074.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-074.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 74.2</div> <div class="figure-caption"> <p>Comparison 74: DaxibotulinumtoxinA 40 units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0216">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-074.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0217"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-074.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 74: DaxibotulinumtoxinA 40 units versus placebo one cycle of treatment in glabellar lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0217" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-074.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-074.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 74.3</div> <div class="figure-caption"> <p>Comparison 74: DaxibotulinumtoxinA 40 units versus placebo one cycle of treatment in glabellar lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0217">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-074.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0218"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-074.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 74: DaxibotulinumtoxinA 40 units versus placebo one cycle of treatment in glabellar lines, Outcome 4: Duration of treatment effect, weeks" data-id="CD011301-fig-0218" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-074.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-074.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 74.4</div> <div class="figure-caption"> <p>Comparison 74: DaxibotulinumtoxinA 40 units versus placebo one cycle of treatment in glabellar lines, Outcome 4: Duration of treatment effect, weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0218">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-074.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0219"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-075.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 75: DaxibotulinumtoxinA 20units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0219" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-075.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-075.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 75.1</div> <div class="figure-caption"> <p>Comparison 75: DaxibotulinumtoxinA 20units versus placebo one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0219">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-075.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0220"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-075.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 75: DaxibotulinumtoxinA 20units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0220" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-075.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-075.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 75.2</div> <div class="figure-caption"> <p>Comparison 75: DaxibotulinumtoxinA 20units versus placebo one cycle of treatment in glabellar lines, Outcome 2: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0220">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-075.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0221"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-075.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 75: DaxibotulinumtoxinA 20units versus placebo one cycle of treatment in glabellar lines, Outcome 3: Total adverse events" data-id="CD011301-fig-0221" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-075.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-075.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 75.3</div> <div class="figure-caption"> <p>Comparison 75: DaxibotulinumtoxinA 20units versus placebo one cycle of treatment in glabellar lines, Outcome 3: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0221">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-075.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0222"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-075.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 75: DaxibotulinumtoxinA 20units versus placebo one cycle of treatment in glabellar lines, Outcome 4: Duration of treatment" data-id="CD011301-fig-0222" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-075.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-075.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 75.4</div> <div class="figure-caption"> <p>Comparison 75: DaxibotulinumtoxinA 20units versus placebo one cycle of treatment in glabellar lines, Outcome 4: Duration of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0222">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-075.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0223"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-076.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 76: DaxibotulinumtoxinA 60 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0223" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-076.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-076.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 76.1</div> <div class="figure-caption"> <p>Comparison 76: DaxibotulinumtoxinA 60 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0223">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-076.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0224"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-076.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 76: DaxibotulinumtoxinA 60 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0224" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-076.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-076.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 76.2</div> <div class="figure-caption"> <p>Comparison 76: DaxibotulinumtoxinA 60 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0224">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-076.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0225"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-076.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 76: DaxibotulinumtoxinA 60 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0225" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-076.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-076.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 76.3</div> <div class="figure-caption"> <p>Comparison 76: DaxibotulinumtoxinA 60 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0225">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-076.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0226"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-076.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 76: DaxibotulinumtoxinA 60 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0226" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-076.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-076.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 76.4</div> <div class="figure-caption"> <p>Comparison 76: DaxibotulinumtoxinA 60 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0226">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-076.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0227"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-076.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 76: DaxibotulinumtoxinA 60 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 5: Duration of treatment" data-id="CD011301-fig-0227" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-076.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-076.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 76.5</div> <div class="figure-caption"> <p>Comparison 76: DaxibotulinumtoxinA 60 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 5: Duration of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0227">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-076.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0228"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-077.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 77: DaxibotulinumtoxinA 40 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0228" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-077.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-077.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 77.1</div> <div class="figure-caption"> <p>Comparison 77: DaxibotulinumtoxinA 40 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0228">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-077.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0229"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-077.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 77: DaxibotulinumtoxinA 40 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0229" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-077.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-077.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 77.2</div> <div class="figure-caption"> <p>Comparison 77: DaxibotulinumtoxinA 40 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0229">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-077.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0230"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-077.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 77: DaxibotulinumtoxinA 40 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0230" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-077.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-077.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 77.3</div> <div class="figure-caption"> <p>Comparison 77: DaxibotulinumtoxinA 40 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0230">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-077.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0231"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-077.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 77: DaxibotulinumtoxinA 40 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0231" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-077.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-077.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 77.4</div> <div class="figure-caption"> <p>Comparison 77: DaxibotulinumtoxinA 40 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0231">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-077.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0232"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-077.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 77: DaxibotulinumtoxinA 40 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 5: Duration of treatment" data-id="CD011301-fig-0232" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-077.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-077.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 77.5</div> <div class="figure-caption"> <p>Comparison 77: DaxibotulinumtoxinA 40 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 5: Duration of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0232">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-077.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0233"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-078.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 78: DaxibotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0233" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-078.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-078.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 78.1</div> <div class="figure-caption"> <p>Comparison 78: DaxibotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0233">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-078.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0234"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-078.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 78: DaxibotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0234" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-078.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-078.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 78.2</div> <div class="figure-caption"> <p>Comparison 78: DaxibotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0234">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-078.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0235"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-078.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 78: DaxibotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0235" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-078.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-078.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 78.3</div> <div class="figure-caption"> <p>Comparison 78: DaxibotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0235">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-078.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0236"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-078.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 78: DaxibotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0236" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-078.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-078.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 78.4</div> <div class="figure-caption"> <p>Comparison 78: DaxibotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0236">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-078.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0237"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-078.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 78: DaxibotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 5: Duration of treatment" data-id="CD011301-fig-0237" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-078.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-078.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 78.5</div> <div class="figure-caption"> <p>Comparison 78: DaxibotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines, Outcome 5: Duration of treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0237">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-078.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0238"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-079.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 79: PrabotulinumtoxinA 20 units versus placebo one cycle of treatment, glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0238" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-079.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-079.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 79.1</div> <div class="figure-caption"> <p>Comparison 79: PrabotulinumtoxinA 20 units versus placebo one cycle of treatment, glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0238">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-079.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0239"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-079.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 79: PrabotulinumtoxinA 20 units versus placebo one cycle of treatment, glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0239" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-079.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-079.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 79.2</div> <div class="figure-caption"> <p>Comparison 79: PrabotulinumtoxinA 20 units versus placebo one cycle of treatment, glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0239">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-079.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0240"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-079.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 79: PrabotulinumtoxinA 20 units versus placebo one cycle of treatment, glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0240" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-079.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-079.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 79.3</div> <div class="figure-caption"> <p>Comparison 79: PrabotulinumtoxinA 20 units versus placebo one cycle of treatment, glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0240">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-079.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0241"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-079.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 79: PrabotulinumtoxinA 20 units versus placebo one cycle of treatment, glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0241" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-079.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-079.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 79.4</div> <div class="figure-caption"> <p>Comparison 79: PrabotulinumtoxinA 20 units versus placebo one cycle of treatment, glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0241">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-079.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0242"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-080.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 80: PrabotulinumtoxinA 20 units versus OnabotulimtoxinA 20units one cycle of treatment, glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales" data-id="CD011301-fig-0242" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-080.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-080.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 80.1</div> <div class="figure-caption"> <p>Comparison 80: PrabotulinumtoxinA 20 units versus OnabotulimtoxinA 20units one cycle of treatment, glabellar lines, Outcome 1: Participant assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0242">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-080.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0243"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-080.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 80: PrabotulinumtoxinA 20 units versus OnabotulimtoxinA 20units one cycle of treatment, glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)" data-id="CD011301-fig-0243" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-080.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-080.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 80.2</div> <div class="figure-caption"> <p>Comparison 80: PrabotulinumtoxinA 20 units versus OnabotulimtoxinA 20units one cycle of treatment, glabellar lines, Outcome 2: Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0243">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-080.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0244"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-080.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 80: PrabotulinumtoxinA 20 units versus OnabotulimtoxinA 20units one cycle of treatment, glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales" data-id="CD011301-fig-0244" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-080.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-080.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 80.3</div> <div class="figure-caption"> <p>Comparison 80: PrabotulinumtoxinA 20 units versus OnabotulimtoxinA 20units one cycle of treatment, glabellar lines, Outcome 3: Physician assessment of success by analysing scores and scales </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0244">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-080.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0245"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-080.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 80: PrabotulinumtoxinA 20 units versus OnabotulimtoxinA 20units one cycle of treatment, glabellar lines, Outcome 4: Total adverse events" data-id="CD011301-fig-0245" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-080.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-080.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 80.4</div> <div class="figure-caption"> <p>Comparison 80: PrabotulinumtoxinA 20 units versus OnabotulimtoxinA 20units one cycle of treatment, glabellar lines, Outcome 4: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0245">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-080.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0246"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-081.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 81: OnabotulinumtoxinA 9 units versus hyaluronic acid [JUVEDERM ULTRA ® and/or JUVEDERM ULTRA PLUS®] one treatment in lips and perioral lines, Outcome 1: Total adverse events" data-id="CD011301-fig-0246" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-081.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-081.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 81.1</div> <div class="figure-caption"> <p>Comparison 81: OnabotulinumtoxinA 9 units versus hyaluronic acid [JUVEDERM ULTRA ® and/or JUVEDERM ULTRA PLUS®] one treatment in lips and perioral lines, Outcome 1: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0246">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-081.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0247"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-082.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 82: OnabotulinumtoxinA 9 units associated with hyaluronic acid [JUVEDERM ULTRA ® and/or JUVEDERM ULTRA PLUS®] versus OnabotulinumtoxinA one treatment in lips and perioral lines, Outcome 1: Total adverse events" data-id="CD011301-fig-0247" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-082.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-082.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 82.1</div> <div class="figure-caption"> <p>Comparison 82: OnabotulinumtoxinA 9 units associated with hyaluronic acid [JUVEDERM ULTRA ® and/or JUVEDERM ULTRA PLUS®] versus OnabotulinumtoxinA one treatment in lips and perioral lines, Outcome 1: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0247">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-082.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011301-fig-0248"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/urn:x-wiley:14651858:media:CD011301:CD011301-CMP-083.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 83: Hyaluronic acid [JUVEDERM ULTRA ® and/or JUVEDERM ULTRA PLUS®]versus OnabotulinumtoxinA 9 units associated with hyaluronic acid one treatment in lips and perioral lines, Outcome 1: Total adverse events" data-id="CD011301-fig-0248" src="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-083.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_t/tCD011301-CMP-083.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 83.1</div> <div class="figure-caption"> <p>Comparison 83: Hyaluronic acid [JUVEDERM ULTRA ® and/or JUVEDERM ULTRA PLUS®]versus OnabotulinumtoxinA 9 units associated with hyaluronic acid one treatment in lips and perioral lines, Outcome 1: Total adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-fig-0248">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/media/CDSR/CD011301/image_n/nCD011301-CMP-083.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011301-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of Findings Table ‐ OnabotulinumtoxinA 20U compared to placebo in glabellar lines</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>OnabotulinumtoxinA 20U compared to placebo in glabellar lines</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : glabellar lines <b>Setting</b> : Outpatient <b>Intervention</b> : OnabotulinumtoxinA 20U <b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with OnabotulinumtoxinA 20U</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Partcipant assessment of success<br/>assessed with: Validated tools, considering wrinkles and lines at maximum contraction <br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>65 per 100</b><br/>(29 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 19.45</b><br/>(8.60 to 43.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>575<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major adverse events <br/>follow up: range 4 weeks to 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>2 per 100</b><br/>(1 to 5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 3.62</b><br/>(1.50 to 8.74) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1390<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician assessment of success<br/>assessed with: Validate tools, wrinkles and lines at maximum contraction<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>61 per 100</b><br/>(36 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 17.10</b><br/>(10.07 to 29.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1339<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events<br/>follow up: range 4 weeks to 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>27 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>31 per 100</b><br/>(24 to 39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.14</b><br/>(0.89 to 1.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1388<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of treatment effect<br/>assessed with: weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean duration of treatment effect was <b>0.4</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>18.4 higher</b><br/>(16.17 higher to 20.63 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio; <b>MD:</b> Mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103355840383514" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103355840383514</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> Downgraded one level due to serious risk of bias:, unclear risk of bias from blinding of participants, personnel, and outcome assessors.<br/><b>b.</b> Downgraded one level due to serious imprecision: wide 95% CI, crossing the null. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of Findings Table ‐ OnabotulinumtoxinA 20U compared to placebo in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011301-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of Findings Table ‐ AbobotulinumtoxinA 50U compared to placebo for glabellar lines</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>AbobotulinumtoxinA 50U compared to placebo for glabellar lines</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : glabellar lines <b>Setting</b> : Outpatient <b>Intervention</b> : AbobotulinumtoxinA 50U <b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with AbobotulinumtoxinA 50U</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant assessment of success by analysing scores and scales ‐ 20 weeks (Validated tools, wrinkles and lines at maximum contraction)<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>16 per 100</b><br/>(5 to 51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 5.33</b><br/>(1.67 to 16.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)<br/>follow up: range 4 weeks to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 100</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 3.36</b><br/>(0.88 to 12.87) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1294<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unable to calculate the risk with the intervention as no major adverse events occurred in the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician assessment of success by analysing scores and scales ‐ 4 weeks<br/>assessed with: Validated tools, wrinkles and lines at maximum contraction<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>53 per 100</b><br/>(30 to 96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 15.78</b><br/>(8.75 to 28.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1060<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events<br/>follow up: range 4 weeks to 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>20 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>25 per 100</b><br/>(21 to 30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.25</b><br/>(1.05 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1471<br/>(8 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of treatment effect<br/>assessed with: weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean duration of treatment effect was <b>99.7</b> days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>17.3 days higher</b><br/>(15.82 higher to 18.78 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>MD:</b> Mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103454361439144" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103454361439144</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> Downgraded one level due to serious imprecision: wide 95% CI, crossing the null.<br/><b>b.</b> Downgraded one level due to serious risk of bias: unclear risk of bias from blinding of participants, personnel, and assessors. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of Findings Table ‐ AbobotulinumtoxinA 50U compared to placebo for glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011301-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of Findings Table ‐ IncobotulinumtoxinA 20U compared to placebo for glabellar lines</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>IncobotulinumtoxinA 20U compared to placebo for glabellar lines</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : glabellar lines <b>Setting</b> : Outpatient <b>Intervention</b> : IncobotulinumtoxinA 20U <b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with IncobotulinumtoxinA 20U</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant assessment of success by analysing scores and scales ‐ 4 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>37 per 100</b><br/>(7 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 66.57</b><br/>(13.50 to 328.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>547<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major adverse events<br/>follow up: range 4 weeks to 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>No major adverse events were observed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>547<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician assessment of success by analysing scores and scales<br/>assessed with: Validated tools, wrinkles and lines at maximum contraction<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 100</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 134.62</b><br/>(19.05 to 951.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>547<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unable to calculate the risk with the intervention as no events occurred in the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events<br/>follow up: range 4 weeks to 16 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>29 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>34 per 100</b><br/>(26 to 45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.17</b><br/>(0.90 to 1.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>547<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of treatment effect ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103474800544813" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103474800544813</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> Downgraded one level due to serious risk of bias: unclear risk of bias from blinding of participants, personnel, and assessors.<br/><b>b.</b> Downgraded one level due to serious imprecision: wide 95% CI, crossing the null </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of Findings Table ‐ IncobotulinumtoxinA 20U compared to placebo for glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011301-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of Findings Table ‐ AbobotulinumtoxinA 50U compared to OnabotulinumtoxinA 20U in glabellar lines</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>AbobotulinumtoxinA 50U compared to OnabotulinumtoxinA 20U in glabellar lines</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : glabellar lines <b>Setting</b> : Outpatient <b>Intervention</b> : AbobotulinumtoxinA 50U <b>Comparison</b>: OnabotulinumtoxinA 20U </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with OnabotulinumtoxinA 20U</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with AbobotulinumtoxinA 50U</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant assessment success by analysing scores and scales ‐ 4 weeks<br/>assessed with: Validated tools, wrinkles and lines at maximum contraction<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>894 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>894 per 1000</b><br/>(822 to 965) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.00</b><br/>(0.92 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>388<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major adverse events ‐ Any major adverse events (eyelid ptosis, eyelid sensory disorder, s<br/>follow up: range 4 weeks to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>2 per 100</b><br/>(1 to 8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 2.65</b><br/>(0.77 to 9.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>433<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction)<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>95 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>96 per 100</b><br/>(90 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.01</b><br/>(0.95 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>388<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events<br/>follow up: range 4 weeks to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>18 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>19 per 100</b><br/>(12 to 28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.02</b><br/>(0.67 to 1.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>492<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of treatment effect ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103510517664820" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103510517664820</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> Downgraded one level due to serious imprecision: wide 95% CI, crossing the null. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of Findings Table ‐ AbobotulinumtoxinA 50U compared to OnabotulinumtoxinA 20U in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011301-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of Findings Table ‐ IncobotulinumtoxinA 24U compared to OnabotulinumtoxinA 24U in glabellar lines</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>IncobotulinumtoxinA 24U compared to OnabotulinumtoxinA 24U in glabellar lines</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : glabellar lines <b>Setting</b> : Outpatient <b>Intervention</b> : IncobotulinumtoxinA 24U <b>Comparison</b>: OnabotulinumtoxinA 24U </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with OnabotulinumtoxinA 24U</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with IncobotulinumtoxinA 24U</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant assessment of success by analysing scores and scales ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major adverse events<br/>follow up: range 4 weeks to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 100</b><br/>(0 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.02</b><br/>(0.00 to 1.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>381<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,</sup><sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ptosis was reported in one participant in onabotulinumtoxinA group</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction)<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>96 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>97 per 100</b><br/>(92 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.01</b><br/>(0.96 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>381<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/>LOW <sup>a,</sup><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events<br/>follow up: range 4 weeks to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>1 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>0 per 100</b><br/>(0 to 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 0.02</b><br/>(0.00 to 1.77) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>381<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>a,</sup><sup>b,</sup><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of treatment effect ‐ not measured</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103538603772987" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103538603772987</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> Downgraded one level due to serious risk of bias: unclear risk of bias from randomisation, allocation concealment and blinding.<br/><b>b.</b> Downgraded one level due to serious imprecision: wide 95% CI, crossing the null.<br/><b>c.</b> Downgraded one level due to serious imprecision: low number of events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of Findings Table ‐ IncobotulinumtoxinA 24U compared to OnabotulinumtoxinA 24U in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011301-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of Findings Table ‐ DaxibotulinumtoxinA 40U compared to placebo in glabellar lines</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>DaxibotulinumtoxinA 40U compared to placebo in glabellar lines</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : glabellar lines <b>Setting</b> : Outpatient <b>Intervention</b> : DaxibotulinumtoxinA 40U <b>Comparison</b>: placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>№ of participants <br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with DaxibotulinumtoxinA 40U</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction)<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>79 per 100</b><br/>(43 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 21.10</b><br/>(11.31 to 39.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>683<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Major adverse events<br/>follow up: range 4 weeks to 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>No major adverse events were observed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>716<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physician assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction)<br/>follow up: 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>88 per 100</b><br/>(47 to 100) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 23.40</b><br/>(12.56 to 43.61) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>683<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events<br/>follow up: range 4 weeks to 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>9 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>21 per 100</b><br/>(14 to 32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 2.23</b><br/>(1.46 to 3.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>716<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of treatment effect</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean duration of treatment effect was <b>0.4</b> weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>MD <b>22.8 weeks higher</b><br/>(20.74 higher to 24.8 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/>MODERATE <sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). <br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>MD:</b> Mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>See interactive version of this table: <a href="https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103545427906155" target="_blank">https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_423103545427906155</a>. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>a.</b> Downgraded one level due to serious risk of bias: unclear allocation concealment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of Findings Table ‐ DaxibotulinumtoxinA 40U compared to placebo in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/full#CD011301-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">OnabotulinumtoxinA 10units versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">OnabotulinumtoxinA 10units versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">OnabotulinumtoxinA 20 units versus placebo one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.45 [8.60, 43.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>204</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>28.45 [5.92, 136.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.77 [2.78, 58.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.71 [2.82, 151.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.5 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.19 [0.21, 84.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.62 [1.50, 8.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.10 [10.07, 29.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.50 [9.68, 47.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1046</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.81 [5.79, 20.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>933</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.13 [5.98, 38.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.86 [0.31, 109.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.19 [0.21, 84.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.89, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Duration of treatment (weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.40 [16.17, 20.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">OnabotulinumtoxinA 20 units versus placebo one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">OnabotulinumtoxinA 20units versus 10 units one treatment glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.96, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.01, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.75, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.20, 18.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.91, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.76, 3.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.3 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.76, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.49, 2.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">OnabotulinumtoxinA 20units versus 10 units one treatment glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">OnabotulinumtoxinA 64units versus placebo one cycle of treatment, upper wrinkles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">OnabotulinumtoxinA 64units versus placebo one cycle of treatment, upper wrinkles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">OnabotulinumtoxinA 40units versus placebo one cycle of treatment, upper wrinkles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.41 [4.02, 13.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>86.13 [5.38, 1378.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>39.87 [2.47, 644.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.32 [0.67, 190.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [0.12, 50.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.06, 36.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.41 [4.02, 13.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>86.13 [5.38, 1378.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>39.87 [2.47, 644.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.32 [0.67, 190.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.46 [0.12, 50.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.06, 36.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">OnabotulinumtoxinA 40units versus placebo one cycle of treatment, upper wrinkles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">OnabotulinumtoxinA 64units versus OnabotulinumoxinA 40U one cycle of treatment, upper wrinkles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">OnabotulinumtoxinA 64units versus OnabotulinumoxinA 40U one cycle of treatment, upper wrinkles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">OnabotulinumtoxinA 64units versus 32 units one cycle of treatment upper wrinkles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 4 and 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.3 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.4 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">OnabotulinumtoxinA 64units versus 32 units one cycle of treatment upper wrinkles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">OnabotulinumtoxinA 96 units versus 32 units one cycle of treatment upper wrinkles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.7 28 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.8 32 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.7 28 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.8 32 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">OnabotulinumtoxinA 96 units versus 32 units one cycle of treatment upper wrinkles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">OnabotulinumtoxinA 96 units versus 64 units one cycle of treatment upper wrinkles</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.7 28 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1.8 32 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.7 28 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.8 32 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">OnabotulinumtoxinA 96 units versus 64 units one cycle of treatment upper wrinkles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">OnabotulinumtoxinA 32 units versus 16 units one cycle of treatment forehead lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1.1 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3.1 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">OnabotulinumtoxinA 32 units versus 16 units one cycle of treatment forehead lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">OnabotulinumtoxinA 60 units versus 20 units one cycle of treatment glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">OnabotulinumtoxinA 60 units versus 20 units one cycle of treatment glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">OnabotulinumtoxinA 48 units versus 32 units one cycle of treatment forehead lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1.1 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3.1 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">OnabotulinumtoxinA 48 units versus 32 units one cycle of treatment forehead lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">OnabotulinumtoxinA 40 units versus placebo one cycle of treatment for forehead lines and glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">OnabotulinumtoxinA 40 units versus placebo one cycle of treatment for forehead lines and glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">OnabotulinumtoxinA 30 units versus placebo one cycle of treatment for forehead lines and glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>24.00 [6.11, 94.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>43.00 [6.12, 302.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.67 [2.77, 27.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.33 [1.44, 7.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.00 [2.05, 109.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.00 [1.03, 61.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">OnabotulinumtoxinA 30 units versus placebo one cycle of treatment for forehead lines and glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">OnabotulinumtoxinA 40 units versus OnabotulinumonabotulinumtoxinA 30 units one cycle of treatment for forehead lines and glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">OnabotulinumtoxinA 40 units versus OnabotulinumonabotulinumtoxinA 30 units one cycle of treatment for forehead lines and glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">OnabotulinumtoxinA 40 units versus 20 units one treatment glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.13, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.77, 2.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1.3 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.51 [0.88, 7.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.93, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.82, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2.3 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.51, 3.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.53, 7.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">OnabotulinumtoxinA 40 units versus 20 units one treatment glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">OnabotulinumtoxinA 48 units versus 16 units one cycle of treatment forehead lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1.1 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3.1 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">OnabotulinumtoxinA 48 units versus 16 units one cycle of treatment forehead lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">OnabotulinumtoxinA 80 units versus 20 units one cycle of treatment glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.1 Participant assessment, maximum contraction (responder rate) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">OnabotulinumtoxinA 80 units versus 20 units one cycle of treatment glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">OnabotulinumtoxinA 80 units versus 60 units one cycle of treatment glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">OnabotulinumtoxinA 80 units versus 60 units one cycle of treatment glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">OnabotulinumtoxinA 30 units versus 10 units one cycle of treatment glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">OnabotulinumtoxinA 30 units versus 10 units one cycle of treatment glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">OnabotulinumtoxinA 40 units versus 10 units one cycle of treatment glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">OnabotulinumtoxinA 40 units versus 10 units one cycle of treatment glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">OnabotulinumtoxinA 40 units versus 30 units one cycle of treatment glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">OnabotulinumtoxinA 40 units versus 30 units one cycle of treatment glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">OnabotulinumtoxinA 30 units versus 20 units one cycle of treatment glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">OnabotulinumtoxinA 30 units versus 20 units one cycle of treatment glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">OnabotulinumtoxinA 60 units versus 40 units one cycle of treatment glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">OnabotulinumtoxinA 60 units versus 40 units one cycle of treatment glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">OnabotulinumtoxinA 80 units versus 40 units one cycle of treatment glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">OnabotulinumtoxinA 80 units versus 40 units one cycle of treatment glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">OnabotulinumtoxinA 80units versus 60units one cycle of treatment glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">OnabotulinumtoxinA 80units versus 60units one cycle of treatment glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">OnabotulinumtoxinA 12 units versus 7.5 units one cycle of treatment perioral lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">OnabotulinumtoxinA 12 units versus 7.5 units one cycle of treatment perioral lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">OnabotulinumtoxinA 20units versus placebo in glabellar lines three cycles of treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28.1 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">OnabotulinumtoxinA 20units versus placebo in glabellar lines three cycles of treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">OnabotulinumtoxinA24 units versus placebo one treatment in crow's feet lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.71 [8.67, 18.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.25 [7.02, 14.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.70 [4.81, 12.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.31 [4.68, 32.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.33 [3.35, 31.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.12, 13.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.38 [8.93, 17.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.13 [5.34, 19.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.29 [5.95, 14.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1057</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.46 [3.19, 9.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>692</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.94, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">OnabotulinumtoxinA24 units versus placebo one treatment in crow's feet lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">OnabotulinumtoxinA 12 units versus placebo one treatment in crow's feet lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30.1 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.87, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">OnabotulinumtoxinA 12 units versus placebo one treatment in crow's feet lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0036">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0037"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">OnabotulinumtoxinA 24 units versus OnabotulinumtoxinA 12 units one treatment in crow's feet lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31.1 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">OnabotulinumtoxinA 24 units versus OnabotulinumtoxinA 12 units one treatment in crow's feet lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0037">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0038"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">OnabotulinumtoxinA 44 units versus placebo one treatments in glabellar lines and crow's feet lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.33 [9.27, 28.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.95 [5.03, 15.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.10 [2.80, 9.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.51 [1.31, 4.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.09 [4.12, 29.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.94 [1.78, 55.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.96 [0.60, 58.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">OnabotulinumtoxinA 44 units versus placebo one treatments in glabellar lines and crow's feet lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0038">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0039"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">OnabotulinumtoxinA 44 units versus placebo two cycles of treatments in crow's feet lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.12 [6.36, 16.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.95 [5.03, 15.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.85 [2.66, 8.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.63 [9.50, 32.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.86 [9.90, 39.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.98, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">OnabotulinumtoxinA 44 units versus placebo two cycles of treatments in crow's feet lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0039">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0040"> <div class="table-heading"><span class="table-label">Comparison 34.</span> <span class="table-title">OnabotulinumtoxinA 24 units versus 12 units five cycles of treatment in crow's feet lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34.1 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.41, 4.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 34.</span> <span class="table-title">OnabotulinumtoxinA 24 units versus 12 units five cycles of treatment in crow's feet lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0040">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0041"> <div class="table-heading"><span class="table-label">Comparison 35.</span> <span class="table-title">AbobotulinumtoxinA 25 units versus placebo one cycle of treatment, glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1.4 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 35.</span> <span class="table-title">AbobotulinumtoxinA 25 units versus placebo one cycle of treatment, glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0041">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0042"> <div class="table-heading"><span class="table-label">Comparison 36.</span> <span class="table-title">AbobotulinumtoxinA 30 units versus placebo one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 36.</span> <span class="table-title">AbobotulinumtoxinA 30 units versus placebo one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0042">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0043"> <div class="table-heading"><span class="table-label">Comparison 37.</span> <span class="table-title">AbobotulinumtoxinA 50 units versus placebo one treatment glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.22 [7.43, 60.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>725</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>39.89 [14.10, 112.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>725</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>28.83 [10.16, 81.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.78 [4.12, 33.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.33 [1.67, 16.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37.2 Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.36 [0.88, 12.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1060</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.78 [8.75, 28.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>30.84 [11.58, 82.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.79 [6.70, 47.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>29.88 [6.01, 148.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.3.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.00 [2.36, 122.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.05, 1.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37.5 Duration of treatment (days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 37.</span> <span class="table-title">AbobotulinumtoxinA 50 units versus placebo one treatment glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0043">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0044"> <div class="table-heading"><span class="table-label">Comparison 38.</span> <span class="table-title">AbobotulinumtoxinA 50 units versus 25 units one cycle of treatment, glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1.4 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 38.</span> <span class="table-title">AbobotulinumtoxinA 50 units versus 25 units one cycle of treatment, glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0044">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0045"> <div class="table-heading"><span class="table-label">Comparison 39.</span> <span class="table-title">AbobotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 39.</span> <span class="table-title">AbobotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0045">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0046"> <div class="table-heading"><span class="table-label">Comparison 40.</span> <span class="table-title">AbobotulinumtoxinA 70 units versus placebo one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 40.</span> <span class="table-title">AbobotulinumtoxinA 70 units versus placebo one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0046">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0047"> <div class="table-heading"><span class="table-label">Comparison 41.</span> <span class="table-title">AbobotulinumtoxinA 75 units versus placebo one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1.4 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 41.</span> <span class="table-title">AbobotulinumtoxinA 75 units versus placebo one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0047">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0048"> <div class="table-heading"><span class="table-label">Comparison 42.</span> <span class="table-title">AbobotulinumtoxinA 75 units versus 25 units one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1.4 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 42.</span> <span class="table-title">AbobotulinumtoxinA 75 units versus 25 units one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0048">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0049"> <div class="table-heading"><span class="table-label">Comparison 43.</span> <span class="table-title">AbobotulinumtoxinA 75 units versus 50 units one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1.4 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 43.</span> <span class="table-title">AbobotulinumtoxinA 75 units versus 50 units one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0049">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0050"> <div class="table-heading"><span class="table-label">Comparison 44.</span> <span class="table-title">AbobotulinumtoxinA 80 units versus placebo one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 44.</span> <span class="table-title">AbobotulinumtoxinA 80 units versus placebo one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0050">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0051"> <div class="table-heading"><span class="table-label">Comparison 45.</span> <span class="table-title">AbobotulinumtoxinA 15 units versus placebo one cycle of treatment crow's feet lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 45.</span> <span class="table-title">AbobotulinumtoxinA 15 units versus placebo one cycle of treatment crow's feet lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0051">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0052"> <div class="table-heading"><span class="table-label">Comparison 46.</span> <span class="table-title">AbobotulinumtoxinA 30 units versus placebo one cycle of treatment crow's feet lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 46.</span> <span class="table-title">AbobotulinumtoxinA 30 units versus placebo one cycle of treatment crow's feet lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0052">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0053"> <div class="table-heading"><span class="table-label">Comparison 47.</span> <span class="table-title">AbobotulinumtoxinA 45 units versus placebo one cycle of treatment crow's feet lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 47.</span> <span class="table-title">AbobotulinumtoxinA 45 units versus placebo one cycle of treatment crow's feet lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0053">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0054"> <div class="table-heading"><span class="table-label">Comparison 48.</span> <span class="table-title">AbobotulinumtoxinA 50 units versus placebo, three cycles of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 48.</span> <span class="table-title">AbobotulinumtoxinA 50 units versus placebo, three cycles of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0054">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0055"> <div class="table-heading"><span class="table-label">Comparison 49.</span> <span class="table-title">IncobotulinumtoxinA 20 units versus placebo one treatment glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>66.57 [13.50, 328.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.35 [4.79, 11.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.29 [4.38, 12.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.40 [2.61, 7.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>134.62 [19.05, 951.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.90, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 49.</span> <span class="table-title">IncobotulinumtoxinA 20 units versus placebo one treatment glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0055">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0056"> <div class="table-heading"><span class="table-label">Comparison 50.</span> <span class="table-title">IncobotulinumtoxinA 54 to 64units versus placebo one cycles of treatment glabellar lines, forehead liens, crow's feet lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50.1 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.2.1 4 weeks‐ Glabella</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.2.2 4 weeks ‐ forehead</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.2.3 4 weeks crow's feet line</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 50.</span> <span class="table-title">IncobotulinumtoxinA 54 to 64units versus placebo one cycles of treatment glabellar lines, forehead liens, crow's feet lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0056">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0057"> <div class="table-heading"><span class="table-label">Comparison 51.</span> <span class="table-title">HBTX‐A 10 units versus placebo one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.1.3 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 51.</span> <span class="table-title">HBTX‐A 10 units versus placebo one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0057">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0058"> <div class="table-heading"><span class="table-label">Comparison 52.</span> <span class="table-title">HBTX‐A 20 units versus placebo one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.1.3 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 52.</span> <span class="table-title">HBTX‐A 20 units versus placebo one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0058">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0059"> <div class="table-heading"><span class="table-label">Comparison 53.</span> <span class="table-title">HBTX‐A 50 units versus placebo one cycle of treatment, glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53.1  Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>42.68 [6.08, 299.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>43.28 [6.18, 303.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.67 [3.06, 153.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>49.69 [7.10, 347.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>53.52 [7.65, 374.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.2.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>33.17 [4.72, 233.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.02, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.3.1 Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.02, 2.50]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 53.</span> <span class="table-title">HBTX‐A 50 units versus placebo one cycle of treatment, glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0059">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0060"> <div class="table-heading"><span class="table-label">Comparison 54.</span> <span class="table-title">HBTX‐A 20 units versus 10 units one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.1.3 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54.2 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 54.</span> <span class="table-title">HBTX‐A 20 units versus 10 units one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0060">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0061"> <div class="table-heading"><span class="table-label">Comparison 55.</span> <span class="table-title">AbobotulinumtoxinA 50 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55.1 Participant assessment success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.92, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.88, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.81, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55.2 Major adverse events  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.2.1 Any major adverse events (eyelid ptosis, eyelid sensory disorder, s</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.65 [0.77, 9.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.95, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>449</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.89, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.60, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.13, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.67, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 55.</span> <span class="table-title">AbobotulinumtoxinA 50 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0061">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0062"> <div class="table-heading"><span class="table-label">Comparison 56.</span> <span class="table-title">IncobotulinumtoxinA 30 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">56.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.1.2 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.1.3 14 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">56.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.2.2 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.2.3 14 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.2.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">56.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 56.</span> <span class="table-title">IncobotulinumtoxinA 30 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0062">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0063"> <div class="table-heading"><span class="table-label">Comparison 57.</span> <span class="table-title">IncobotulinumtoxinA 24 units versus OnabotulinumtoxinA 24 units one treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">57.1 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">57.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.2.2 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">57.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 57.</span> <span class="table-title">IncobotulinumtoxinA 24 units versus OnabotulinumtoxinA 24 units one treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0063">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0064"> <div class="table-heading"><span class="table-label">Comparison 58.</span> <span class="table-title">IncobotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58.1 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58.2 Physician assessment of success by analysing scores and scales ‐ injector <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.2.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.2.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58.3 Physician assessment of success by analysing scores and scales ‐ independent observer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 58.</span> <span class="table-title">IncobotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0064">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0065"> <div class="table-heading"><span class="table-label">Comparison 59.</span> <span class="table-title">NewBontA [Medytox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">59.1 Physician assessment, maximum contraction (responder rate) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 59.</span> <span class="table-title">NewBontA [Medytox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0065">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0066"> <div class="table-heading"><span class="table-label">Comparison 60.</span> <span class="table-title">NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 60.</span> <span class="table-title">NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0066">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0067"> <div class="table-heading"><span class="table-label">Comparison 61.</span> <span class="table-title">NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in crow’s feet lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.89, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.83, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.90, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.70, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.89, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.86, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.88, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.83, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.4.1 Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 61.</span> <span class="table-title">NewBontA [Neuronox®] 20 units versus OnabotulinumtoxinA 20 units one treatment in crow’s feet lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0067">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0068"> <div class="table-heading"><span class="table-label">Comparison 62.</span> <span class="table-title">Liquid BontA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">62.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.1.2 10 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.1.3 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">62.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.2.2 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">62.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 62.</span> <span class="table-title">Liquid BontA 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0068">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0069"> <div class="table-heading"><span class="table-label">Comparison 63.</span> <span class="table-title">NewBontA (Prosigne®) 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">63.1 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.1.1 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 63.</span> <span class="table-title">NewBontA (Prosigne®) 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0069">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0070"> <div class="table-heading"><span class="table-label">Comparison 64.</span> <span class="table-title">CBFC26 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">64.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">64.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">64.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">64.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 64.</span> <span class="table-title">CBFC26 20 units versus OnabotulinumtoxinA 20 units one treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0070">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0071"> <div class="table-heading"><span class="table-label">Comparison 65.</span> <span class="table-title">Liquid AbobotulinumtoxinA 20 units versus placebo one treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">65.1  Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>66.81 [4.25, 1050.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>42.14 [2.65, 670.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>44.19 [2.78, 702.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>27.75 [1.71, 449.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">65.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.2.1 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.60 [0.15, 383.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">65.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>66.81 [4.25, 1050.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>58.58 [3.71, 923.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>40.08 [2.51, 639.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.53 [1.18, 323.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">65.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.4.1 Totl adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.41, 3.68]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 65.</span> <span class="table-title">Liquid AbobotulinumtoxinA 20 units versus placebo one treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0071">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0072"> <div class="table-heading"><span class="table-label">Comparison 66.</span> <span class="table-title">Liquid AbobotulinumtoxinA 50 units versus placebo one treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">66.1 Participant assessment success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>46.95 [9.57, 230.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>41.87 [8.52, 205.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>24.61 [4.97, 121.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.54 [1.70, 25.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.35 [1.71, 6.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">66.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.39 [0.07, 289.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">66.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.73 [2.84, 98.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>48.98 [9.99, 240.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>35.93 [7.30, 176.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.25 [2.95, 152.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.3.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>25.86 [1.60, 417.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">66.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.4.1 Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.72, 1.71]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 66.</span> <span class="table-title">Liquid AbobotulinumtoxinA 50 units versus placebo one treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0072">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0073"> <div class="table-heading"><span class="table-label">Comparison 67.</span> <span class="table-title">Liquid AbobotulinumtoxinA 75 units versus placebo one treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">67.1  Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>49.64 [12.47, 197.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>60.64 [3.85, 955.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>62.69 [3.98, 987.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>44.19 [2.78, 702.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>35.97 [2.25, 576.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">67.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.83 [0.48, 127.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">67.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">67.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.24, 2.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 67.</span> <span class="table-title">Liquid AbobotulinumtoxinA 75 units versus placebo one treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0073">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0074"> <div class="table-heading"><span class="table-label">Comparison 68.</span> <span class="table-title">Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">68.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.90, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.69, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.84, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.58, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">68.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.2.1 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.39 [0.15, 372.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">68.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.90, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.04, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.74, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.36, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">68.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.46, 4.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.4.1 Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.46, 4.86]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 68.</span> <span class="table-title">Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0074">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0075"> <div class="table-heading"><span class="table-label">Comparison 69.</span> <span class="table-title">Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">69.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.92, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.49, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.66, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.44, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">69.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.2.1 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 5.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">69.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.88, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.77, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.49, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.29, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">69.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.4.1 Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.87, 7.22]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 69.</span> <span class="table-title">Liquid AbobotulinumtoxinA 20 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0075">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0076"> <div class="table-heading"><span class="table-label">Comparison 70.</span> <span class="table-title">Liquid AbobotulinumtoxinA 50 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">70.1  Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.83, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.45, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.49, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.40, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">70.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.2.1 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">70.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.81, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.47, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.40, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.35, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">70.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.4.1 Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.27, 3.69]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 70.</span> <span class="table-title">Liquid AbobotulinumtoxinA 50 units versus Liquid AbobotulinumtoxinA 75 units one cycle of treatment, glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0076">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0077"> <div class="table-heading"><span class="table-label">Comparison 71.</span> <span class="table-title">Liquid AbobotulinumtoxinA 20 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">71.1  Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.92, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.62, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.92, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.51, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">71.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.2.1 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.39 [0.15, 372.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">71.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.96, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.79, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.65, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.34, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">71.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.4.1 Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.65, 13.86]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 71.</span> <span class="table-title">Liquid AbobotulinumtoxinA 20 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0077">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0078"> <div class="table-heading"><span class="table-label">Comparison 72.</span> <span class="table-title">Liquid AbobotulinumtoxinA 75 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">72.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.81, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.02, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.97, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.91, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">72.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.2.1 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.61 [0.47, 124.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">72.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.93, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.83, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.00, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.92, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">72.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.4.1 Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.39, 10.22]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 72.</span> <span class="table-title">Liquid AbobotulinumtoxinA 75 units versus  AbobotulinumtoxinA 50 units one cycle of treatment, glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0078">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0079"> <div class="table-heading"><span class="table-label">Comparison 73.</span> <span class="table-title">DaxibotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">73.1 Participants assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.1.2 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.1.3 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">73.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">73.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.3.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.3.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">73.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">73.5 Duration of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 73.</span> <span class="table-title">DaxibotulinumtoxinA 60 units versus placebo one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0079">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0080"> <div class="table-heading"><span class="table-label">Comparison 74.</span> <span class="table-title">DaxibotulinumtoxinA 40 units versus placebo one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">74.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.10 [11.31, 39.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.1.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.75 [8.85, 28.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>24.51 [11.12, 54.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.74 [6.80, 23.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.1.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>609</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.60 [6.13, 30.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.1.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.25 [4.01, 26.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">74.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.40 [12.56, 43.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.09 [10.30, 31.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.2.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>29.46 [13.79, 62.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.2.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.84 [9.01, 31.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.2.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.06 [8.42, 38.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.2.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.33 [6.06, 38.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">74.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [1.46, 3.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">74.4 Duration of treatment effect, weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>22.80 [20.74, 24.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 74.</span> <span class="table-title">DaxibotulinumtoxinA 40 units versus placebo one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0080">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0081"> <div class="table-heading"><span class="table-label">Comparison 75.</span> <span class="table-title">DaxibotulinumtoxinA 20units versus placebo one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">75.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>75.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>75.1.2 16weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>75.1.3 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">75.2 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>75.2.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>75.2.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>75.2.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>75.2.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>75.2.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>75.2.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">75.3 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">75.4 Duration of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 75.</span> <span class="table-title">DaxibotulinumtoxinA 20units versus placebo one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0081">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0082"> <div class="table-heading"><span class="table-label">Comparison 76.</span> <span class="table-title">DaxibotulinumtoxinA 60 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">76.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.1.2 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.1.3 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">76.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">76.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.05, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.07, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.60, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [0.67, 6.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.3.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.73 [0.78, 9.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.3.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.15, 6.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">76.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">76.5 Duration of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 76.</span> <span class="table-title">DaxibotulinumtoxinA 60 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0082">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0083"> <div class="table-heading"><span class="table-label">Comparison 77.</span> <span class="table-title">DaxibotulinumtoxinA 40 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">77.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>77.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>77.1.2 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>77.1.3 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">77.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">77.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>77.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.01, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>77.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.01, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>77.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.59, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>77.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.77 [1.36, 10.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>77.3.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [0.82, 10.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>77.3.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [0.42, 11.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">77.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">77.5 Duration of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 77.</span> <span class="table-title">DaxibotulinumtoxinA 40 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0083">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0084"> <div class="table-heading"><span class="table-label">Comparison 78.</span> <span class="table-title">DaxibotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">78.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>78.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>78.1.2 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>78.1.3 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">78.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">78.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>78.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>78.3.2 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>78.3.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>78.3.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>78.3.5 20 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>78.3.6 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">78.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.46, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">78.5 Duration of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 78.</span> <span class="table-title">DaxibotulinumtoxinA 20 units versus OnabotulinumtoxinA 20 units one cycle of treatment in glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0084">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0085"> <div class="table-heading"><span class="table-label">Comparison 79.</span> <span class="table-title">PrabotulinumtoxinA 20 units versus placebo one cycle of treatment, glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">79.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.34 [9.68, 34.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>79.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.34 [9.68, 34.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">79.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>939</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.06, 5.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">79.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>929</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.96 [9.35, 61.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>79.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>929</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.96 [9.35, 61.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">79.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>948</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.91, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 79.</span> <span class="table-title">PrabotulinumtoxinA 20 units versus placebo one cycle of treatment, glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0085">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0086"> <div class="table-heading"><span class="table-label">Comparison 80.</span> <span class="table-title">PrabotulinumtoxinA 20 units versus OnabotulimtoxinA 20units one cycle of treatment, glabellar lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">80.1 Participant assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.99, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>80.1.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [1.00, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>80.1.2 8weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>80.1.3 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.97, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>80.1.4 16 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.91, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">80.2 Any major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">80.3 Physician assessment of success by analysing scores and scales <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>80.3.1 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">80.4 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.74, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 80.</span> <span class="table-title">PrabotulinumtoxinA 20 units versus OnabotulimtoxinA 20units one cycle of treatment, glabellar lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0086">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0087"> <div class="table-heading"><span class="table-label">Comparison 81.</span> <span class="table-title">OnabotulinumtoxinA 9 units versus hyaluronic acid [JUVEDERM ULTRA ® and/or JUVEDERM ULTRA PLUS®] one treatment in lips and perioral lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">81.1 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 81.</span> <span class="table-title">OnabotulinumtoxinA 9 units versus hyaluronic acid [JUVEDERM ULTRA ® and/or JUVEDERM ULTRA PLUS®] one treatment in lips and perioral lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0087">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0088"> <div class="table-heading"><span class="table-label">Comparison 82.</span> <span class="table-title">OnabotulinumtoxinA 9 units associated with hyaluronic acid [JUVEDERM ULTRA ® and/or JUVEDERM ULTRA PLUS®] versus OnabotulinumtoxinA one treatment in lips and perioral lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">82.1 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 82.</span> <span class="table-title">OnabotulinumtoxinA 9 units associated with hyaluronic acid [JUVEDERM ULTRA ® and/or JUVEDERM ULTRA PLUS®] versus OnabotulinumtoxinA one treatment in lips and perioral lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0088">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011301-tbl-0089"> <div class="table-heading"><span class="table-label">Comparison 83.</span> <span class="table-title">Hyaluronic acid [JUVEDERM ULTRA ® and/or JUVEDERM ULTRA PLUS®]versus OnabotulinumtoxinA 9 units associated with hyaluronic acid one treatment in lips and perioral lines</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">83.1 Total adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 83.</span> <span class="table-title">Hyaluronic acid [JUVEDERM ULTRA ® and/or JUVEDERM ULTRA PLUS®]versus OnabotulinumtoxinA 9 units associated with hyaluronic acid one treatment in lips and perioral lines</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011301.pub2/references#CD011301-tbl-0089">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011301.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011301-note-0017">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011301-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011301-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD011301-note-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011301-note-0016">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD011301-note-0011">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD011301-note-0012">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011301-note-0009">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011301-note-0010">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011301\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011301\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011301\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011301\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011301\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011301\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011301\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011301\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011301\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011301\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011301\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011301\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011301\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011301\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011301\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011301\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011301\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011301\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=i9CklieH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011301.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011301.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011301.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011301.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011301.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717052198"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011301.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717052201"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011301.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dae77c9e7f3f1',t:'MTc0MDcxNzA1Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 